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ABSTRACT
BIOPHYSICAL EXPLORATION OF CONFORMATIONAL ENVIRONMENTS IN
ZYMOGEN PROTHROMBIN AND BLOOD COAGULANT THROMBIN
Ramya Billur
April 30, 2018

The serine protease thrombin plays important roles in coagulation, anticoagulation,
and platelet activation. Thrombin is initially expressed as the inactive zymogen
prothrombin (ProT). The final cleaved and activated form of thrombin has mature anion
binding exosites (ABEs) and several regulatory loops. Engagement with these exosites
helps define the fate of thrombin as a procoagulant or an anticoagulant. Researchers
previously reported that zymogen ProT may already bind exosite ligands. Little is known
about conformational changes associated with ProT maturation, resultant ligand binding
affinities, individual ligand-protein contacts, and long-range communication between
thrombin exosites.
Protease Activated Receptors (PARs) play critical roles in controlling platelet
activation. Using solution NMR methods, we demonstrated that PAR3 (44-56) and weaker
binding version PAR3G (44-56, P51G) can already bind to immature pro-ABE I. 1D and
2D 1H-15N HSQC titrations revealed that PAR3G 15N-E48 and 15N-D54 both entered into
higher affinity, intermediate exchange regimes as ProT was converted into thrombin. The
high affinity of PAR3G D54 suggests that the thrombin R77a region is better oriented for
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binding than thrombin R75. PAR3G 15N-F47 and 15N-L52 experienced significant changes
in chemical shift and thus chemical environment upon ABE I maturation. However, the
ProT 30s loop made better contacts with PAR3 than the ProT hydrophobic cluster (F34,
L65, and I82).
The project was extended to PAR1 (49-62). Both PAR1P and weaker version
PAR1G (P54G) bound to ProT and proton NMR line broadening increased with thrombin.
1D and 2D 1H-15N HSQC titrations revealed that unlike PAR3G (44-56), PAR1G (49-62)
15

N- K51, E53, F55, D58, and E60 exhibited little interactions with ProT. Affinities

increased with mature thrombin ABE I. NMR titrations could probe PAR1 (58DEEKN62),
a region previously unresolved by X-ray crystallography. Interestingly, the ABE II ligand
GpIbα (269-282, 3YP) influenced the NMR binding affinities of PAR1G and PAR3G
supporting long-range communication between the ABE II and ABE I exosites. Finally,
our studies shifted toward the thrombin active site region. Kinetic assays and 2D trNOESY studies provided clues on why Fibrinogen Bβ (5-16) is such a weak thrombin
substrate. The Fibrinogen Bβ 10FFSAR14 sequence contributes towards hindering binding
(Km) and product turnover (kcat).
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CHAPTER I
INTRODUCTION

Over time, an important host defense mechanism that highly evolved vertebrates
adopted was hemostasis. Hemostasis can be defined as a mechanism for formation of a
blood clot at the site of vascular injury, while not disturbing the blood flow throughout the
rest of the body. During a vascular injury, platelet interactions with several clotting factors,
red blood cells, and white blood cells forms a protective plug, which stops the flow of
blood. To maintain balance, fibrinolytic mechanisms also evolved to degrade the clot and
restore normal blood flow in the injured blood vessels.1,2
Since the 1800s, blood coagulation has been recognized as an important biological
phenomenon and has drawn the attention of many world class biochemists and physicians.3
Over the years, there were debates about the different nomenclatures being used for clotting
factors. All this came to an end by the establishment of a standard nomenclature approved
by an international committee and now regularly reviewed by the ISTH (International
Society on Thrombosis and Hemostasis). For most of the clotting factors, a Roman
Numeral nomenclature was assigned based on their time of discovery.4 This chapter will
highlight the various coagulation pathways, the individual clotting factors, and the
receptors that help control coagulation.

1

Blood coagulation cascade
Fibrinogen, also called factor I, was the first factor isolated and is an abundant
glycoprotein in plasma.5,6 Fibrin is formed by the limited proteolysis of fibrinogen and
followed by polymerization. Fibrin is the only coagulation protein whose existence has not
been debated. Schmidt isolated fibrin ferment from fresh serum and later named the
reactive component as thrombin. This thrombin was proposed to polymerize fibrinogen
when tissue extracts could not convert fibrinogen to fibrin.3 The discovery of prothrombin
(factor II or ProT), through differential precipitation strategies from blood, led the
researchers to believe that thrombin cannot be extracted from blood. Thrombin must
instead be generated from ProT following limited proteolysis.7-10 Morawitz developed a
classical theory of blood coagulation. He proposed a four-factor theory, where tissue factor,
also called thromboplastin (or thrombokinase), converts ProT to thrombin in the presence
of calcium ions. Later, the activated thrombin converts fibrinogen into a meshy clot called
fibrin. This four-factor theory was accepted for 50 years.4,11 However in 1947 based on a
natural clotting defect, Owren put an end to the classical theory by concluding that normal
plasma needs another factor to complete the action of thromboplastin. Further research led
to the discovery of factor V (Proaccelerin).12 Later, additional natural clotting defects led
to the discovery of factors VII and X (Stuart-Prower factor). At the same time, a
phospholipid environment was identified as being important in the conversion of
prothrombin to thrombin. Biggs, Douglas, and Macfarlane demonstrated that haemophilic
blood cannot produce fibrin.13,14 They also showed that fibrin production can be triggered
by adding antihaemophilic globulin that was later found to contain factor VIII
(Antihaemophilic factor).15-18 Characterizing several other clotting deficiencies led to the
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discoveries of clotting factors IX (Christmas factor), XI (PTA, Plasma Thromboplastin
Antecedant) and XII (Hageman factor). Laki and Lorand partially purified a fibrinstabilizing factor which is now called factor XIII.19 Chen and Doolittle subsequently
identified that factor XIII has transglutaminase activity and is responsible for the formation
of cross links between fibrin monomers.20
In 1964, Macfaralane incorporated the newly discovered proteins into an updated
blood coagulation cascade.11 He classified the cascade into two pathways: Intrinsic and
Extrinsic. As the name suggests, the intrinsic pathway is triggered by the components
which are already present in plasma. For the extrinsic pathway to occur, it requires
exposure of tissue factors on the damaged cell wall. A clearer picture of caoagulation
evolved over time.

Intrinsic pathway
Upon encountering a negatively charged surface such as a membrane, Factor XII
(FXII) in the presence of cofactor High Molecular Weight Kininogen HMWK or HK gets
activated to FXIIa. The letter “a” indicates that FXII has been activated. The minute
amounts of FXIIa produced then use HMWK as an anchor to convert prekallikrein to
kallikrien. Newly formed kallikrien acts as a positive feedback to accelerate FXIIa
production. FXIIa then proteolytically cleaves FXI to form FXIa consecutively forming
FIXa from FIX with HMWK as a cofactor. A complex called “tenase” consisting of
FVIIIa, FIXa, Ca+2, and phospholipid membrane next converts FX to FXa. Finally, FXa
with the help of cofactor FVa and in the presence of Ca+2 and phospholipid membrane
forms a complex called “prothrombinase” which converts prothrombin (II) to thrombin
(IIa) (Figure 1).21
3

Extrinsic pathway
The extrinsic pathway is initiated by the formation of a complex between FVII and
TF (Tissue Factor). Tissue factor is a receptor for FVII and is located on cell surfaces.
Whenever there is an injury to endothelium cells, FVII encounters TF and is
nonproteolytically activated to FVIIa. Activated FVII proteolytically activates FIX, which
accelerates the function of the tenase complex leading to the formation of FXa. With the
formation of FXa, the prothrombinase complex is established leading to the formation of
FIIa from FII. Biochemists have debated whether the extrinsic pathway is more
physiologically relevant than the intrinsic pathway. Published results have provided
evidence that even in the absence of FXII, the time taken for clot formation is not changed.
Both the intrinsic and extrinsic pathways merge at a common point where FX is
converted to FXa from the tenase complex. FXa is then the first factor to trigger the rest of
the cascade. As mentioned earlier, FXa is a key component of the prothrombinase complex
that is responsible for thrombin (FIIa) formation. The resultant serine protease thrombin
converts freely flowing fibrinogen into a fibrin network. This fibrin network is later
susceptible to proteolysis by plasmin. To maintain complete hemostasis, FIIa converts
FXIII to FXIIIa, which covalently cross links fibrin monomers into a hard clot.
Interestingly, the production of thrombin acts as a positive feedback by helping to activate
cofactors FV and FVIII.21,22

4

(Intrinsic Pathway)

(ExtrinsicPathway)

Figure 1: Blood coagulation factors are shown as Roman numerals. The letter “a” after the Roman
numerals denotes the active form of the factor. Other abbreviations include: HK-High Molecular Weight
Kininogen, Ca-Calcium ion and PL-phospholipid. The common final pathway for both extrinsic and
intrinsic pathways is the formation of Xa and Va.

Modern blood coagulation and the importance of platelets
None of the above-mentioned pathways indicated the importance of platelets. From
1996 to 2001, several changes were made to generate a more general Modern Blood
Coagulation Cascade (Figure 2).23

The updated viewpoint involved three steps: a)

Initiation b) Amplification, and c) Propagation. The initiation step involves exposure of
Tissue Factor (TF) on injured endothelium cells and formation of a complex between FVIIa
and TF. This assembly leads to generation of minute amounts of FIXa and FXa. FXa on
the TF bearing cell accumulates the prothrombinase complex components to convert
prothrombin (II) to thrombin (IIa). Later in the amplification stage, the small amount of
thrombin that is formed in the initiation stage activates platelets, thereby exposing receptors
for clotting factors to adhere on to platelets. The activated platelets slowly expose FVa and
5

FVIIIa which leads to positive feedback for higher amounts of thrombin generation.
Meanwhile, platelet adhesion starts to develop to initiate the propagation step. A burst of
thrombin production occurs during the propagation step. TF bearing cells sequentially
activate FIX, FX, FVIII, and FV leading to the formation of thrombin in higher amounts.
The resultant active thrombin finally converts fibrinogen to fibrin.23,24

Figure 2: A) Initiation- TF on endothelium cell is exposed. FVIIa and TF interacts leading to the formation
of IXa and Xa and minute amounts of FIIa. B) Amplification- Thrombin activates platelets, cofactors V and
VIII and exposes various receptors on platelet surfaces. C) Propagation- platelet adhesion increases, factors
IX, XI, X and VIII are activated to trigger thrombin burst which leads to the conversion of fibrinogen to
fibrin.

Anticoagulation
To control the growth of unwanted thrombi in normal vascular areas, the
anticoagulant pathway is triggered. Three anticoagulants that terminate the coagulation
cascade are antithrombin (ATIII), Protein C, and Protein S.25 ATIII in the presence of
heparin inhibits the activities of serine proteases like FIIa, FIXa, FXa, FXIa, and FXIIa
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Thrombomodulin (TM) when bound to endothelial cells accelerates the thrombin
activation of Protein C by several thousand-fold. Protein C with the help of Protein S inhibit
cofactors FVa and FVIIIa.26,27 Finally, Tissue Factor Pathway Inihibitor (TFPI) forms a
complex with FXa and TF/FVIIa to hinder the start of the extrinsic pathway.

Fibrinogen
Fibrinogen (340 kDa) is an abundant glycoprotein composed of a dimer of
nonidentical polypeptide chains (A, B and )2. This protein is 450 Å long and is held
together with several disulfide linkages (Figure 3A).1,6 The fibrinogen dimer of trimers is
sigmoidal in shape due to the following features. The N-termini of all six polypetides merge
together to form a central globular “E” region. The C-termini of three chains meet at a point
forming a globular “D”. This region is mainly composed of B and  chains.28,29 During
fibrin formation, adjacent knobs in the “E” region make favorable contacts with the holes
in the “D” region which increases the stability of fibrin. An interesting feature of the A
chain is its C-terminus. It is a long flexible coiled-coil which ends with the C domain.
The C regions (C-connector and C-domain) are not detected by X-ray crystallography
and are considered as free-swimming appendages of fibrinogen. The C domains associate
to form a dimeric domain near the central E region (Figure 3B).5,30 Fibrin clot stability
and mechanical stiffness is improved when C is crosslinked by FXIIIa.31 This flexible
C region is susceptible to lysis by the actions of plasmin.32
Another interesting feature of fibrinogen is the presence of 11 Asparaginyl- linked
carbohydrates. Deglycosylation leads to an increase in the acceleration of fibrin formation,
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however, desialidation resulted in the same rates of polymerization. Thus, it is the
electrostatic charge effect that drives or dominates the events of polymerization.33

A
D-region

-chain

E-region

-chain

D-region

-chain
-chain

-chain

-chain

B

Figure 3: A) Fibrinogen ,  and  are represented in blue, green and red. The cartoon includes coiledcoil connecting central E region and terminal D regions. Flexible C and carbohydrates not shown. This
cartoon is generated in Pymol through PDB code 3GHG. B) Fibrin clot formation is initiated by the
cleavage of FpA leading to the formation of protofibrils, next the cleavage of FpB results in lateral
aggregation of fibrin. Finally, FXIIIa imparts isopeptide bonds between two fibrin molecules thereby
stabilizing fibrin architecture. Cartoon was adapted from Weisel, J.W. (2007).

The initial step of fibrin formation is triggered by the release of Fibrinopeptide A
(FpA) by thrombin. Thrombin cleaves at the Arg16-Gly17 peptide bond of Fbg Aα, leading
to the formation of protofibrils. This reaction is followed by thrombin cleavage of
8

Fibrinopeptide B (FpB) at the Arg14-Gly15 peptide bond. Release of these two N-terminal
peptides within the central E region accelerates the lateral aggregation of fibrin (Figure
3B).30 Activated FXIII (FXIIIa) is then responsible for the introduction of covalent glutamyl--lysine cross-links between the fibrin molecules.34,35 These cross links make the
fibrin clot stiffer and less susceptible to fibrinolysis. Interactions observed in the crystal
packing of human fibrinogen are end-to-end interactions between C domains, lateral
antiparallel interactions between C, and antiparallel association of coiled-coil regions. A
and B knobs of the central E region are buried in C and C holes.33,36

Thrombin
The serine protease thrombin is originally produced as the 72 kDa zymogen,
Prothrombin (ProT). ProT is a Vitamin K-dependent protein composed of Fragment-1 (1155), Fragment-2 (156-271) and a protease domain (272-579). Fragment-1 contains a Gla
domain (which contains 10 γ-carboxyglutamates) and disulfide containing Kringle-1.
Fragment-2 contains a second disulfide containing Kringle-2, and the protease domain
contains the A chain (272-320) and the catalytic B chain (321-579).37

ProT is

physiologically activated by the prothrombinase complex consisting of the serine
proteinase Factor Xa and the cofactor Factor Va, a phospholipid membrane, and Ca2+. ProT
is anchored to the membrane surface through the Gla domain of Fragment 1 (F1). The
membrane-associated prothrombinase complex can first be cleaved at ProT R320 leading
to formation of an active intermediate Meizothrombin or cleavage at ProT R155 to form
another inactive intermediate called Prethrombin-1 (PT1) (Figure 4). In platelets, cleavage
of ProT at R271 leads to the formation of the inactive precursor Prethrombin-2 (PT2) and
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Fragment 1.2 (Gla, Kringle 1, and Kringle 2). Subsequent cleavage at R320 gives rise to
the active protease thrombin (36.7 kDa). (Figure 4, 5).38-40 Autolysis of α-thrombin
generates β-thrombin. Further autolysis leaves γ-thrombin.41

Figure 4: Schematic representation showing cleavages that occur in the conversion of
prothrombin to meizothrombin or prethrombin-2 and then to thrombin. Autolysis leads to βthrombin and then to γ-thrombin (Straight numbering is presented for β and γ- thrombin).

Figure 5: Surface structures of A) Prothrombin (4HZH), B) Prethrombin-2 (1MKX), C) Thrombin
(1PPB). Active site is represented in yellow color. Anion Binding Exosite I and II are represented in
green and blue colors. A-chain oriented in the back is in red, Autolysis Loop is in purple. All the structures
were generated with Pymol.
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α-thrombin is highly homologous to serine proteases such as trypsin and
chymotrypsin with His 57, Asp 102 and Ser 195 (chymotrypsin numbering) forming the
catalytic triad of the active site (Figure 6). Hydrolysis of the R-X or K-X substrate bond
occurs by the mechanism shared with trypsin, chymotrypsin, and other serine proteases.
This mechanism is shown in Figure 7. A nucleophilic attack of Ser 195 on the carbonyl
atom of the scissile peptide bond initiates the reaction. As the carbonyl rearranges to give
an acyl-enzyme intermediate, the new N-terminus of the hydrolyzed peptide chain is
released. A water molecule enters the active site and participates in the reverse sequence,
releasing the new C-terminus of the hydrolyzed substrate and regenerating the active
enzyme.42,43
Thrombin enzyme specificity is controlled through several loops including the 60s
loop (or β insertion loop), autolysis loop (or γ loop), and the 220s loop (or Na+ binding
loop) (Figure 6). The presence of prolines, tryptophans, and tyrosines in the β-insertion
loop serves as a rigid hydrophobic cap over the active site and mediates contacts with the
hydrophobic substrate residues N-terminal to the scissile bond.37 The autolysis loop is
more hydrophilic and flexible in nature and makes contact with residues C-terminal to the
active site thereby influencing the substrate specificity. A third important loop (220s loop)
contains a site for Na+ binding, which controls the activities of thrombin and is important
for considering allostery. Na+ bound thrombin is denoted as “fast” thrombin and whereas
the Na+ free enzyme is denoted as “slow” thrombin. The chymotrypsin numbering is
followed for thrombin.44-46 For example, the 9-residue insertion between thrombin residues
60 and 61 is known as the Trp60s insertion loop. Residue 60 is followed by 60a, 60b, 60c,
and so forth until residue 61 is reached.

11

Figure 6: PDB structure of Thrombin (1PPB). Active site (His 57, Asp 102 and Ser 195) is
represented in yellow color. Anion Binding Exosite I and II are represented in green and blue colors.
A-chain oriented back is in red,60 Loop is in cyan, Autolysis Loop is in purple.

Figure 7: The Serine Protease Mechanism. Product from second reaction is the acyl
intermediate.
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Apart from the insertion loops, thrombin specificity is also dictated by secondary
anchoring sites called exosites. Anion Binding Exosites I and II are rich in positively
charged residues and are located on the opposite sides of the active site.47,48 Residues from
ABE-I include F34, K36, R67, R75, R77a, K81, K109, K110, and K149e. Ligands that
bind to ABE- I include the Protease Activated Receptors PAR1 (49-62)49 and PAR3 (4456),50 and the leech derived thrombin inhibitor Hirudin (54-65).51 Residues from ABE-II
include R93, R97, R101, R126, R173, R175, R233, K235, K236, and K240. Ligands
binding to ABE-II include glycoprotein GpIbα (269-286),52 fibrinogen γ´(410-427),53
another leech derived thrombin inhibitor Haemadin (45-57),54 and heparin.55 X-ray crystal
structures shown below display the binding modes of PAR3 and GpIbα ligands to their
respective exosites is shown below (Figure 8):

B

A

Figure 8: Ligands bound to thrombin A) PAR3 (44-56) B) GpIbα (269-286), PDB structures
include 1P8V for GpIbα and 2PUX for PAR3. Anion Binding Exosite I and II are represented
in green and blue colors. GpIbα (269-286) is depicted in orange sticks, PAR3 (44-56) is depicted
in blue sticks.

Published literature supports the hypothesis that communication is possible
between the exosites and with the catalytic center.56-59 Amide hydrogen/deuterium
exchange coupled with mass spectrometry revealed that ligand binding at the exosites
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promoted both local and long-range effects, but the ligands did not exhibit identical
conformational changes to thrombin.60 When considering ABE I ligands, Hirudin could
show local effects but PAR3 and PAR1 showed both local and long-range effects. Turning
to ABE II ligands, GpIbα and fibrinogen γ´ could both show local and long-range effects.60
The substrate amino acid sequence on the N-terminal side of the scissile bond
makes significant contributions to thrombin binding and hydrolysis rates. The P
nomenclature system (P3 P2P1P1'P2'P3') is used to assign the individual amino acid
positions on the substrate peptides.61 The scissile bond is designated as P1-P1'. The serine
protease thrombin specifically cleaves after arginine or lysine residues located at the P1
position. A deep active site cleft accommodates the positively charged side chains of R and
K. Sequences of some thrombin substrates and an inhibitor are shown in Table 1.
Table 1: Substrate sequences that target thrombin active site region.  indicates the
cleavage between R-X bond.
_______________________________________________________________________
P3P2P1 P1'P2'P3'
28T

V E L Q G V V P R G V N L41

Fibrinogen Aα (7-20)

7D

F L A E G G G V R G P R V20

Fibrinogen Bβ (5-16)

5D

N E E G F F S A R G H

PAR1 (29-45)

29K

Factor XIII (28-41) V34 AP

PAR4 (38-51)

38S

A T N A T L D P R S F L L45
T P S I L P A P R G Y P G51
D-F P R-ck

PPAck

________________________________________________________________________
Human sequences were taken from the following sources: PPAck is D-phe-Pro-Arg-chloromethylketone,37
Factor XIII, 62 Fibrinogen Aα and Bβ chains,63 and thrombin receptors PAR164 and PAR465.
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Interactions between thrombin and PAR1 (38LDPR41) are shown in Figure 9. The
Arg 41 residue at the P1 position forms a salt bridge with thrombin D189, Pro 40 at P2
makes extensive IIa contacts (Y60a and W60d), P3 does not necessarily contact thrombin,
and Leu 38 at P4 contacts the aryl binding pocket (L99, I174, and W215).66

P4P3P2P1

Figure 9: Thrombin receptor PAR1 segment 38LDPR41 bound to thrombin, PAR1 can
accommodate thrombin’s active site effectively with the P 1-P4 residues. PDB code 1NRS.

Fibrin-stabilizing factor: FXIIIa
Transglutaminase FXIIIa is involved in crosslinking the fibrin monomers that are
generated by thrombin cleavage of fibrinogen. The major crosslinking sites include the γγ and α-α contacts that are crucial for stabilizing the fibrin clot structure. FXIIIa also
crosslinks clot stabilizing proteins like α2-antiplasmin and Plasminogen Activator Inhibitor
1 (PAI1) to protect the clot from premature lysis. Besides its role in blood coagulation,
15

FXIII has also been identified as an important enzyme in maintaining pregnancy, vascular
permeability, bone biology, and wound healing.67
In plasma, pFXIII exists as a hetero tetramer, consisting of two catalytic A subunits
and two carrier B subunits (FXIIIA2B2) (Figure 10A). The FXIII- A subunit contains an
activation peptide- AP (1-37), a - sandwich domain (38-184), a catalytic domain (185515), and two -barrel domains (516-628, 629-731) (Figure 10B).68 V34L is a notable
polymorphism within the AP region which seems to have cardioprotective functionality.69
The FXIII- A subunit has 9 cysteine residues, and among them is Cys314 a key residue of
the catalytic traid. C314, along with H373 and D396, form the FXIII active site. The Cys
314 residue is protected from the solvent by the FXIII AP. This thiol amino acid is also
hydrogen bonded with Tyr 560. None of the 9 cysteine residues form disulfide linkages.
Arg260 of one FXIII monomer is involved in a salt bridge with Asp404 of another
monomer. Asp 11 of one FXIII AP forms a salt bridge with Asp 343 on the opposite
monomer, thereby demonstrating how the AP of FXIII covers the active site. The FXIII-B
subunit is a glycoprotein consisting of 10 sushi domains held together by disulfide bonds.
The FXIII B subunits protect the catalytic FXIII A2 from degradation and premature
activation.70,71
During the activation of plasma FXIII A2B2, thrombin first cleaves the FXIII A2
activation peptides between Arg37-Gly38. In the presence of Ca+2 ions, the regulatory/
carrier FXIII- B subunits dissociate from FXIII-A. The resultant FXIII-A subunits undergo
conformational change to create active FXIIIa. In the cellular form found in platelets,
cFXIII is only a dimer of A subunits. cFXIII can be activated by thrombin in the presence
of low mM Ca+2 ions or nonproteolytically with high mM Ca+2 ions (Figure 11).72 Recently
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analytical ultracentrifugation (AUC) and size-exclusion chromatography studies revealed
that the FXIII A2 dimer becomes monomeric following both proteolytic and nonproteolytic
activation.73

B

A

Figure 10: A) structure of cellular FXIII A2 subunit rendered in surface model. Catalytic domain shown
in light turquoise, - sandwich is in blue, - barrel 1 and 2 shown in light and dark green colors. B)
structure of cellular FXIII A2 subunit rendered in ribbon model. Catalytic domain shown in light
turquoise, - sandwich is in blue, - barrel 1 and 2 shown in light and dark green colors. Other A monomer
is shown in grey. Structure was generated with Pymol using PDB code 1GGU.

A

B

High mM Ca+2
90º flip

Figure 11: A) structure of catalytic A2 subunit. Catalytic domain shown in light turquoise, - sandwich is
in blue, - barrel 1 and 2 shown in light and dark green colors. Other A monomer is shown in grey. B)
Conversion of inactive FXIIIA2 to FXIIIa in the presence of high mM (40 mM) Ca+2 ion. Structure was
generated with Pymol using PDB codes 1GGU and 4KTY.
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Glycoprotein- GpIbα
To form the platelet plug during vascular injury, several receptors are involved in
platelet adhesion. GpIbα is an important platelet adhesion receptor that belongs to the
leucine-rich repeat family. Before the thrombin burst is generated, GpIbα binds to von
Willebrand factor on the endothelial cells lining the vasculature which accelerates platelet
activation. Activated platelets expose the procoagulant/ negatively-charged phospholipids
for attracting several coagulation factors to trigger the blood coagulation cascade.74-76
Other important ligands of this receptor include thrombin, FXIa, FXIIa, and High
Molecular Weight Kininogen (HMWK). By interacting with these ligands, GpIbα plays an
important role in maintaining hemostasis. This glycoprotein also contributes a role in
inflammation through leukocyte recruitment to fight infection. The absence or low
expression of GpIbα leads to a severe bleeding disorder called Bernard-Soulier
syndrome.75,77 There are two unique features of the GpIbα receptor. The N-terminus (1267) has the Leucine-Rich repeat (LRR) which is responsible for curvature of the protein,
whereas the C-terminus has a highly anionic cluster (269- 286) that is responsible for
binding several clotting factors (Figure 12A and B) including thrombin.52
The present research mainly focuses on interactions of GpIbα (269-286) with
thrombin. The C-terminal region of the N-terminal fragment (1-290) is rich in anionic
residues (269DEGDTDLYSDYSYSPEEDTEGD287) and includes three sulfated tyrosines. In
biochemical studies, the sulfated tyrosines are often replaced with phosphorylated
tyrosines. X-ray, solution NMR, and HDX-MS studies proved that the anionic cluster of
GpIbα (269-286) binds to ABE II of thrombin.78,79 Through HDX-MS studies, Malovichko
et al., showed that GpIbα (269-286) containing up to 3 phosphorylated tyrosines bound to
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thrombin ABE II and can allow for inter-exosite communication over to ABE I.60
Additional studies demonstrated that the presence of GpIbα increases thrombin- catalyzed
hydrolysis of PAR1 (38-60). Such results provide evidence that binding of GpIbα (269286) can influence binding and hydrolysis of substrates at the active site.80.

B

A

Figure 12: A) Ribbon structure of GpIbα (1-267). N-terminus is in blue, LRR is in green, and
C-terminus is in purple. B) von-Willebrand factor shown in cyan (478- 705) is complexed at the
C-terminus region. Structures were generated with Pymol using PDB codes 1MOZ and 1M10.

Protease Activated Receptors (PARs)
Platelets play an important role in hemostasis, inflammation, angiogenesis, and
cancer metastasis. At the site of vascular injury, platelet accumulation, activation, and
aggregation are quite essential to prevent major blood loss. Platelet activation can be
mediated through the small family of G-protein coupled Protease Activated Receptors
PARs. PAR1, PAR2, PAR3, and PAR4 have been identified. PAR1, PAR3, and PAR4 are
activated by thrombin whereas PAR2 is activated by trypsin, FVIIa, and FXa.64,81,82
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Human platelets use PAR1 and PAR4 to trigger platelet secretion and aggregation. In
contrast, murine platelets express PAR3 and PAR4 for platelet activation and
accumulation. In humans PAR3 is known to play a regulatory role in megakaryocytic and
endothelial cell development.83
Thrombin cleaves the N-terminal extracellular domain of PARs at a specific R-X
peptide bond leading to the formation of a tethered ligand which intramolecularly binds to
the body of the receptor to elicit transmembrane signaling (Figure 13).82 However, the
complete mechanisms for the transmembrane signaling of all PARs are not yet known.
N
N

IIa

IIa
N

Plasma membrane

C

Plasma membrane

G

G

C

C
Associated G protein

Free G protein

Figure 13: Mechanism of activation of PAR1. Thrombin is visualized as green sphere, identifying Nterminal exodomain. Thrombin cleaves at R41-S42 to produce a new tethered ligand to elicit
transmembrane signaling. Picture was adapted from Coughlin, S.R (2000).

Thrombin cleavage site
Hir
30

h PAR1
m PAR1
h PAR3
m PAR3
Hirudin

40

WEDEE

50

60
60

ARRPESKATNATLDPRSFLLRNPNDKYEPF-WEDEE-------MSQPESERTDATVNPRSFFLRNPSENTFELVPLGDEEEEE
MENDTNNLAKPTLPIKTFRGAPPN---SFEEFPFSALE-----GINVSDNSAKPTLTIKSFNGGPQN----TFEEFPLSDIE------TGEGTPKPQSH----NDGDFEEIP-EEYLQ
׀
SO42-

Figure 14: Sequence comparison between human and murine versions of PARs. Picture shows the
Thrombin cleave site (yellow), and hirudin- like sequence (purple and cyan) binds at ABE-I of
thrombin
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Located beyond the thrombin cleavage sites, PAR1 and PAR3 both contain hirudinlike sequences.49,50,84,85 Hirudin is a leech derived inhibitor that utilizes a DFEEI sequence
to anchor on to thrombin ABE I. Human and murine versions of PAR1 and PAR3 also
contain segments with highly anionic residues (51KYEPF55 in PAR1 and
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TFEEF50 in

PAR3) that target ABE I (Figure 14).84 These residues help increase the affinities of PAR1
and PAR3 for thrombin. PAR1 is the best substrate for thrombin in terms of kcat/Km. In
murine models, PAR3 acts as cofactor for PAR4 activation at low thrombin concentration.
PAR3 has been documented to dimerize with PAR4 for further transmembrane signaling.86

Physiological relevance and research goals
25% of deaths worldwide are due to ischaemic heart disease and strokes. Being a
global disease burden, this health issue attracted many biochemists to decipher the
mechanism involved in hemostasis.87 Hemostasis is an important physiological process to
control the unwanted loss of blood during trauma. The three-step process begins with
vasoconstriction of the blood vessel. Next, platelet plug formation to reduce the gap and
minimize the blood flow occurs. The last and most important step involves the 30 important
biomolecules that are part of the blood coagulation cascade.88,89 The coagulation factors
and cofactors work together to convert the liquid blood to an insoluble fibrin network
which is less susceptible to lysis.30 Imbalances in the blood coagulation pathway may lead
to deleterious effects like stroke, heart attacks, and pulmonary embolism. To control the
unwanted formation of blood clots, anticoagulation events are in place. Key features about
blood coagulation including the various factors involved in coagulation and
anticoagulation were described in detail earlier in this chapter. Therapeutic anticoagulants
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are administered to the patients when the physiological levels of natural anticoagulants are
not enough to elicit their functions. Several anticoagulant drugs have been developed and
new generation versions have been developed in recent years. Some intriguing therapeutic
strategies are currently being developed to reduce the side effects of anticoagulants and to
actually reverse the anticoagulation event.90
A few blood coagulation factors utilize a Gla domain to anchor on to a phospholipid
membrane. This Gla domain contains the specialized amino acid γ-carboxy glutamate that
is generated with the help of Vitamin K. Vitamin K antagonists acts as competitive
inhibitors, hindering the the formation of the Gla residue and thus hindering zymogen
activation. Dicoumarol and its synthetic analog Warfarin are the most famous Vitamin K
antagonists. They inhibit the redox step of the Vitamin K cycle and hamper the generation
of vitamin K, and thus induce their anticoagulation activity. A well-known side effect in
patients administered Vitamin K antagonists is excessive bleeding.91
Heparin is another anticoagulant that is administered to patients with cardiovascular
abnormalities. Heparin is known to promote conformational changes to Antithrombin III.
The properly oriented antithrombin-heparin complex then binds to factors Xa and IIa to
hinder their serine protease activities. However, heparin induces thrombocytopenia and
dysfunction of platelet activation. Heparin is also known to have non-specific plasma
binding effects. Because of these concerns, research slowly shifted towards targeting
specific factors and binding sites in blood coagulation.92
Factor X is a common factor of both the intrinsic and extrinsic pathways and is
involved in activating the final serine protease thrombin. As a result, several drugs are
available on the market which directly bind to the active site of Xa. Among them are
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Fondaparinux, Rivaroxaban, Apixaban, and Endoxaban. These drugs work more
efficiently than Vitamin K antagonists and heparin and have fewer side effects. However,
a critical issue concerned with FXa inhibitors is the lack of an antidote to reverse the
anticoagulant activity.93
Since thrombin is known to have more than a dozen substrates that are involved in
both coagulation and anticoagulation, extensive time has been dedicated toward
developing direct thrombin inhibitors. Three types of direct thrombin inhibitors are
available on the market. The first type is the univalent inhibitor which binds to the thrombin
active site and includes drugs like Argatroban, Melagatran, and Dabigatran. Like FXa
inhibitors, such IIa inhibitors do not have a universal antidote to reverse the anticoagulant
effect.94 Also, univalent inhibitors lead to coagulopathy. The second inhibitor type is the
bivalent inhibitor where the drugs take advantage of ABE I in addition to the active site to
improve affinity with thrombin. Bivalirudin is known to bind reversibly to thrombin and
bridge both the ABE I and the active site.95 However, the half-life of bivalirudin is low
due to spontaneous chemical degradation by proteases in the body.
Allosteric inhibitors are the third class of direct thrombin inhibitors and include
DNA96 and RNA aptamers,97 benzofuran dimers, benzofuran trimers, and heparin based
analogs.98 These molecules take advantage of ABE I, ABE II, and the sodium ion binding
loop. The best DNA aptamers are selected from a pool of nucleic acids through a technique
called “SELEX” (systematic evolution of ligands by exponential enrichment) to elicit the
anticoagulation activity.99 The SELEX approach is still evolving and might take several
decades to make a “druggable” form. Meanwhile, a non-enzymatic protein called
Bothrojaracin has been isolated from snake venom which binds to pro-ABE I of ProT and

23

blocks the thrombin activation.100,101 This venom protein is also known to compete with
ProT F2. Such an effect would indicate that bothrojaracin can also bind to ABE II of
thrombin. However, bothrojaracin is known for its toxicity.
A few antagonists targeting the physiological substrate ligands have also been
developed. PAR targeted therapy is taking shape to inhibit PAR activation and platelet
aggregation. RWJ-56110 acts as antagonist to PARs which not only blocks platelet
aggregation but also hinders PAR1 and PAR4 dimerization responsible for several
signaling events.102,103
Keeping these different anticoagulant functionalities in mind, researchers will want
to develop future drug candidates that regulate hemostasis with fewer side effects and
enable reversal of their functionalities with effective antidotes. Considering this big picture
and the use of (pro)thrombin as the drug target, we wanted to better understand the
conformational changes of the active site region and the (pro)-ABEs of (pro)thrombin that
lead to different physiological processes. Understanding different conformations of
biomolecules can help develop novel therapeutics that target specific hot spots on
(pro)thrombin. Also, binding affinities between the drug and its binding partner plays a key
role in improving the efficacy. Probing the binding affinities of individual residues within
the physiological peptide ligand will be a big asset for developing better therapeutics.
Hence, the dissertation is divided into the following chapters. Chapter 2 mainly
focuses on different techniques employed in this research and includes the theory behind
1D proton line broadening, 2D TOCSY, 2D tr-NOESY, and 2D HSQC. These solution
based techniques are used as complementary methods to X-ray crystallography to evaluate
different conformations and binding interactions involving (pro)thrombin and PARs. Also,
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the principle behind ITC (Isothermal Titration Calorimetry) is explained as it is used as a
supplementary technique to evaluate the global KDs between two binding partners. Chapter
3 then emphasizes on how a PAR based ligand (PAR3) probes exosite maturation at single
amino acid levels. This chapter will also include the quantitative measurements of binding
affinities of 15N- labeled PAR3 amino acids towards zymogen ProT vs mature thrombin.
As a continuation of this study, Chapter 4 discusses the comparative studies between the
binding affinities of two PAR based ligands (PAR1 and PAR3) towards (pro)-exosites. The
most striking segment in this chapter is further proof of allosteric communication between
exosites ABE I and ABE II. Chapter 5 describes the thrombin catalyzed hydrolysis of Fbg
Bβ (5-16) and compares the kinetic parameters with common substrates of thrombin. In
addition, 1D and 2D solution NMR results are used to explain secondary structural
information for the thrombin bound FpB (5-14) and the weak kinetics associated with
thrombin- catalyzed release of FpB (5-14). As a wrap up, Chapter 6 includes a summary
of all the different research projects, some new preliminary results attained so far, and
possible future directions for the above discussed research projects.
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CHAPTER II
EXPERIMENTAL TECHNIQUES

NUCLEAR MAGENTIC RESONANCE (NMR)
Nuclear Magnetic Resonance (NMR) examines the magnetic properties of such
nuclei as the proton (1H), the carbon 13 isotope of carbon, and the nitrogen 15 isotope of
nitrogen. Unlike some other biophysical methods, NMR is a non-destructive technique
which enables us to deduce the positions of the nuclei within the molecule, identify
different types of environments, and assess the types of atoms within the molecule.104
Any charged particle that spins behaves like a tiny bar magnet, and it generates
a magnetic field. The proton in the hydrogen atom being a charged particle also behaves as
a tiny magnet, generating its own magnetic field. In the presence of an external magnetic
field, the spin ½ proton can adopt two orientations with respect to the applied magnetic
field. One is the lower energy state where it aligns with the magnetic field, and the other is
the higher energy state, opposing the magnetic field. The spinning proton can move under
the influence of the external magnetic field. A spinning proton can be considered as a
spinning top. If the spinning axis is not parallel to the applied magnetic field it will precess
around the axis of the external field (Figure 15). The precessional frequency ν, is directly
proportional to the strength of the external magnetic field B0. When nuclei are irradiated
with radiowaves whose frequency is the same as the precession frequency, the spinning
26

axis is tilted away from the axis of B0. If the radio frequency field is pulsed on for a time
such that the spinning axis and the magnetic field axis are perpendicular, the pulse is known
as a 90º pulse.

opposed

High energy

E

ΔE = hν

aligned

Low energy

B0
Figure 15: Types of orientation a precessing nuclei can adopt in presence of external magnetic field.

ν ∝ B0
𝛾𝐵
𝜈 = 2𝛱0

(1a)
(1b)

γ is the gyromagnetic ratio between the nuclear magnetic moment μ and the nuclear angular
momentum I. The ν values for a few magnetic nuclei with different field strengths is given
in Table 2.105
Table 2: Precessional frequencies (in MHz) as a function of field strength (Tesla).105
B0 (Tesla)
1.4
1.9
2.3
4.7
7.1
11.7 14.1
________________________________________________________________________
Nucleus
1
H
60
80
100
200
300
500
600
2
H
9.2
12.3
15.3
30.6
46.0
76.8 92
13
C
15.1
20.1
25.1
50.3
75.5 125.7 151
15
N
6.1
8.1
10.1
20.3
30.4
50.7
61
19
F
56.5
75.3
94.1 188.2
288.2 470.5 565
31
P
24.3
32.4 40.5
81.0
121.5 202.4 243
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When the nuclei precess, they emit radiowaves, which can be recorded by a
radiofrequency detector. However, there can be two types of radiationless mechanisms for
a high-energy state nucleus to lose (relax) energy.104 The first type of relaxation is the
spin-lattice relaxation or longitudinal relaxation with time constant T1. In this process, the
nuclei transfer energy to the surrounding lattice. Surrounding molecules can be from the
solvent or from the same molecule. The second type of relaxation is spin-spin relaxation
or transverse relaxation with time constant T2. Here, the energy is transferred to
neighboring nuclei. In this mechanism, one nucleus loses energy whereas another nucleus
gains energy and hence both nuclei are coupled. In protons, spin-spin relaxation is the
predominant way for radiationless energy transfer.105
Molecular weight plays an important role in dipolar coupling. The rotational
correlational time (τc) is the time required for a molecule to rotate 1 radian, which is
proportional to the size of a protein and the viscosity of the solution. τc is 1nsec /2.6 kDa
of protein mass at T= 300 K. Thus, a smaller protein can fluctuate/tumble (ωτc <<1) more
rapidly than a larger protein (ωτc >>1), where a is the radius of the protein, and η is the
viscosity
𝜏𝑐 =

4𝛱𝜂𝑎3
3𝑘𝑇

(2)

The rates of relaxation are important. They determine the width of the NMR peaks.
If both T1 and T2 are small, the lifetime of the high energy nucleus is short and will lead to
broad spectral lines. If both T1 and T2 are large, then sharp spectral lines can be seen. The
uncertainty principle can give us a qualitative relation between relaxation time and
frequency spread in NMR spectra. If Δt (life time of particular energy state) is large, Δν
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(frequency) must be small, which means the frequency spread is small thus leading to
narrow lines. By contrast, if Δt is small, the large Δν will result in large spread of
frequency.105
ℎ

𝛥𝐸 ∗ 𝛥𝑡 ~ 2𝛱
as E = hν
1
𝛥𝜈 ∗ 𝛥𝑡 ~ 2𝜫

(3a)
(3b)
(3c)

Proteins in solution are highly dynamic. Folded proteins reorient due to rotational
diffusion. In addition, proteins can have internal degrees of flexibility. Different
conformations can lead to different protein functions. A protein can be defined as an
ensemble of different conformations that sample between various spatial and temporal
scales ranging from nanometers to micrometers and femtoseconds to hours. In short,
proteins are highly “dynamic molecules”. NMR provides the greatest advantage to study
different structural changes ranging from bond breakage/formation to domain motions
which fall within a time scale from 10-15 secs to 103 secs. Figure 16 provides a range of
timescales enabling various biological functions.106
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Figure 16: Protein conformational changes over a broad range of timescales. Adapted
from Kleckner I.R. et al. (2011)
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The remainder of this chapter focuses on 2D TOCSY, 2D tr-NOESY, and 2D
HSQC experiments and how these NMR techniques can be used to obtain structural
information about a protein or the ligand. Any 2D NMR experiment requires four essential
steps. The first step is recovery, during which spins return to equilibrium. This phase
typically ranges from 0.5-5.0 secs. Exciting the first spin type (let suppose A) by applying
a single 90º pulse will end this phase. The second phase is the evolution period (t1) which
can encode the chemical shift of A. This period measures the A chemical shift indirectly
i.e., it is not directly detected by the receiver coil. This evolution phase ranges from 0-5
secs. In the third phase, the magnetization of A spins is transferred to coupled B spins. The
coupling is either J-coupling or dipolar coupling. The fourth and final phase is the detection
period, where the FID of B spins is observed directly. This period ranges from 50-200 ms.
These four steps are typically repeated 2 to 32 times to increase the signal to noise ratio
several fold (Figure 17).106
Evolution

Detection

t

t1
Preparation

Mixing

Figure 17: General pulse sequence of 2D- NMR.

2D TOCSY (Total Correlation Spectroscopy)
2D TOCSY is used to identify networks of spins that are scalar coupled.
Spectra from this homonuclear experiment reveal the cross peaks between spins which are
connected by bonds. The TOCSY pulse sequence involves a 90º pulse in the beginning, a
frequency labeling time t1, followed by series of 180º (∏) pulses during which scalar
coupled spins exchange magnetization. This pulse sequence is then followed by detection
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of the FID. 2D transformation of the data table shows both diagonal and off diagonal peaks.
The off diagonal peaks correlate scalar coupled spin pairs(Figure 18).105

Mixing time (τmix)

90x

t1

∏ ∏ ∏

∏ ∏

∏ ∏ ∏

∏

t2

Figure 18. Pulse sequence of 2D TOCSY experiment.

Consider three different spins, A, B, and C. If spin A is coupled with spin B, and
spin B is coupled with spin C, then in the TOCSY spectrum one can see a cross peak
between A and C, even though there is no direct coupling between these two spins. In
Figure 19, black peaks correspond to cross-peaks between spins A and B due to 3J coupling,
orange peaks correspond to cross-peaks between spins B and C due to 3J coupling, grey
peak correspond to cross- peaks between spins A and C. Cross-peaks between A and C are
due to an unbroken chain of couplings. Green peaks on the diagonal indicate that they are
connected through bond.107
B

A

C

B

ω1

A

C

ω2
Figure 19: Schematic TOCSY spectrum for the three spins.
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2D tr-NOESY (2D transferred nuclear overhauser enhancement spectroscopy)
Nuclear spins also interact through space via dipolar coupling making it possible to
learn interesting structural information about a biomolecule. The magnitude of the dipolar
coupling depends on the strength of the magnetic field generated by one spin and the
magnetic moment of the other spin. If the cross-peak is seen between two dipolar coupled
spins which are spatially interacting, then it leads to the nuclear Overhauser effect and the
peak is referred to as an NOE. The NOE intensity is related to the distance “r” between
between two coupled spins which can be derived with the following equation. Ideally if
two spatially interacting protons are separated by a distance of less than 5 Å, then a NOE
can be observed.108
1

𝑁𝑂𝐸 ∝ <r6 > ∗ 𝑓 (𝜏𝑐 )

(4)

In the pulse sequence of an NOE experiment, a 90º-t1-90º pulse is used to frequency
label the spins and return the magnetization to the z-axis. Subsequently, dipolar coupled
exchange longitudinal magnetization occurs during the τm phase. The observed transverse
relaxation time is created by the final 90º pulse. Like the TOCSY experiment, 2D
transformation of the data table shows both diagonal and off diagonal peaks. Here, the offdiagonal peaks correlate to dipolar coupled spin pairs (Figure 20).104

90ºΦ1

90ºΦ2
τmix

t2 Φ3
90º

t1

Figure 20. Pulse sequence of 2D tr-NOESY experiment.
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For 2D tr-NOESY experiments, protein-ligand complexes are examined that
contain less than stoichiometric amounts of a large binding protein. A free peptide ligand
of up to 20 amino acids can tumble very fast in solution due to the absence of
conformational restraints. This property results in ωτc ≤1 and longer transverse relaxation
(T2) time. The 1D proton spectrum displays very sharp peaks and the 2D tr-NOESY will
have very few NOEs. Once the peptide binds to the protein, the conformations accessible
to the ligand become restricted by the geometry of the binding protein partner, and the
peptide becomes part of a larger protein-ligand complex. The peptide may also adopt some
secondary structure. These properties result in an increase in correlation time ωτc >> 1 and
a shorter T2 time. As a result, many NOEs (Figure 21)109-112

can be observed.

Intramolecular NOEs for the bound state of the peptide can be observed.
The use of 2D tr-NOESY for structural determination is based upon the assumption
that the ligand is under fast exchange conditions (higher kon and koff rates from the protein
surface). For a typical 2D tr-NOESY experiment, 10:1 ligand to protein ratios are preferred
to increase the exchange rates. Increased exchange rates will make it possible for the
peptide to associate and dissociate at least a few times during the NOE mixing time. During
this time, NOE information is transferred from the bound to the free state. Typically, a 100200 ms mixing time is employed to obtain sufficiently intense cross peaks that can be
correlated to inter- proton distances. If the ligand has relatively low exchange rates, then
changes to pH, ionic strength, or temperature can alter the exchange rates to enable the trNOESY experiments to reveal more productive information. Other modifications that can
alter the exchange rate include removal of phosphate groups from tyrosines or serines, and
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amidation of a C-terminal carboxyl group. Individual amino acid substitution within a
peptide ligand can also be used to alter the affinities of protein-ligand complexes.110

Figure 21: Cartoon showing NOE and 1D line broadening of free and bound form of PAR3 (44-56).

Ligand Binding Kinetics
Studying enzyme-ligand interactions through NMR is achieved through observing
the changes in chemical shift with respect to changing either protein or ligand
concentrations. These types of chemical shift changes fall under three regimes- fast,
intermediate, and slow exchange (Fig 22). For the fast exchange regime (kex >> |∆ω|), only
one signal is observed reflecting the population-weighted averages of chemical shift,
intensity, and linewidth. For the intermediate exchange regime (kex ≈ |∆ω|), only one signal
with anomalous peak broadening and an intermediate chemical shift is seen. Finally, for
slow exchange regime (kex << |∆ω|), signals from both states are observed reflecting their
distinct chemical shifts, intensities, and line widths. ∆ω = ωP – ωPL, where ∆ω is the change
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in resonance frequencies of nuclear spins calculated as a difference between the resonance
frequencies of free (ωP) and bound (ωPL) (Figure 22).106,111

(5)
kex = kon [L] + koff
Fast exchange

Free
Bound

Bound

(6)

Intermediate exchange

Free

Bound

Slow exchange

Free

Bound

Figure 22: Three different exchange regimes: Fast, Intermediate, and Slow regimes in 2D
and 1D NMR spectra.

The chemical shifts of homonuclear spins mostly overlap. To detect the correlation
between protons and their attached heteronuclear spins, heteronuclear J-correlated
spectroscopy is employed. HMQC (Heteronuclear Multiple-Quantum Coherence) and
HSQC (Heteronuclear Single- Quantum Coherence) are two methodologies that provide
this type of information. Our research has mainly employed 2D- HSQC to examine protons
that are directly attached to particular nitrogens or carbons. The HSQC pulse sequence
involves the transfer of magnetization from 1H to usually

15

N or

13

C through INEPT

(insensitive nuclei enhanced by polarization transfer). After a time delay of t1, the
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magnetization is transferred back to the proton through the retro-INEPT step. The 1H signal
is detected in the direct dimension, and the heteroatom 15N or 13C is detected in the indirect
dimension (Figure 23).104
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180x
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180x

90x

180x

180x

τ

τ

τ
90x

90x

t2

180x

15

N
t1

Decouple

INEPT

INEPT

Figure 23: Pulse sequence of 2D HSQC

Chemical shift peturbations (CSP) reflect the changes in chemical shift that occur to a
ligand or protein when the binding partner is added. These CSP provide a tremendous
wealth of information about the environment of the binding site, the binding affinity, and/or
possible structural features of the complex. For the current research, one use of CSP was
to calculate the binding affinities between the ligand and the protein. CSP can be recorded
for different nuclei like protons (1H), 13C, and 15N. The CSP for 1H are affected by several
factors including paramagnetic effects, magnetic anisotropy around bonds, aromatic ring
currents, and electrostatic field effects. Carbons are mainly affected by local dihedral
angles. Nitrogens and carbonyl groups depend on hydrogen bonding and on the identity
and side chain conformation of the preceding amino acid.113
CSP can be an asset in determining weak binding affinities if the protein-ligand kinetics
fall under the fast exchange regime. Under such conditions, there are often enough titration
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points in the Δobs versus the protein/ligand concentration plot to approach saturation and
thus obtain a more accurate KD value. Binding affinities are calculated using the equation
shown below, where KD is binding affinity, [L0] is the ligand concentration, [P0] is the total
protein concentration, and Δobs is the CSP between the free and bound form.106
Δobs = Δmax ∗

(KD +[L0 ]+[P0 ])−√(KD +[L0 ]+[P0 ])2 −(4[P0 ][L0 ])
2[P0 ]

(7)

ISOTHERMAL TITRATION CALORIMETRY (ITC)
Interactions between a series of biological molecules can lead to important biological
processes like immune response, signal transduction, and gene expression. It is therefore
important to know the nature of forces that help in stabilizing the individual interactions.
Isothermal Titration Calorimetry (ITC) is an excellent biophysical technique which not
only gives binding affinities KD but also gives information about the thermodynamic
parameters like free energy of binding (ΔG), enthalpy of binding (ΔH) , and stoichiometry
(n). The entropy of the system (ΔS) can be calculated from the well- known Gibbs
fundamental equation (Figure 24).114
ΔG = - RT ln Ka

(8a)

ΔG = ΔH – TΔS

(8b)

Figure 24: ITC binding curve. Picture taken from http://www.endocytosis.org
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An ITC instrument consists of two identical cells composed of a highly efficient
thermal conducting material, mostly hasteloy or gold, that is surrounded by an adiabatic
jacket. A sensitive thermopile/thermocouple detects the temperature differences between
the two cells and between the cells and the jacket. Heaters in both cells are activated when
there is a temperature difference between the cells. Furthermore, these heaters seek to
maintain identical temperatures between the two cells (Figure 25). In a typical ITC
experiment, the macromolecule is placed in the sample cell, whereas the reference cell has
either water or buffer. During the experiment, titrant will be injected into the sample cell,
and based upon the type of association, heat will be evolved or taken up. If the association
is exothermic, temperature of the sample cell will increase, and for an endothermic
reaction, the temperature will decrease. Over the course of an ITC experiment, there is a
time-dependent input of power applied to maintain equal temperatures in the sample and
reference cell.115,116

Cell feedback
heater

𝚫𝐓

Reference
heater

Calibr
ation
heater

Reference cell

Sample cell

Figure 25: Schematic diagram of an ITC experiment.

The isothermal titration calorimeter is an extremely sensitive instrument and utmost
care should be taken from sample preparation to data analysis. The experimental binding

38

isotherm can be characterized by a unitless value c (wiseman parameter), which is the
product of the association constant Ka, the macromolecular concentration [M], and the
stoichiometry n (Figure 26).117 A large c is seen for complexes where saturation is
achieved already at 2 or 3 injections of ligand. A smaller c occurs when the characteristic
sigmoidal curve is completely lost. For a single-site binding model, a c value between 10
and 500 is said to be optimal for curve fitting.118 The fitting process is erroneous if c < 10,
and finally it said to be not feasible if c < 1. For accurate measurements of affinities and
thermodynamic parameters 10 ≤ c ≤ 500 is preferable.

Normalized
heat

c = Ka*[M]*n

Mole ratio
Figure 26: Dependence of ITC binding curve on c value. Picture adapted from
Turnbull (2003).
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(9)

CHAPTER III
DECIPHERING CONFORMATIONAL CHANGES ASSOCIATED WITH THE
MATURATION OF THROMBIN ANION BINDING EXOSITE I

INTRODUCTION
Thrombin (factor IIa) is a multifunctional enzyme that plays critical roles associated
with procoagulation and anticoagulation. Procoagulant functions of thrombin include
activating other coagulation proteins (zymogen factors V, VIII, and XIII), converting
fibrinogen into fibrin that then polymerizes into a blood clot, and helping to activate
platelets by cleaving the protease-activated receptors (PARs). An important anticoagulant
function of thrombin is to activate protein C and thereby help inhibit a set of coagulant
proteins.47
Thrombin also has two anion binding exosites, ABE I and ABE II, located on
opposite sides of the serine protease active site (Figure 27A). These exosites have been
shown to direct substrates to the active site, contribute to opening of the active site region,
and help in attracting other regulatory molecules. Direct allosteric linkage may exist
between ABE I and ABE II to modulate thrombin activity.60
Thrombin is expressed as the zymogen Prothrombin (ProT) (Figure 27B).38,119 As
ProT is proteolytically converted to thrombin, the immature pro-ABEs develop into the
mature, active ABEs I and II 38,39 (Figure 27C). In ProT, access to pro-ABE II is blocked
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by the kringle-containing Fragment 1.2 (F1.2). This pro-ABE II region becomes exposed
during the cleavage and activation process.38,120,121 By contrast, the pro-ABE I region is
not directly affected by a cleavage event. Instead, subsequent conformational changes
likely lead to ABE I maturation. 38,122

Figure 27: Crystal structures of thrombin [Protein Data Bank (PDB) entry 1PPB] and prothrombin
(PDB entry 4HZH). A) Ribbon diagram of thrombin in which the catalytic triad (His 57, Asp 102, and
Ser 195) is colored yellow, (Pro)- ABE I is colored green, (Pro)- ABE II is colored blue, the autolysis
Loop is colored purple, the 60s Loop is colored cyan, and the A chain is colored red. B) Space filling
model of zymogen prothrombin missing the Gla domain. Kringles 1 and 2 are colored orange. The
other colored regions match those shown in panel A. C) Thrombin is generated from prothrombin
following cleavages after Arg 271 and Arg 320. The space filling model highlights the removal of
the kringles (orange), the exposure of the active site (yellow), and full maturation of ABE I (green)
and ABE II (blue).

Designing new therapeutic anticoagulants that are directed toward individual
thrombin exosites is a promising area of investigation.98,123,124 Different segments of the
mature exosite surfaces could be targeted without directly occluding the active site with a
small molecule. Unexpectedly, there are reports that ABE I - directed ligands based on
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hirudin 125,126 and DNA/RNA aptamers 127,128 can already bind to the immature pro-ABE I
on ProT.
Similar to hirudin and the aptamers, PAR3 also contains a binding region directed
to thrombin ABE I.50 PARs are members of the G protein-coupled receptor family and
are involved in platelet activation129 vascular remodeling, and vascular permeability.130 A
fragment of PAR3 including amino acid residues
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QNTFEEFPLSDIE56 has been

confirmed to bind in a specific manner to thrombin ABE I by X-ray crystallography.50 A
review of the crystal structure reveals that thrombin residues located < 4 Å from the PAR3
include F34, L65, R75, Y76, R77a, I82, and K110. Chymotrypsin numbering is used to
define the thrombin sequence. Thrombin R77a is an extra amino acid residue located after
E77, which is not found in chymotrypsin.

Figure 28: Crystal structure of thrombin in complex with murine PAR3 fragment (44-56). The
thrombin surface is rendered as gray ribbons and the PAR3 peptide as blue sticks. Thrombin
ABE-I residues that are located < 4 Å from PAR3 (44-56) are displayed as green ribbons or
green sticks. The PAR3 residues later chosen for 15N-HSQC titration studies include acidic
residues D54 and E48 (red stars) and hydrophobic residues F47 and L52 (purple stars).
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The PAR3 (44-56) sequence is similar to the ABE I-directed region found within
the leech-derived inhibitor hirudin (Figure 28).51 PAR3 could thus be a valuable new
system for helping decipher the specific conformational changes that occur as pro-ABE I
on prothrombin matures to ABE I on thrombin. An examination of the X-ray crystal
structures of prothrombin,120 thrombin-PAR3,50 and active site -inhibited PPACKthrombin37 reveals no striking differences between their pro-ABE I and ABE I regions
(Figure 29).

Figure 29: Structural alignment of the ABE I regions of prothrombin (PDB entry 4HZH), thrombinPAR3 (PDB entry 2PUX), and PPACK-thrombin (PDB entry 1PPB). Regions encompassing exosite
I (residues F34-M84, thrombin straight numbering) were selected, and then a backbone alignment was
performed using MolMol. The backbone ABE 1 root-mean-square deviation values for the different
protein -protein comparisons were then determined: 0.79 Å for ProT and thrombin-PAR3, 0.47Å for
PPACK-thrombin and thrombin-PAR3 and 0.63 Å for ProT and PPACK-thrombin. This analysis
reveals no striking differences for the backbone atoms located in ABE I.

The backbone root-mean-square deviation131 values for these three anion binding
exosite regions were <0.8 Å. These values indicate that conformational changes may have
been missed by crystallographic studies and are transient in nature. Nuclear magnetic
resonance (NMR) could thus provide a critical alternative strategy for directly monitoring
exosite maturation. To achieve this goal, we have performed NMR titration projects
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comparing the binding of PAR3 amino acid residues (44-56) to the original zymogen state
ProT versus the final active protease thrombin. For the first time, the ability of the PAR3
fragment (44-56) to target the immature (pro)-ABE I site on ProT could be explored.
Previous hydrogen-deuterium exchange studies coupled with mass spectrometry
(HDX-MS) demonstrated that regions of pro-ABE I experience increases in their level of
solvent exposure as ProT is converted to thrombin.39 These exposures are hypothesized to
be part of the exosite maturation process. NMR removes the issue of only probing segments
of a protein and would allow for single -amino acid residue analysis. Moreover, NMR has
the unique advantage of allowing KD measurements in solution at this individual residue
level.
Thrombin is highly dynamic and adopts distinct states in the presence of ligands,
which enable this enzyme to fulfill its array of protease activities.56,132-135 Previous NMR
studies of thrombin revealed that there are key residues within the 30s and 70s loop regions
of ABE I that cannot be monitored by NMR.56,132-135 Some of these thrombin residues
become NMR-visible following introduction of ABE I ligands, whereas others do not.
Intriguingly, surface loops and the ABE I region can remain flexible even when the active
site of thrombin is inhibited.133-135 Because of the flexible nature of thrombin, development
of the mature 30s and 70s loop regions can be challenging to probe. To overcome this issue,
a novel NMR titration approach was needed. For the current project, the PAR3 (44-56)
peptides were labeled with 15N at the amide nitrogen of specific amino acid residues, and
ProT and thrombin remained unlabeled.136
Critical NMR information about how the PAR3 peptide (44-56) responds to the
changing environment that occurs upon exosite maturation could now be collected. NMR
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titration studies first revealed that the native PAR3 (44-56) sequence bound too tightly to
be monitored by NMR. A P51G substitution was successful in decreasing the PAR3
affinity. One-dimensional (1D) 1H line broadening NMR studies revealed that PAR3G (4456) could bind to immature pro-ABE I on ProT and also mature ABE I on thrombin. 1H15

N- heteronuclear single -quantum coherence (HSQC) NMR titrations were then perfomed

with selectively labeled PAR3G peptides. Acidic PAR3G

15

N-E48 and

15

N-D54 both

entered into higher affinity, intermediate exchange regimes as ProT was converted to
thrombin. Strong binding events involving PAR3G D54 could be weakened with thrombin
mutant R77aA, thus supporting the presence of a salt bridge. By contrast, PAR3G [15N-]
F47 and [15N-] L52 both bound more weakly to ProT/thrombin than the acidic PAR3G
residues did. Furthermore, [15N-] F47 and [15N-] L52 were able to document important
changes to the hydrophobic exosite environment as pro-ABE I matures to ABE I.

MATERIALS AND METHODS

Materials
Human plasma Prothrombin (ProT) and thrombin were purchased from Haematologic
Technologies, Inc (Essex Junction, VT).

Recombinant thrombin mutant R77aA

(chymotrypsin numbering) was a kind gift from E. Di Cera and L. Leslie Pelc (St. Louis
University School of Medicine, St. Louis, MO).137 R77a is an extra thrombin amino acid
residue located after E77, which is not found in chymotrypsin. For the R77aA project, the
basic R77a was replaced with a small, neutral A. The active sites of the thrombin species
were protected from autolysis by blocking with PPACK (D-phenylalanyl-L-prolyl-Larginine chloromethyl ketone). This serine protease active site inhibitor was purchased
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from Calbiochem (San Diego, CA). D2O (99.96%) was from Cambridge Isotope
Laboratories (Andover, MA)
Synthetic Peptides
A series of PAR3 -based peptides were custom synthesized by New England Peptide
(Gardner, MA). PAR3 (44Q N T 15F E E F P L S 15D I E56), abbreviated as PAR3 (44-56),
is the original PAR3 sequence, and amino acid residues F47 and D54 were labeled with
15

N at their amide nitrogens. PAR3 (44-56, P51G, 15F47, 15D54) (44Q N T 15F E E F G L S

15D

I E56), abbreviated as PAR3GFD (44-56), contains a Pro51 to Gly substitution (G) and

furthermore, F47 and D54 were labeled with 15N. PAR3 (44-56, P51G, 15E48, 15L52) (44Q
N T F 15E E F G 15L S D I E56), abbreviated as PAR3GEL (44-56), also contains the P51G
substitution (G) but now E48 and L52 are labeled with 15N. The purity of each synthesized
peptide was verified by high-performance liquid chromatography and matrix-assisted laser
desorption ionization time-of-flight mass spectrometry. Initial stock solutions of peptide
were solubilized in deionized water, and the concentration was determined by amino acid
analysis (AAA Service Laboratory, Inc., Damascus, OR). Peptides were later diluted into
25 mM H3PO4, 150 mM NaCl, and 0.2 mM EDTA (pH) 6.5 for NMR studies.
The proton chemical shift values for all the PAR3 peptide amino acid residues were
determined using a combination of two-dimensional (2D) TOCSY and 2D-transferred
NOESY

65,109

experiments performed on a Varian Inova 700 MHz NMR spectrometer.

Standard TOCSY and NOESY pulse sequences were employed. As is typical for trNOESY
experiments, the ligand-protein complex contained a 10-fold excess of PAR3 (44-56)
peptide fragment, and the chemical shifts report on the solution environment encountered
by the peptide in the presence of the target protein.65 The amide proton 1H chemical shift

46

assignments derived from the TOCSY and trNOESY experiments were later matched with
their respective peaks found in 1H-15N HSQC NMR experiments. Both 1H and 15N values
could be followed in the HSQC titrations.
Theoretical Basis for 1D Proton Line Broadening NMR and 1H-15N HSQC NMR
1D proton line broadening studies were performed to monitor binding of the
PAR3/PAR3G (44-56) peptide fragment to prothrombin versus thrombin.109-111 Proteinpeptide complexes were prepared with a 10-fold excess of peptide. Peptide protons that
undergo interactions experience transient on/off events that cause an increase in the proton
transverse relaxation rate and/or cause changes in the observed chemical shift position
depending on the time scale of the interaction. The resultant alterations in peptide proton
line width/shape reflect the weighted contributions of bound and free populations. This
NMR line broadening approach can help map the peptide residue protons that come into
direct contact with the protein surface.109,110
1

H-15N HSQC NMR titrations were used to assess whether specific

15

N-labeled

residues located within a peptide ligand exhibited fast, intermediate, or slow exchange
on/off a protein surface.138 In these titrations, changes in chemical shift are monitored as
a function of protein-ligand ratios. For weak binding, the interaction is under the fast
exchange regime (kex >> |Δω|) where kex is the exchange rate of the interaction and Δω is
the resonance frequency difference between the bound and free states. Only one signal per
15

N-labeled residue is observed reflecting the population-weighted average of bound and

free states in terms of chemical shift, intensity, and line width. Furthermore, NMR chemical
shifts can be used to quantitatively evaluate affinities for individual

15

N labeled

residues.106,139 For the moderate affinity, intermediate exchange regime (kex ≈ |Δω|), the

47

15

N peak may disappear during the titration because of extensive line broadening and with

an increase in the bound population will later reappear. Finally, for tight binding in which
the interaction is described by the slow exchange regime (kex << |Δω|), two sets of
resonances are observed: one corresponding to the free and the other to the bound state.
Under this situation, the change in the intensity of the peaks will correspond to the relative
population of each state during the course of the titration.
Sample Preparation and Analysis for 1D Proton Line Broadening Experiments
All NMR experiments were performed at pH 6.5 and at 25 °C. Under these conditions,
the highly exchangeable [15N-] amide proton could still be readily observed by NMR at pH
was not far from physiological (7.4). To prevent autolysis, the serine protease inhibitor
PPACK was added to thrombin at a ratio of 4:1, and the mixture was incubated at 37 °C
for 30 min. Previous NMR relaxation studies have confirmed that the ABE I region remains
flexible in PPACK-inhibited IIa and can engage in long-range communication across the
enzyme surface.135 Plasma versions of ProT and PPACK- thrombin were buffer exchanged
into NMR buffer- [25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, (pH 6.5)] using a
Vivaspin 2 ultrafiltration unit with a 5000 Da molecular weight cutoff (Sartorius,
Göttingen, Germany). Protein concentrations were determined using extinction
coefficients (E1%280 nm) of 18.3 for thrombin and 13.8 for ProT.
Ligand-protein complexes with ratios of at least 10:1 were then prepared. The
complexes included 1 mM PAR3 (44-56) with 74 M ProT, 1 mM PAR3 (44-56) with 77
M PPACK-thrombin, 960 M PAR3G (44-56) with 76 M ProT, and 1 mM PAR3G (4456) with 76 M PPACK-thrombin. The peptide at a minimum concentration of 1 mM was
used as a free ligand control. The resultant NMR experiments and all others in this project

48

were performed on a Varian Inova 700 MHz spectrometer with a triple resonance cold
probe and pulsed-field Z-axis gradients run at 25 °C. The 1H NMR spectra were processed
using Mnova NMR (Mestrelab Research software).
2D 1H-13C HSQC Natural Abundance Experiments
Before proceeding to 1H-15N HSQC NMR titrations, we performed 1H-13C HSQC
natural abundance experiments on both PAR3 (44-56) and PAR3G (44-56) to assess
whether the proline to glycine substitution would change the PAR3 peptide conformations.
For this project, 1 mM PAR3 and 1 mM PAR3G were prepared in NMR buffer- ([25 mM
H3PO4, 150 mM NaCl, and 0.2 mM EDTA, (pH 6.5)]. Parameters for the 2D 1H-13C HSQC
project included 128 transients with 64 complex points in the indirect dimension, sweep
widths of 8064.5 and 24635.3 Hz for the direct and indirect dimensions, respectively, and
3000 complex points acquired in the direct dimension. 2D 1H-13C HSQC data were
processed using NMRPipe and nmrDraw and then further visualized using Sparky. The
ability to superimpose the spectra of PAR3 (red) and PAR3G (black) confirmed that
replacement of proline with flexible glycine did not change the overall peptide structure
(Appendix 1)
1D and 2D 1H-15N HSQC NMR Titration
ProT and active site inhibited PPACK- thrombin were exchanged into NMR buffer
using Vivaspin 2 ultrafiltration units with a 5000 Da molecular weight cutoff. A series of
protein–ligand complexes were then prepared involving PAR fragments PAR3 (44-56),
PAR3GFD (44-56), and PAR3GEL (44-56). ProT and PPACK-thrombin exhibit limited
solubility at the high concentrations typically used for NMR titrations. As a result, an
alternative titration strategy was employed for the current NMR project.
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The protein

concentration typically started in the range of 100-200 μM and was serially diluted while
maintaining a constant concentration of

15

N-labeled ligand. These conditions were

achieved by removing a certain volume of the protein-ligand solution and replacing it with
the same volume of the ligand solution. The titrations were thus initiated with a high
protein: ligand ratio and ended with low protein: ligand ratios all while maintaining a
constant peptide ligand concentration. The NMR titrations were therefore monitoring the
ability of ProT or thrombin to bind to the 15N-labeled PAR3 fragment.
For the first PAR3 binding studies, the starting complexes included 50 M PAR3 (4456) in either 137 M ProT or 210 M PPACK-thrombin. The serial dilutions resulted in
ProT: PAR3 ratios that spanned from 3:1 to 0.1:1. PPACK-thrombin: PAR3 ratios spanned
from 4:1 to 0.1:1. For the PAR3GFD binding studies, starting complexes included 37.5 M
PAR3GFD (44-56) in 70 M ProT or in PPACK-thrombin. ProT: PAR3GFD ratios during
the titrations then spanned from 2:1 to 0.3:1. PPACK-thrombin: PAR3GFD ratios spanned
from 2:1 to 0.05:1.
To evaluate the importance of electrostatic interactions between the
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N-labeled D54

of PAR3GFD and R77a of wild-type thrombin, a series of 1D and 2D 1H-15N HSQC
titrations involving recombinant thrombin mutant R77aA and PAR3GFD were perfomed.
The stock solution of R77aA thrombin was in 20 mM Tris (pH 7.4) and 400mM NaCl.
After PPACK treatment, active site inhibited R77aA thrombin was buffer exchanged into
25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, (pH 6.5) using a 3 mL Slide-A-Lyzer
Dialysis cassette G2 (Thermo Scientific, Rockford, IL) with a 3500 Da molecular weight
cutoff and then concentrated using a 5000 Da molecular Weight Cut Off Vivaspin 2
ultrafiltration unit. Starting complexes included 50 M PAR3GFD (44-56) with 150 M
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PPACK-thrombin (R77aA). PPACK-thrombin (R77aA) to PAR3GFD ratios spanned from
3:1 to 0.1:1.
For the PAR3GEL binding studies, the starting complexes included 50 M PAR3GEL
(44-56) with either 180 M ProT or 211 M PPACK-thrombin. The protein: ligand ratio
of ProT to PAR3GEL and PPACK to thrombin to PAR3GEL complexes spanned from 4:1
to 0.1:1.
Parameters for the 1D 1H-15N HSQC titrations included 512 transients, sweep width of
7022.5 Hz, and 1242 complex points in the direct dimension with PAR3 and 4096 with the
PAR3G complexes. Parameters for the 2D 1H-15N HSQC titrations included 16 transients
with 64 complex points in the indirect dimension, sweep widths of 7022.5 Hz and 1944.3
Hz for the direct and indirect dimensions, respectively, and 1242 complex points acquired
in the direct dimension. The 15N labeled free peptide was used as a control for each titration.
1D 1H-15N HSQC data were stacked using Mnova NMR and 2D 1H-15N HSQC data were
processed using NMRPipe and nmrDraw and then further visualized using Sparky.
Quantitative estimates of binding interactions between individual 15N-labeled peptide
ligand residues and specific proteins were determined using in-house scripts written using
Python.140 Information provided to such scripts included the total enzyme ([𝑃0 ]) and total
peptide ([𝐿0 ]) concentrations employed in the different steps of the HSQC titrations. In
addition, the NMR chemical shift difference (Δobs) between each set of free and bound
conditions was provided. For the current NMR project, it is important to note that the
peptide ligand concentration was kept constant and the protein was serially diluted. As a
result, the NMR titrations were measuring the binding of protein to a defined peptide ligand
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concentration. The equation for determining the binding affinity values (KD) was thus
modified so that the denominator now contains [𝐿0 ] instead of the more typical [P0].138,139
𝛥𝑜𝑏𝑠 = 𝛥𝑚𝑎𝑥 ∗

(𝐾𝐷 +[𝐿0 ]+[𝑃0 ])−√(𝐾𝐷 +[𝐿0 ]+[𝑃0 ])2 −(4[𝑃0 ][𝐿0 ])
2[𝐿0 ]

(1)

NMR titrations were performed at least in triplicate to determine KD values involving
plasma- derived ProT and thrombin. Duplicate titrations were performed for thrombin
R77aA. An error analysis of the KD values was performed using a Monte-Carlo approach
in which a 10% error was imposed on the serially diluted thrombin concentration. 140

RESULTS
1D Proton Line Broadening NMR Studies with PAR3 (44-56)
One dimensional 1H line broadening NMR experiments were performed on PAR3
(44-56) in the presence of ProT versus PPACK- thrombin (Figure 30 A-C). The active site
inhibitor PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone) was used to
protect thrombin from autolysis during the NMR experiments. Proton (1H) peak
broadening could be detected for aliphatic, amide, and aromatic protons of PAR3 in
complex with ProT. Such results indicate that a binding surface for PAR3 (44-56) is already
available within the immature pro-ABE I on ProT. Substantial peak line broadening was
also observed when the peptide was introduced into a solution of PPACK-thrombin
containing mature exosite ABE I. Such broadening is impressive considering the lower
molecular weight of thrombin (37 kDa) versus that of ProT (72 kDa).111 The overall,
extensive thrombin-induced peak broadening provides further justification that mature
ABE I is well suited for accommodating PAR3 (44-56). The 1H chemical shift overlaps
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observed across the different Figure 30 panels make it difficult to quantitatively evaluate
individual proton line effects.

Figure 30: Proton line broadening spectra for PAR3 and PAR3G peptides in the presence of
prothrombin and PPACK-thrombin. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2
mM EDTA and 10 % D2O (pH 6.5). A) 1D 1H-NMR spectrum of 1 mM PAR3 (44- 56) peptide in
solution B) 1D 1H-NMR spectrum of 1 mM PAR3 (44-56) in the presence of 74 μM ProT C) 1D
1
H NMR spectrum of 1 mM PAR3 (44-56) in the presence of 77 μM PPACK-IIa D) 1D NMR
spectrum of 1 mM PAR3G (44- 56) in solution E) 1D 1H NMR spectrum of 960 μM PAR3G (4456) in the presence of 76 μM ProT. F) 1D NMR spectrum of 1 mM PAR3G (44-56) in the presence
of 76 μM PPACK-IIa. Line broadening was observed for residues of PAR3 (44-56) and PAR3G
(44-56) when either peptide was bound to prothrombin and PPACK- IIa. The amide protons that
were later selected for HSQC titrations are labeled.
15N-HSQC

Titration Studies with PAR3 (44-56) Labeled at D54 and F47

An HSQC titration project was designed to systematically characterize binding of
PAR3-based peptides that are selectively labeled at amide nitrogen locations. The X-ray
crystal structure of the thrombin - PAR3 (44-56) complex was first consulted to select sets
of acidic and hydrophobic amino acid residues of PAR3 that display interactions with the
30s and 70s loop regions on thrombin (Figure 28).50 2D total correlation spectroscopy
(TOCSY) spectra of the bound PAR3 peptide then provided a valuable guide for choosing
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amino acid residues with amide chemical shift positions that would be less likely to overlap
in the proton dimension during the course of the PAR3-protein 1H-15N HSQC titrations.
The first amino acid residues selected included PAR3 F47 and D54. According to the
X-ray crystal structure, acidic PAR3 D54 makes a salt bridge contact with thrombin R77a
of the 70s ABE I loop whereas PAR3 F47 exhibits π-π stacking interactions with thrombin
F34 in the 30s ABE I loop region (Figure 28).50

15

N-HSQC NMR titrations were thus

performed with PAR3 (44-56) labeled with 15N at D54 and F47. These two PAR3 residues
both exhibited proton line broadening in the presence of ProT and PPACK-thrombin
confirming contact with the target protein in solution (Figure 30A-C).
The HSQC titrations started out with a 3:1 ProT: PAR3 ratio (containing the
[15N]D54 and [15N-]F47 residues). Extensive peak broadening was observed for both [15N] D54 and [15N-]F47 until the ProT:PAR3 ratios were serially diluted to 0.3:1 (D54) or
0.6:1 (F47) and lower. With PPACK-thrombin, peaks for both PAR3 residues could not be
detected until ratios of 0.3:1 were reached (Appendix 2 and 3). These NMR results
suggest that PAR3 D54 and F47 can already interact with pro-ABE I on ProT, and tightens
in the presence of PPACK-thrombin with a mature ABE I.
Proton Line Broadening NMR and 15N-HSQC NMR Titration Studies with PAR3GFD
(44-56) Labeled at D54 and F47
The extensive line broadening observed for PAR3 (44-56) bound to PPACK-IIa was
a major hindrance for

15

N-NMR titration studies, and binding affinities could not be

determined. To weaken this interaction, a modified sequence was designed in which the
P51 was replaced with a flexible glycine (P51G). The resultant PAR3GFD (44-56) showed
1D proton line broadening with both ProT and PPACK- thrombin (Figure 30 D-F). Natural
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abundance 13C HSQC spectra were recorded for both PAR3 peptides. As seen Appendix
2, the two spectra show good overlap suggesting that the Pro to Gly substitution has not
caused substantial changes to the conformation or the chemical environments of the two
peptides.
1

H-15N HSQC titrations were then performed with PAR3GFD containing 15N-labeled

D54 and F47. The ProT:PAR3GFD ratios spanned from 2:1 to 0.3:1 and PPACK thrombin:
PAR3GFD ratios spanned from 2:1 to 0.05:1. Results from 1D displays of the

15

N-HSQC

studies revealed that the PAR3GFD D54 peak became more broadened than the F47 peak
in the presence of ProT and PPACK-thrombin (Appendix 4). Further information about
interactions occurring with these two proteins was obtained by examining the 2D HSQC
titrations (Figures 31A and 31B). In the presence of ProT, the PAR3GFD residue D54
exhibited changes in chemical shift that resemble a fast exchange scenario corresponding
to an interaction with weakened affinity.

This interaction creates a new protein

environment for the ligand. By contrast, PAR3GFD residue F47 residue exhibited little
change in chemical shift during the ProT titration suggesting this residue did not experience
a substantial change in its chemical environment relative to that of the free peptide (Figure
31A). The project then proceeded to titrations with PPACK-thrombin where additional new
effects were observed. The 2D HSQC crosspeak for D54 underwent extensive line
broadening and could only be observed for thrombin: PAR3GFD ratios of 0.16:1 to 0.05:1
(Figure 31B). Such a peak broadening reflects improved interactions with the mature ABE
I site and is consistent with intermediate exchange conditions. Interestingly, the F47
residue was observed to undergo a wider range of chemical shift changes for the 2:1 to
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0.05:1 titration series. F47 was now experiencing a chemical environment different from
what had been observed with ProT containing an immature (pro)-ABE I.

Figure 31: 2D 1H-15N HSQC NMR titrations of PAR3GFD (44-56) in the presence of ProT and
PPACK- IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O
(pH 6.5). A) For the PAR3GFD binding studies with ProT, starting complexes included 37.5 M
PAR3GFD (44-56, [15N]-F47, [15N-]D54) in 70 M ProT. The serial dilutions resulted in
ProT:PAR3GFD ratios that spanned from 2:1 to 0.3:1. B) For PPACK -IIa, starting complexes included
37.5 M PAR3GFD (44-56, [15N-]F47, [15N-]D54) in 70 M PPACK-IIa. The serial dilutions resulted
in PPACK-IIa:PAR3GFD ratios that spanned from 2:1 to 0.05:1. Representative data sets are shown.
Colors for the HSQC crosspeaks span from blue (highest protein:peptide ratio) to red (free peptide).

The chemical shift changes for the D54 and F47 titrations proceed in the same
directions across the NMR panels when probing ProT versus PPACK-IIa (upfield for F47
and downfield for D54). These similarities are consistent with the PAR3 and PAR3G
peptides interacting within the same binding region of ProT versus PPACK-IIa.
Nonspecific binding to a separate area on ProT is not evident. In further support of this
proposal, Andersen et al. confirmed that hirudin (54-65) can bind specifically to the (pro)exosites of prothrombin and thrombin.126 Moreover, HDX-MS studies demonstrated that
hirudin and PAR3 (44-56) both bind to thrombin ABE I region 65-84.60
NMR HSQC titrations can be used to quantitatively characterize binding interactions
for individual 15N-labeled amino acid residues. These calculations work the best when there
are distinct changes in chemical shift position when
56
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N-labeled peptide amino acid

residues interact with a target protein. Furthermore, the binding curves should approach
saturation.138,139 With the current project, the peptide concentration remained constant, and
the protein solutions were serially diluted. For these protein- peptide ligand systems,
affinity estimates could be made for some of the 15N-labeled PAR3G (44-56) amino acid
residues. On the basis of the titration data that were collected, D54 had a binding affinity
(KD) of 65 ± 12 µM in the presence of ProT and a maximal chemical shift difference
(Δωmax) of 0.39± 0.03 ppm. (Table 3, and Figure 32B). The interaction became stronger
with thrombin, however, the binding of D54 was too tight and the peak broadening was too
severe to determine a KD value from the titration curve. The labeled PAR3 F47 residue had
an estimated KD value of 64 ± 8 µM and a Δωmax of 0.23± 0.01 ppm for ProT and a KD
value of 40 ± 10 µM and a Δωmax of 1.98 ± 0.19 ppm with thrombin (Table 3, and Figures
32A and C). Curiously, F47 experienced a marginal increase in affinity upon exosite
maturation even though this residue clearly encountered a new environment reflected by
its now larger chemical shift spread (Δωmax) (Table 3, and Figure 32C)
Table 3: KD and |Δωmax| Values Determined from 2D HSQC Titrations for 15N Labeled PAR3GFD
and PAR3GEL Bound to Human Prothrombin and Thrombin (wild type and mutant)a
[ProT]
(M)

|Δωmax|
(ppm)

Peptide

Residue

PAR3GFD

F47

64 ± 8

0.23 ± 0.01

PAR3GFD

D54

65 ± 12

0.39 ± 0.03

PAR3GEL

L52

124 ± 27

0.37 ± 0.04

PAR3GEL

E48

>200

NA

a

wild type
PPACKIIa
40 ± 10 μM

|Δωmax|
(ppm)

too tight to
calculate
47 ± 6 μM

insufficient
data points
1.84± 0.08

too tight to
calculate

insufficient
data points

1.98± 0.2

R77aA
PPACKIIa
173 ± 85
μM
168 ± 88
μM
salt bridge
not
involved
salt bridge
not
involved

For these NMR titrations, the peptide ligand concentrations were kept constant and the protein concentrations were serially
diluted. Estimated KD were calculated using in house scripts written in Python. Experimental data employed in the calculations
include the individual protein and peptide concentrations and also the 15N NMR chemical shift differences between each set of
free and bound conditions. The plasma-derived ProT and IIa titration series were carried out at least in triplicate. The studies
with recombinant R77aA-IIa were done in duplicate. Error analysis was carried out using a Monte-Carlo approach assuming a
10% error in the serially diluted protein samples. See Materials and Methods for more details.
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Figure 32: Determination of the binding Affinity (KD) for 15N-labeled F47 and D54 of PAR3GFD
interacting with prothrombin and PPACK-IIa. For this NMR titration series, the peptide ligand
concentration was kept constant and the ProT and PPACK-IIa concentrations were serially diluted.
As a result, the NMR titrations were measuring the binding of protein to a defined peptide
concentration. Interactions between A) ProT and PAR3G [15N-]F47 led to a KD of 64 ± 8 µM, B)
ProT and PAR3G [15N-]D54 led to a KD of 65 ± 12 µM, and C) PPACK-IIa and PAR3G [15N-]F47
led to a KD of 40 ± 10 µM. NMR titrations were perfomed in triplicate. The reported KD values
were determined using in-house scripts written using Python. The term |Δδ obs| 15N ppm = δ15Nbound –
δ15N free reflects the absolute difference in chemical shift between the bound and free states of the
particular 15N-residue. Error analysis was performed using a Monte-Carlo approach assuming a 10%
error in the serially diluted protein samples. See Materials and Methods for more details.
15N-HSQC

NMR Titration Studies with PAR3G (44-56) Labeled at D54 and F47

Interacting with the Thrombin Mutant R77aA
The HSQC titrations described above revealed a significant increase in affinity for
PAR3 residue D54 as ProT is converted to thrombin. Acidic PAR3 D54 has been reported
to make salt bridge contact with basic thrombin residue R77a (Figure 28).50 Interactions
between these two residues likely become more effective once the mature ABE I is formed.
To probe whether electrostatic interactions are occurring between R77a and D54, 1H-15N
HSQC titrations were performed with a thrombin R77aA - PAR3GFD complex (Figure 33).
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Unlike the wild-type PPACK-thrombin titrations, D54 and F47 chemical shifts could be
followed for the full titration series for PPACK-thrombin R77aA: PAR3GFD ratios of 3:1
to 0.13:1. The D54 crosspeak exhibited a broad range of chemical shifts and even
overlapped with the F47 crosspeak for a portion of the titration (Figures 33A and 33B).
Note in Figure 33A that at the start of the titration (3:1 protein:peptide ratio) the amide
proton for PAR3G F47 was at 8.3 ppm and for PAR3G D54 at 8.2 ppm. By a ratio of 0.7:1,
the two peaks overlapped into a single peak. As the PPACK-R77aA was further diluted,
the F47 and D54 peaks continued to change resonance positions and eventually matched
those of the free PAR3GFD peptide. A similar set of trends can be observed in the 2D HSQC
crosspeaks shown in Figure 33B. Overall, the 2D crosspeak patterns for both F47 and D54
were consistent with fast exchange conditions. For PAR3G D54, the estimated KD was 168
± 88 µM and the Δωmax = 1.83 ± 0.62 ppm, whereas for PAR3G F47 the values were a KD
of 173 ± 85 µM and the Δωmax = 1.79 ± 1.05 ppm (Table 3, and Appendix 6A and, B). The
removal of the salt bridge between PAR3 D54 and thrombin R77a clearly weakened the
interaction of D54 with the ABE I surface, and a KD value could now be estimated. In
addition, an 3-fold loss of affinity was observed for PAR3G F47 in the presence of the
R77aA thrombin mutant. Even with the weakened affinity, thrombin R77aA still incurred
large structural changes as reflected in the >1.8 ppm changes in the maximal chemical shift.
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Figure 33: 1D and 2D 1H-15N HSQC NMR titrations of PAR3GFD (44-56) in the presence of
PPACK- R77aA. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10
% D2O (pH 6.5). A) For the 1D HSQC NMR titrations, the starting complexes included 50 M
PAR3GFD (44-56, 15N-F47, 15N-D54) in 150 M PPACK- R77aA. The serial dilutions resulted in
PPACK- R77aA:PAR3GFD ratios that spanned from 3:1 to 0.1:1. Note that at the start of the titration
(3:1 protein to peptide) the amide proton for PAR3G F47 was at 8.3 ppm and for PAR3G D54 at 8.2
ppm. By a ratio of 0.7:1, the two peaks overlapped into a single peak. As the PPACK-R77aA
thrombin was further diluted, the F47 and D54 peaks continued to change resonance positions and
eventually matched those of the free PAR3GFD peptide. Representative data sets are shown. B) For
the 2D 1H-15N HSQC titrations, starting complexes included 50 M PAR3GFD (44-56, [15N-]F47,
[15N-]D54) in 150 M PPACK- R77aA. The serial dilutions resulted in PPACK-thrombin: PAR3GFD
ratios that spanned from 3:1 to 0.1:1. Representative data sets are shown. Colors for the 2D 1H-15N
HSQC crosspeaks span from blue (highest protein:peptide ratio) to red (free peptide).
15N-HSQC

NMR Titration Studies with PAR3G (44-56) Labeled at L52 and E48

Two additional PAR3 residues were chosen to probe the environments of the 30s and
70s loop regions of (pro)-ABE I. E48 of PAR3 (44-56) makes a salt bridge with R75 of
thrombin, and L52 of PAR3 (44-56) is positioned within a hydrophobic pocket containing
thrombin residues F34, L65, and I82 (Figure 28).50 As observed with F47 and D54, the
two new PAR3 residues E48 and L52 also exhibited 1D proton line broadening when
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complexed with ProT and PPACK-IIa (Figure 30). Thus, HSQC NMR titrations could be
performed with PAR3G (44-56) labeled at [15N-]E48 and [15N-]L52.
The titration ratios for ProT-PAR3GEL and (PPACK-thrombin)-PAR3GEL spanned
from 4:1 to 0.1:1. For the ProT bound complex, 1D and 2D displays of HSQC titration
peaks could be followed for all the titrations points (Appendix 5A and Figure 34). Unlike
those of PAR3GFD, the binding affinities for L52 and E48 were weaker resulting in KD
values of 124 ± 27 and > 200 µM, respectively (Table 3, Figure Appendix 7A and
Appendix 8B). Moreover, both E48 and L52 exhibited fewer changes in chemical shift
position. These results suggested that E48 and L52 did not encounter much of a change in
binding environment when they were tethered weakly to the surface of ProT.

Figure 34: 2D 1H-15N HSQC NMR titrations of PAR3GEL (44-56) in the presence of ProT and
PPACK- IIa. All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 %
D2O (pH 6.5).A) For the PAR3GEL binding studies with ProT, starting complexes included 50 M
PAR3GEL (44-56, 15N-E48, 15N-L52) in 180 M ProT. The serial dilutions resulted in ProT to
PAR3G ratios that spanned from 4:1 to 0.1:1. B) For the PPACK - IIa, starting complexes included
50 M PAR3GEL (44-56, 15N-E48, 15N-L52) in 211 M PPACK- IIa. The serial dilutions resulted
in PPACK- IIa to PAR3GEL ratios that spanned from 4:1 to 0.1:1. Representative data sets are
shown. Colors for the 2D 1H-15N HSQC crosspeaks span from blue (highest protein-peptide ratio)
to red (free peptide).

Furthermore, we propose that ProT R75 is less available for interacting with E48
of PAR3 than the distinct interactions already observed between ProT R77a and D54 of
PAR3. When the peptide was titrated with PPACK- thrombin (Appendix 6B and Figure
34B), L52 exhibited a greater change in chemical shift position. By contrast, E48
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resembled intermediate exchange on/off the thrombin surface. Extensive peak broadening
could already be observed at 1.2:1 protein: ligand ratios. In the presence of PPACKthrombin, L52 showed a 3-fold improvement in KD (47 ± 6 µM) and E48 underwent
extensive peak broadening preventing a KD value from being calculated. For L52, a Δωmax
of 0.37 ± 0.04 ppm was obtained for ProT and increased to 1.84 ± 0.08 ppm upon
conversion to thrombin (Table 3, and Figures Appendix 7A, C).
DISCUSSION
With thrombosis becoming a global disease burden, the urge to develop better
anticoagulants has increased.87 Novel oral anticoagulants 141,142 that target the active sites
of FXa and thrombin 143 have shown much medical promise but reversing their therapeutic
activities during heavy bleeding scenarios can be challenging.144,145 Drug candidates
123,124,146

that target thrombin ABE I are an alternative strategy. Thrombin is, however,

proteolytically derived from the zymogen prothrombin (Figure 27). Unexpectedly, some
ABE I ligands can already bind to the immature pro-ABE I site on this zymogen.
101,125,126,128,147

Future ABE I directed therapeutics might therefore be designed to target or

avoid specific regions of pro-ABE I on ProT versus ABE I on thrombin.
With our NMR titration approaches, we characterized, for the first time, the binding of
ABE I directed PAR3 peptides to ProT versus PPACK-thrombin. Previous NMR relaxation
studies had already revealed that communication from ABE I toward the active site region
is still preserved with PPACK-thrombin.133 Our 1D 1H line broadening NMR results
demonstrated that PAR3 (44-56) and its weaker binding version PAR3G (44-56) could
interact with both ProT and PPACK-thrombin (Figure 30).50 NMR 1H-15N-HSQC titration
studies were then performed with a series of 15N-labeled PAR3 peptides to characterize our
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ability to bind ProT versus PPACK-thrombin (Figure 31-34, and Figure Appendix 1-8).
Such an approach has the distinct advantage of monitoring exosite maturation at the
individual amino acid residue level. Isothermal titration calorimetry, fluorescence, and
surface plasmon resonance all provide a global KD fit using all peptide amino acid residues.
NMR, by contrast, preserves the ability to measure individual binding interactions in
solution and thus document their contributions. Moreover, NMR works best with weaker
affinity systems.
For the current NMR project, PAR3 peptides were prepared with [15N-] amide labeling
of F47, E48, L52, and D54. HSQC titrations were performed at the typical NMR pH of 6.5.
The acidic and hydrophobic residues [15N-] D54 and [15N-]F47 on PAR3 (44-56) were
examined first. This native PAR3 sequence bound too tightly to thrombin hindering ability
to assess KD values by NMR titration methods. Prior fluorescence titrations revealed a KD
of 2 µM for a related PAR3 sequence thus confirming our observation of intermediate/slow
exchange conditions in the NMR titrations.148

Greater success was achieved with

PAR3GFD (44-56) in which P51 was replaced with G51. With ProT, PAR3G D54 and F47
both had individual KD values in the range of 65 µM. The immature pro-ABE I can thus
accommodate both residues to a similar extent. Upon maturation to ABE I, PAR3G D54
bound too tightly to PPACK-thrombin for binding affinity calculation. By contrast, the F47
binding affinity increased only modestly as ProT was converted to thrombin. Interestingly,
the F47 also documented a substantial change in the chemical environment (Δωmax = 1.8
ppm) within the 30s loop region following activation to thrombin. Structural
rearrangements are proposed to occur in the vicinity of ProT/thrombin residue F34 but do
not result in a significant change in affinity (Figure 28).
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The PAR3G D54 residue was hypothesized to be influenced by its electrostatic
interaction with thrombin R77a (Figure 28).50 This acidic PAR3 residue may have
properties similar to those of hirudin.149 The hirudin sequence (56FEEI59) has already been
proposed to electrostatically steer toward the ABE I surface.149,150 Ionic tethering between
acidic hirudin residues and specific basic residues on ABE I might then be promoted
followed by stabilizing hydrophobic interactions.149,150 These hypotheses could now be
tested with the PAR3G sequence and thrombin R77aA. As predicted, the affinity for D54
weakened 3-fold upon loss of its salt bridge partner. In response, the F47 also displayed a
much weaker affinity value.
PAR3G residues E48 and L52 provided the opportunity to probe two additional regions
of ProT versus PPACK-thrombin.

E48 makes a salt bridge with thrombin R75, a

neighboring region of the 70s loop. PAR3G L52 interacts with a cluster of hydrophobic
residues including thrombin F34, L65, and I82 (Figure 28).50 Curiously, both E48 and L52
exhibited only minor changes in chemical shift upon binding to ProT. Furthermore, the
estimated individual KD values for L52 and E48 bound to ProT were 2-fold weaker than
those for D54 and F47. The pro-ABE I surface on ProT may not accommodate these two
residues as well as it does PAR3 D54 and F47. Similar to PAR3G D54, there was extensive
line broadening for E48 upon conversion to thrombin and KD values could not be
determined. By contrast, L52 exhibited a broad series of chemical shift changes during the
thrombin titration (Δωmax = 1.8 ppm). Interestingly, the estimated KD for binding of L52
(KD = 47 ± 6 µM) to PPACK-thrombin was similar to the value determined for F47 (KD =
40 ± 10 µM). Both L52 and F47 interact at the more hydrophobic surface area of ABE I
with a common overlapping influence from thrombin F34 (Figure 28).
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CONCLUSIONS
Overall, our solution NMR studies have elucidated changes in the exosite
environment that occur as zymogen ProT is converted to active thrombin. 1D proton line
broadening NMR and 1H-15N-HSQC studies demonstrated that PAR3G E48 and D54 could
already interact with ProT and the affinity increased upon maturation to thrombin. In the
NMR studies, the 3-fold tighter binding affinity for D54 versus that of E48 suggests that
the 70s loop region surrounding thrombin R77a may be better oriented to bind PAR3G
D54 than the interaction between thrombin R75 and PAR3G E48 (Figure 28). Moreover,
a close review of the crystal structure overlays in Figure 3 suggests that the 70s loop region
of ProT may assume an orientation that is preconfigured to that of PAR3-thrombin and
PPACK-thrombin. As the ionic PAR3G D54 – ProT/IIa R77a and PAR3G E48- ProT/IIa
R75 interactions are stabilized, PAR3G F47 and L52 are proposed to take further advantage
of interacting with thrombin F34 (within the 30-40s loop) and the thrombin hydrophobic
cluster F34, L65, and I82 (Figure 28). Aromatic PAR3G F47 and aliphatic PAR3G L52
both reported on significant changes in the chemical environment upon conversion of ProT
to thrombin. The region surrounding the ProT/IIa 30s loop appears to be more affected than
the hydrophobic pocket containing F34, L65, and I82.
Curiously, no striking differences are observed between the crystal structures of
immature pro-ABE I in ProT versus the mature ABE I regions of thrombin-ligand
complexes (Figure 29). Moreover, there are no X-ray crystal structures for a ligand bound
to the pro-ABE I region of ProT. We can speculate that there are transient structural states
within this coagulation protein system that are differentially explored by ProT and
thrombin.

Some of these states may be shared whereas others may be unique.
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Interestingly, ProT already possesses a binding competent state. Additional research has
implicated transient, or lowly populated, structures as playing an essential role in molecular
interactions.151-153 Thus, we believe that the mature thrombin likely visits a binding
competent state more often than ProT does, thereby promoting the higher affinity of PAR3
for thrombin.
In conclusion, our NMR titration studies have clearly revealed that individual
PAR3 amino acid residues are documenting structural rearrangements that occur upon
ABE I maturation. Moreover, these amino acid residues make individual contributions to
the overall binding affinity. The knowledge gained from this NMR project may be used to
help decipher the characteristic features of pro-ABE I versus ABE I that become accessible
to physiological ligands or future drug candidates.

NOTE:
1.) 2D 1H-15N HSQC titration for PAR3GFD and thrombin without PPACK incubation was
performed as a control experiment to verify whether chemical shift pattern of 15N-labeled
F47 and D54 are in the same direction as the one with PPACK-incubation (Appendix 8).
2.) This chapter is reproduced in part from the published manuscript:
Ramya Billur, David Ban, T. Michael Sabo, Muriel C. Maurer. (2017). “Deciphering the
Conformational Changes Associated with the Maturation of Thrombin Anion Binding
Exosite I”, Biochemistry, 56, 6343- 6354.154
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CHAPTER IV
BINDING INTERACTIONS OF PAR1 AND PAR3 FOR THROMBIN AND
DISSECTING ALLOSTERIC LINKAGE BETWEEN THE EXOSITES

INTRODUCTION
Thrombin is a serine protease whose functions are controlled by surface loops and
two anion binding exosites.48 These exosites ABE I and ABE II are located on opposite
sides of the active site region (Figure 6 from chapter 1).37 Thrombin is originally
expressed as the zymogen prothrombin (ProT) that contains immature exosites pro-ABE I
and pro-ABE II (Figure 5 from chapter 1).38 These immature exosites convert into mature
ligand binding sites upon activation of ProT to thrombin.48,57,89
Unexpectedly, there are reports that ABE I directed ligands can already bind to
immature pro-ABE I on ProT.125,126,128

In the previous chapter, we successfully

demonstrated how NMR titrations could be used to decipher conformational changes that
occur as pro- ABE I on ProT is converted into thrombin. In that project, a peptide based on
the protease activated receptor PAR3 (46-54) was successfully shown to bind to ProT and
affinity increased upon thrombin maturation.154

Moreover, the valuable roles that

individual 15N-labeled PAR3 residues play in the binding process were determined. Both
electrostatic (E48, D54) and hydrophobic residues (F47, L52) of PAR3 (46-54) made
unique contributions toward interacting with pro-ABE I and ABE I.
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PAR3 is just one member of the protease activated receptor family. PARs are
membrane bound proteins containing seven transmembrane domains. Among this family,
thrombin exhibits the greatest substrate specificity towards PAR1 reflected by its highest
kcat/Km.155 PAR1 is well known for its roles in platelet activation, aggregation, and for
helping to trigger inflammatory processes.81,102,156,157 PAR1 has gained attention for its
role in controlling the metastasis of cancer cells.158,159
PAR1 needs to be activated for this receptor to initiate its biosignaling functions.
Thrombin cleaves PAR1 at the R41-S42 peptide bond, and a portion of the new N-terminus
then serves as a tethered ligand to help activate PAR1. The required cleavage of PAR1 at
the thrombin active site is helped by having a portion of PAR1 also bind to thrombin ABE
I. Interestingly, PAR3 and PAR1 have both been shown to bind at ABE I and assist in
cleavage of PAR4 which lacks an ABE I binding segment. Following their activations,
PAR1 and PAR4 can illicit transmembrane signaling events like coupling to heterotrimeric
G-proteins, regulating kinase signaling cascades, and promoting receptor phosphorylation
and internalization.156,160
Gandhi and coworkers reported the X-ray crystal structure of PAR1 (33-62,
33

ATNATLDPRSFLLRNPNDKYEPFWEDEEKN62) bound to catalytically inactive

thrombin S195A.49,85 The 38LDPRSFLLRNP48 segment spans the active site with thrombin
cleavage occurring at the R41-S42 peptide bond. The segment

50

DKYEPF55 is

hypothesized to be important for binding to ABE I.149 Similar to other ABE I directed
ligands such as hirudin51,161 and PAR3, this PAR1 sequence has both electrostatic and
hydrophobic residues to interact with thrombin. A careful review of the X-ray crystal
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structure revealed that key thrombin sites located < 4 Å away from PAR1 include F34,
R35, Q38, L40, L65, R67, R73, T74, Y76, and I82 (Figure 35).

Figure 35: Crystal structure of thrombin in complex with human PAR1 fragment (49-57) PDB
code 3LU9. The thrombin surface is rendered in gray. ABE-I residues that are located < 4 Å
from PAR1 (49-57) are displayed as green ribbons or green sticks and PAR1 (49-57) in red
sticks. The PAR1 residues later chosen for 15N-HSQC titration studies include residues D50,
K51, E53 and F55 (highlighted in red).

PAR1 50DKYEP54, similar to 56FEEI59 of hirudin,161 is proposed to be responsible
for docking PAR1 on to thrombin ABE I. The next step is thought to be locking of
38

LDPR41 on to the thrombin active site for cleavage. Molecular modeling studies have

suggested that the C-terminal 58DEEKN62 binds to ABE I, but this flexible PAR1 segment
is not observed in the Gandhi X-ray crystal structure.49,85 Similar to our previous work
with PAR3 peptides, solution NMR could provide a successful strategy to further map the
binding of PAR1 to ABE I.154 Moreover, exosite maturation from ProT to thrombin could
be explored.
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Events at thrombin ABE I can also be influenced by occupancy at ABE II. Similar
to PAR1 and PAR3, glycoprotein GpIbα is also found on the surface of platelets. GpIbα
recruits thrombin to the platelet environment by binding an anionic cluster (269-286) to
thrombin ABE II (R93, R101, R126, K235, K236, and K240).79 GpIbα binding then affects
a variety of thrombin functions. The GpIbα-thrombin complex enhances PAR1
hydrolysis,80 hinders release of FpA,162 and decreases affinity for FVIII.163 Previous
HDX-MS studies demonstrated that GpIbα binding at thrombin ABE II can influence the
solvent accessibility of thrombin ABE I regions.60,78

There have been reports that

Prothrombin F2 and Fibrinogen γ' can each bind to ABE II and also elicit both local and
long range allosteric effects.164 Keeping these observations in mind, we wanted to further
probe how GpIbα is involved in allosteric communication with ABE I bound ligands.
X-ray crystal structures are available for prothrombin,120 active site inhibited
thrombin,37 PAR1 bound thrombin,49 PAR3 bound thrombin,50 and GpIbα bound
thrombin.52 An overlay of ABE-I regions for these proteins reveals no striking structural
differences across the series (Figure 36). The backbone root mean square deviation for
those five ABE-I regions range from 0.47 to 0.76 Å.131 Our current solution NMR titration
methods have the ability to reveal conformational changes that occur upon activation of
prothrombin to thrombin and to monitor how individual peptide ligand residues respond to
the new environments. Conformational changes that are transient in nature and may have
been missed by X-ray crystallography can be identified.
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Figure 36: Structural alignment of the ABE I regions of prothrombin (PDB entry 4HZH), thrombinPAR1 (PDB entry 3LU9), and PPACK-thrombin (PDB entry 1PPB), thrombin- GpIb (PDB entry 1PBV
and 1OOK). Regions encompassing exosite I (residues F34-M84, thrombin straight numbering) were
selected, and then a backbone alignment was performed using MolMol. The backbone ABE 1 root-meansquare deviation values for the different protein -protein comparisons were then determined: 0.79 Å for
ProT and thrombin-PAR1, 0.47Å for PPACK-thrombin and thrombin-PAR1, 0.63 Å for ProT and
PPACK-thrombin, 0.76Å and 0.62Å for ProT and two crystal structures of GpIb, 0.48Å and 0.50Å for
thrombin-PAR1 and two crystal structures of GpIb. Finally, 1PBV and 1OOK had an RMSD of 0.34Å.

Important information on how individual PAR1 amino acids interact with ProT and
mature IIa were obtained in this second NMR titration project. With our 1D 1H line
broadening NMR experiments, we successfully monitored the native PAR1P sequence (4962) binding to immature zymogen Prothrombin (ProT) versus the mature protease thrombin
(IIa). Proton line broadening for PAR1P (49-62) increased when bound to PPACK-IIa. 2D
trNOESY suggested an extended conformation for PAR1 (49-62) with the Xaa-Pro
adopting a trans conformation. Studies then proceeded to 1H-15N HSQC titrations using
selectively labeled PAR1 peptides.

15

N- labeled F55 of PAR1P interacted already with

ProT indicating the existence of hydrophobic interactions with the immature exosite.
However, NMR titrations with 15N- labeled PAR1P with PPACK-IIa could not be followed
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due to severe exchange broadening. Hence, a weaker binding version PAR1 (P54G) was
employed for all
for

15

15

N- labeled titrations. Upon ABE I maturation, the affinities increased

N- labeled K51, F55, and D58 of PAR1G (49-62) owing to the formation of more

optimal contacts. For the first time, thrombin binding interactions could be monitored for
PAR1G D58 and E60 which were missed in X-ray structures. By having GpIb bind at
ABE II, long-range communication between exosites could be explored and effects on
binding affinities determined. Both PAR1 (49-62) and PAR3 (44-56) responded to the
presence of the ABE II ligand GpIb (269-286). New evidence is available that interactions
between PARs and thrombin are ligand dependent.

MATERIALS AND METHODS
Materials
Human plasma Prothrombin (ProT) and thrombin were purchased from
Haematologic Technologies, Inc (Essex Junction, VT). The active sites of the thrombin
species were protected from autolysis by blocking with PPACK (D-phenylalanyl-L-prolylL-arginine chloromethyl ketone). This serine protease active site inhibitor was purchased
from Calbiochem (San Diego, CA). D2O (99.96%) was from Cambridge Isotope
Laboratories (Andover, MA).
Synthetic Peptides
A series of PAR1 -based peptides was custom synthesized by New England Peptide
(Gardner, MA). PAR1 (49N 15D K Y E P 15F W E D E E K N62), abbreviated as PAR1P
(49-62), is the original PAR1 sequence, and amino acid residues D50 and F55 were labeled
with

15

N at their amide nitrogens. PAR1 (49N

15D

K Y E G

15F

W E D E E K N62)

abbreviated as PAR1GFD (49-62), contains a Pro54 to Gly substitution (G) and furthermore,
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the D50 and F55 were labeled with 15N. PAR1 (49-62, P54G, 15E53, 15D58) (49N D K Y
15E

G F W E 15D E E K N62), abbreviated as PAR1GED (49-62), also contains the P54G

substitution (G) but now E53 and D58 are labeled with 15N. PAR1 (49-62, P54G, 15K51,
15

E60) (49N D 15K Y E G F W E D E 15E K N62), abbreviated as PAR1GKE (49-62), also

contains the P54G substitution (G) , where K51 and E60 are labeled with 15N. PAR3 (4456), P51G, 15E48, 15L52) ( 44Q N T F 15E E F G 15L S D I E56), abbreviated as PAR3GED
(44-56), contains the P51G substitution (G) , where E48 and L52 are labeled with

15

N.

GpIbα (269- 286) (269D E G D T D L YP P D YP P YP P P E E D T E G289) with the three
tyrosines phosphorylated was synthesized by Bachem Bioscience Inc. The purity of each
synthesized peptide was verified by high-performance liquid chromatography and matrixassisted laser desorption ionization time-of-flight mass spectrometry. Initial stock solutions
of peptide were solubilized in deionized water, and the concentrations were determined by
amino acid analysis (AAA Service Laboratory, Inc., Damascus, OR). Peptides were later
diluted into 25 mM H3PO4, 150 mM NaCl, and 0.2 mM EDTA (pH 6.5) for NMR studies.
The 1H chemical shift assignments for all PAR1 peptide residues were derived from
2D TOCSY and 2D trNOESY experiments. Standard pulse sequences were employed.
Since the aromatic residues (F55 and W56) were challenging to assign for PAR1 (49-62),
2D 1H-13C HSQC natural abundance experiments were also employed. For this project, 1
mM PAR1P and 1 mM PAR1G were prepared in NMR buffer- [25 mM H3PO4, 150 mM
NaCl, and 0.2 mM EDTA, (pH 5.4-6.5)]. Parameters for the 2D 1H-13C HSQC project
included 128 transients with 64 complex points in the indirect dimension, sweep widths of
8064.5 and 24635.3 Hz for the direct and indirect dimensions, respectively, and 3000
complex points acquired in the direct dimension. Each aromatic carbon and hydrogen of
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F55, W56, and Y52 were first assigned in 2D 1H-13C HSQC spectra. Later, aromatic
hydrogens were matched with the fingerprint and amide- amide regions of 2D TOCSY and
2D tr-NOESY spectra.
Sample Preparation and Analysis for 1D Proton Line Broadening and 2D
Transferred NOESY Experiments
All NMR experiments were performed at pH 6.5 and at 25 °C. To prevent autolysis,
the serine protease inhibitor PPACK was added to thrombin at a ratio of 4:1, and the
mixture was incubated at 37 °C for 30 min. Plasma versions of ProT and PPACK- thrombin
were buffer exchanged into NMR buffer- [25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA,
(pH 6.5)] using a Vivaspin 2 ultrafiltration unit with a 5000 Da molecular weight cutoff
(Sartorius, Göttingen, Germany). Protein concentrations were determined using extinction
coefficients (E1%280 nm) of 18.3 for thrombin and 13.8 for ProT. Ligand-protein complexes
with ratios of at least 10:1 were then prepared.
As is typical for trNOESY experiments, the ligand-protein complex contained a 10fold excess of PAR1 (49-62) peptide fragment, and the chemical shifts report on the
solution environment encountered by the peptide in the presence of the target protein. The
complexes included 780 M PAR1 (49-62) with 59 M ProT, 900 M PAR1P (49-62)
with 97 M PPACK-thrombin, 830 M PAR1G (49-62) with 83 M ProT, and 870 M
PAR1G (44-56) with 87 M PPACK-thrombin. Peptide at a minimum concentration of 1
mM was used as a free ligand control.
All NMR experiments in this project were performed on a Varian Inova 700 MHz
spectrometer with a triple resonance cold probe and pulsed-field Z-axis gradients run at 25
°C. The 1H NMR spectra were processed using Mnova NMR (Mestrelab Research

74

software). 2D TOCSY, 2D tr-NOESY, and 2D 1H-13C HSQC data were processed using
NMRPipe and nmrDraw and then further visualized using Sparky.
1D and 2D 1H-15N HSQC NMR Titration
ProT and active site inhibited PPACK- thrombin were exchanged into NMR buffer
using Vivaspin 2 ultrafiltration units with a 5000 Da molecular weight cutoff. A series of
protein–ligand complexes was then prepared involving PAR fragments PAR1P (49-62),
PAR1GFD (49-62), PAR1GED (49-62), and PAR1GKE (49-62). ProT and PPACK-thrombin
exhibit limited solubility at the high concentrations typically used for NMR titrations. As
a result, an alternative titration strategy was employed for the current NMR project. The
protein concentration typically started in the range of 100-200 μM and was serially diluted
while maintaining a constant concentration of 15N-labeled ligand. These conditions were
achieved by removing a certain volume of the protein-ligand solution and replacing it with
the same volume of the ligand solution. The titrations were thus initiated with a high
protein: ligand ratio and ended with low protein: ligand ratios all while maintaining a
constant peptide ligand concentration. The NMR titrations were therefore monitoring the
ability of ProT or PPACK inhibited thrombin to bind to the 15N-labeled PAR1 fragment.
For the first PAR1 binding studies, the starting complexes included 50 M PAR1P (4962) with 150 M ProT and 150 M PPACK-thrombin. The serial dilutions for both ProT:
PAR1P and PPACK-thrombin: PAR1P resulted in ratios that spanned 3:1 to 0.1:1. To
weaken the affinity of the PAR1P peptide for PPACK-IIa, P54 was replaced with the still
flexible Glycine. For these PAR1GFD binding studies, starting complexes included 50 M
PAR1GFD (49-62) with 150 M ProT and with 175 M PPACK-thrombin. Serial dilutions
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for both ProT: PAR1GFD (49-62) and PPACK-thrombin: PAR1GFD resulted in proteinpeptide ratios that spanned 3:1 to 0.1:1.
To evaluate the electrostatic binding contributions at (pro)- ABE I, a series of acidic
and basic PAR1 residues were 15N labeled. For the PAR1GED binding studies, the starting
complexes included 50 M PAR1GED (49-62) with 150 M ProT or PPACK-thrombin.
The protein:ligand ratio of ProT:PAR1GEL and PPACK-thrombin: PAR3GEL complexes
spanned from 3:1 to 0.1:1. For the PAR1GKE binding studies, starting complexes included
50 M PAR1GKE (49-62) with 150 M ProT and with 185 M PPACK-thrombin. The
serial dilutions for both ProT: PAR1GKE (49-62) and PPACK-thrombin: PAR1GKE resulted
in ratios that spanned 3:1 to 0.1:1.
Parameters for the 1D 1H-15N HSQC titrations for both PAR1P and PAR1G complexes
included 512 transients, a sweep width of 9000 Hz, and 4096 complex points in the direct
dimension. Parameters for the 2D 1H-15N HSQC titrations included 16 transients with 64
complex points in the indirect dimension, sweep widths of 9000Hz for both direct and
indirect dimensions, and 1242 complex points acquired in the direct dimension. The

15

N

labeled free peptide was used as a control for each titration. 1D 1H-15N HSQC data were
stacked using Mnova NMR and 2D 1H-15N HSQC data were processed using NMRPipe
and nmrDraw and then further visualized using Sparky. Quantitative estimates of binding
interactions between individual 15N-labeled peptide ligand residues and specific proteins
were determined using in-house scripts written using Python. All the titrations were
repeated at least twice. A Monte-Carlo approach was employed to calculate the errors in
KD values (Refer to Chapter 3).
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1D and 2D 1H-15N HSQC NMR Titration for Long-Range Communication Studies
To elucidate whether long-range communication existed between the two exosites
of thrombin, two PAR based

15

N-labeled peptide ligands were chosen that included

PAR1GED (49-62) and PAR3GEL (44-56). In this titration, triply phosphorylated GpIbα
(269- 286) is expected to bind at ABE II and

15

N-labeled PARs at ABE I. Even though

GpIbα (269- 286) is reported to have a KD of 5.9 nM for IIa,165 we still made sure that
GpIbα (269-286) was at least 99.7 % bound during the entire course of the titration. The
following equation was used to determine the % GpIbα ligand (L) bound to
protein/receptor (R).
% 𝐵𝑜𝑢𝑛𝑑 =

(𝐾𝐷 +𝐿+𝑅)−√(𝐾𝐷 +𝐿+𝑅)2 −(4𝐿𝑅)
2𝑅

(9)

The experimental strategies employed for the NMR titrations were similar to the
previously described project. The only difference was adding the GpIbα to the thrombin
prior to starting the PAR titration. For both PAR1GED and PAR3GEL binding studies, the
starting complexes included 150 M PPACK-IIa, 200 M GpIbα, and 50 M of

15

N-

labeled PAR peptide. The protein: ligand ratio of PPACK-thrombin: PAR1GED/PAR3GEL
complexes spanned from 3:1 to 0.1:1. PPACK- thrombin concentration was diluted from
150 M to 6 M and GpIbα concentration were diluted from 200 M to 8 M. At each
titration point, the concentration of 15N-labeled PAR ligands was kept constant. The same
instrument, parameters, and processing software were used to elucidate long-range
communication in the serine protease thrombin as used for the single ligand binding sites.
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RESULTS
1D Proton Line Broadening Experiments with PAR1 (49-62)
1D 1H- NMR experiments were performed for PAR1P (49-62) in the presence and
absence of enzyme. The appearance of peak broadening can be correlated with particular
peptide protons that come in direct contact with the enzyme surface. Decent amide proton
broadening was seen for both PAR1P (49-62) and PAR1G (49-62) in the presence of ProT
(Figure 37B and 37E). PAR1 residues which had effective line broadening included D50,
K51, E53, F55, D58, and E60. To rule out that line broadening was only due to the
increased relaxation effects of higher molecular weight ProT (72 kDa), we also examined
whether line broadening occurred with lower molecular weight thrombin (37 kDa). The
further line broadening seen with PPACK-IIa supported the proposal for additional contact
with the mature exosite (Figure 37C and 37F). Careful examination of the different line
broadening effects led to the conclusion that PAR1P (49-62) showed better line broadening
and thus enhanced binding than PAR1G (49-62). Later, individual residues with substantial
line broadening (D50, K51, E53, F55, D58, and E60) were selected for 15N labeling.
2D trNOESY revealed that the PAR1P (49-62) is mostly in an extended
conformation when bound to ProT (Figure 38A) as evident from having only nearest
neighbor NOEs. Another feature that was identified was the orientation of the PAR1 XaaPro bond. NOEs resulting from through space interactions between E53CH and P54CH
confirmed that the Xaa-Pro adopts a trans conformation when PAR1P (49-62) is bound to
ProT (Figure 38A and 38B).
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Figure 37: Proton line broadening spectra for PAR1P and PAR1G peptides in the presence of prothrombin
and PPACK-thrombin. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 %
D2O (pH 6.5). A) 1D 1H-NMR spectrum of 1 mM PAR1 (49- 62) peptide in solution B) 1D 1H-NMR
spectrum of 780 μM PAR1 (49-62) in the presence of 59 μM ProT C) 1D 1H NMR spectrum of 700 μM
PAR1 (49-62) in the presence of 97 μM PPACK-IIa D) 1D NMR spectrum of 1 mM PAR1G (49- 62) in
solution E) 1D NMR spectrum of 830 μM PAR1G (49-62) in the presence of 83 μM ProT. F) 1D NMR
spectrum of 870 μM PAR1G (49-62) in the presence of 87 μM PPACK-IIa.

Figure 38. A) selected NOE cross peaks of PAR1P (49-62) when bound to ProT. B)
Red pointers indicate NOE between E53CH and P54CH.

15N-HSQC

Titration Studies with PAR1PFD (49-62) Labeled at D50 and F55

To further evaluate differences in the binding affinities of ABE I directed ligands
and to decipher exosite maturation, we selected PAR1P (49-62) as our next test PAR
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candidate. Results could later be compared with our earlier PAR3 NMR titration studies.
2D TOCSY and 2D tr-NOESY had been performed on PAR1P to obtain chemical shift
values for the amide protons of the amino acid residues. Identifying aromatics like W and
F were however challenging as their side chain protons overlapped in the fingerprint
region. To increase the accuracy of peak assignments, 1H-13C 2D HSQC was employed
(Appendix 9). Once all proton chemical shifts were successfully assigned, the best residues
for 15N labeling were chosen and correlated with the X-ray structures.
For the first HSQC titration studies, PAR1 D50 and F55 were selected for

15

N

labeling. Figure 36 shows that PAR1 D50 is in ionic interaction with R73 of thrombin and
F55 is surrounded by the hydrophobic cluster (F34, L65 and I82) of ABE I.49,85 Thrombin
ABE I is mainly composed of the 30 and 70 loops which are responsible for electrostatic
and hydrophobic interactions with physiological ligands. HSQC titrations started with
ProT: PAR1PFD ratios of 2.3:1, where D50 and F55 were 15N labeled. Unfortunately, the
[15N]-D50 amide proton was not seen throughout the NMR titration series due to fast
exchange with the solvent. This amide proton could be detected at pH 3.0, a more acidic
environment than what ProT/IIa encounters physiologically. By contrast, [15N]-F55 could
be detected during the full NMR titration series at pH 6.5. 1D HSQC titration revealed that
the [15N]-F55 peak exhibited line broadening at higher ProT: PAR1PFD ratios and sharper
peaks started to develop as the enzyme was diluted with a constant amount of 15N- labeled
PAR1PFD (Figure 39A).
2D 1H-15N- HSQC cross peaks could be followed for all the titration points of [15N]F55 , consistent with this residue being in fast exchange with ProT (Figure 39B). Moreover,
there was a clear change in F55 chemical shift position (and thus chemical environment)
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resulting in a binding affinity (KD) of 99 ± 39.4 µM and a maximal chemical shift
difference (Δωmax) of 0.47± 0.09 ppm (Figure 39C and Table 4). Upon exosite maturation,
[15N]-F55 showed extensive line broadening even at the very lower PPACK-IIa: PAR1PFD
(0.1:1) ratios thus hindering the ability to calculate a KD (data not shown). Such line
broadening was due to extensive contacts with the mature ABE I surface of thrombin.

Figure 39: 1D, 2D 1H-15N HSQC NMR titrations, and KD value of PAR1PFD (49-62) in the presence of ProT. All
NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 6.5). A) 1D HSQC of
PAR1PFD binding studies with ProT, starting complexes included 50 M PAR1PFD (49-62, [15N]-D50, [15N]- F55) in
at least 115M ProT. The serial dilutions resulted in ProT: PAR1PFD ratios that spanned from 2:1 to 0.1:1. B) 2D 1H15
N HSQC PAR1PFD binding studies with ProT, starting complexes included 50 M PAR1PFD (49-62, [15N]-D50,
[15N]- F55) in at least 115M ProT. The serial dilutions resulted in ProT: PAR1PFD ratios that spanned from 2:1 to
0.1. Representative data sets are shown. Colors for the HSQC crosspeaks span from blue (highest protein:peptide
ratio) to red (free peptide). C) Determination of the binding Affinity (KD) for 15N-labeled F55 of PAR1PFD interacting
with prothrombin. ProT and PAR1P [ 15N-] F55 led to a KD of 99 ± 39.4 µM. NMR titrations were performed in
duplicate. The reported KD values were determined using in-house scripts written using Python. The term |Δδobs| 15N
ppm = δ15Nbound – δ15N free reflects the absolute difference in chemical shift between the bound and free states of the
particular 15N-residue. Error analysis was performed using a Monte-Carlo approach assuming a 10% error in the
serially diluted protein samples.
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Peptide

Residue

[ProT]
(M)

|Δωmax|
(ppm)

[PPACKIIa] (M)

|Δωmax|
(ppm)

PAR1PFD

F55

99  39.4

D50

NA

R73

PAR1GFD

F55

NA

F34, L65, I82

PAR1GFD

D50

R73

E53

NA

PAR1GED

D58

NA

Solvent
exchange
Too weak
for NMR
366.6

NA

PAR1GED

Solvent
exchange
Too weak
for NMR
Solvent
exchange
Too weak
for NMR
Too weak
for NMR

Too tight
for NMR
Solvent
exchange
251

NA

PAR1PFD

0.47 ±
0.09
NA

IIa residues in
contact with
PAR1 (49-62)
F34, L65, I82

PAR1GKE

K51

NA

16749

PAR1GKE

E60

NA

280

T74, Y76, and
R75
Not seen in Xray (might see
R77a)
In vicinity of
R73
Not seen in Xray (might see
I82, K110)

Too weak
for NMR
Too weak
for NMR

NA
NA
NA

0.41±
0.05
0.09±
0.02
NA

Table 4: KD and |Δωmax| Values Determined from 2D HSQC Titrations for 15N Labeled PAR1PFD,
PAR1GFD and PAR3GEL bound to prothrombin and PPACK-IIa.

15N-HSQC

Titration Studies with PAR1GFD (49-62) Labeled at D50 and F55

The strategy to evaluate individual KD values was hindered due to extensive line
broadening of PAR1PFD [15N]-F55 when bound to PPACK-IIa. Hence, a weaker binding
version of PAR1 (49-62) [P54G] was used to probe the availability of (pro)- ABE I for
binding. A similar P to G substitution had been utilized in our previous PAR3 peptide
project. The titration was initiated with a 3:1 (ProT: PAR1GFD) protein: ligand ratio where
D50 and F55 were 15N labeled. Both 1D and 1H-15N 2D HSQC titrations revealed that the
[15N]-F55 peak showed no change in chemical shift position with ProT (Figure 40A and
40B) indicating that the new PAR1GFD [15N]-F55 sequence exhibited less effective
interactions with the hydrophobic cluster (F34, L65, I82) of zymogen ProT. The
replacement of PAR1 proline to glycine (P54G) had caused a definite weakening of binding
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affinity. With such a change, the mature thrombin ABE I environment might be able to be
probed.

Figure 40: 1D and 2D 1H-15N HSQC NMR titrations of PAR1GFD (49-62) in the presence of ProT. All
NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 6.5). A) 1D
HSQC of PAR1GFD binding studies with ProT, starting complexes included 50 M PAR1GFD (49-62,
[15N]-D50, [15N]- F55) in at least 150M ProT. The serial dilutions resulted in ProT: PAR1GFD ratios
that spanned from 3:1 to 0.1:1. B) 2D 1H-15N HSQC PAR1GFD binding studies with ProT, starting
complexes included 50 M PAR1GFD (49-62, [15N]-D50, [15N]- F55) in at least 150M ProT. The serial
dilutions resulted in ProT: PAR1GFD ratios that spanned from 3:1 to 0.1. NMR titrations were performed
in duplicate.

Upon exosite maturation, [15N]-F55 did indeed undergo a substantial increase in
chemical shift during the titration series. The presence of a new binding environment
around the hydrophobic cluster (F34, L65, I82) of thrombin was thus detected upon ABE
I maturation (Figure 41A and 41B). Also, the chemical shift changes for [15N]-F55 of
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PAR1GFD titrations proceeded in the same direction as [15N]-F55 of PAR1PFD across the
panels. This common pattern is consistent with the idea that both versions of PAR1 are
encountering the same environment when bound to PPACK-IIa. The estimated binding
affinity (KD) of PAR1GFD [15N]-F55 for PPACK-IIa was 251M (Figure 41C, Table 4).
The PAR1 P54G sequence was next used to explore binding affinities of other key PAR1
(49-62) residues in the presence of immature prothrombin versus mature thrombin.

Figure 41: 1D, 2D 1H-15N HSQC NMR titrations, and KD value of PAR1GFD (49-62) in the presence of
PPACK-IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH
6.5). A) 1D HSQC of PAR1GFD binding studies with PPACK-IIa, starting complexes included 50 M
PAR1GFD (49-62, [15N]-D50, [15N]- F55) in at least 150 M PPACK-IIa. The serial dilutions resulted in
PPACK: PAR1GFD ratios that spanned from 3:1 to 0.1:1. B) 2D 1H-15N HSQC PAR1GFD binding studies
with PPACK-IIa, starting complexes included 50 M PAR1GFD (49-62, [15N]-D50, [15N]- F55) in at least
150M PPACK-IIa. The serial dilutions resulted in PPACK-IIa: PAR1PFD ratios that spanned from 3:1 to
0.1. C) Determination of the binding Affinity (KD) for 15N-labeled F55 of PAR1GFD interacting with
prothrombin. PPACK and PAR1G [15N-] F55 led to a KD of 251 µM. NMR titrations were performed in
duplicate.
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15N-HSQC

Titration Studies with PAR1GED (49-62) Labeled at E53 and D58

The success in evaluating the binding affinity of a hydrophobic residue ([15N]-F55)
led to interest in exploring anionic residues which might be involved in effective
interactions with ABE I of thrombin. Gandhi et al., had previously shown that PAR1 E53
is involved in hydrogen bonding with thrombin T74 and Y76.49,85 The acidic PAR1 E53
residue is also in close vicinity of the thrombin ABE I residue R75. Interactions involving
T74, R75, and Y76 supported our idea of 15N labeling E53 to probe the 70 loop of (pro)ABE I. The published X-ray crystal structures of PAR1 bound to thrombin were unable to
detect the electron density for the acidic C-terminal tail of PAR1 (58DEEKN62).84 Solution
NMR would provide an alternative strategy to probe this region of PAR1 by first labeling
PAR1 D58.
1D line broadening studies revealed that PAR1 E53 and D58 both showed some
proton line broadening with ProT. By contrast, both [15N]-E53 and [15N]-D58 did not
exhibit any chemical shift movement during the full 1D and 2D 15N HSQC titration series
with ProT. These results indicated minor interaction with pro-ABE I of ProT but no real
changes in chemical environment relative to that of free peptide. After ABE I maturation,
PAR1GED [15N]-E53 still did not exhibit any change in chemical shift position with
PPACK-IIa (Figure 42A,42B, 43A and 43B, Table 4). By contrast, the 1D
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N HSQC

spectra of the PAR1GED [15N]-D58 peak started to show line broadening and an upfield
chemical shift already at higher PPACK-IIa: ligand ratios. This effect was confirmed with
2D HSQC spectra, where changes in chemical shift position for PAR1GED [15N]-D58 were
clearly observed for the 4:1 to 1:1 PPACK-IIa to PAR1GED ratios. This result provided
valuable information about a flexible C-terminal region whose electron density could not
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be defined by X-ray crystallography. The NMR titration series revealed that PAR1GED
[15N]-D58 is likely in fast exchange with PPACK-IIa with KD of 38 ± 6.6 µM and a
maximal chemical shift difference (Δωmax) of 0.41± 0.05 ppm (Figures 42A, 42B, 43B and
43C, Table 4).

Figure 42: 1D HSQC NMR titrations of PAR1GED (49-62) in the presence of ProT and PPACKIIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH
6.5). A) 1D HSQC of PAR1GED binding studies with ProT, starting complexes included 50 M
PAR1GED (49-62, [15N]-E53, [15N]- D58) in at least 150M ProT. The serial dilutions resulted in
ProT: PAR1GED ratios that spanned from 3:1 to 0.2:1. B) 1D HSQC of PAR1GED binding studies
with PPACK-IIa, starting complexes included 50 M PAR1GED (49-62, [15N]-E53, [15N]- D58) in
at least 200 M PPACK-IIa. The serial dilutions resulted in PPACK: PAR1GED ratios that spanned
from 4:1 to 0.1:1. NMR titrations were performed in duplicate.
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Figure 43: 2D 1H-15N HSQC NMR titrations of PAR1GED (49-62) in the presence of ProT and
PPACK-IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 %
D2O (pH 6.5). A) 1H-15N 2D HSQC of PAR1GED binding studies with ProT, starting complexes
included 50 M PAR1GED (49-62, [15N]-E53, [15N]- D58) in at least 150M ProT. The serial
dilutions resulted in ProT: PAR1GED ratios that spanned from 3:1 to 0.2:1. B) 1H-15N 2D HSQC of
PAR1GED binding studies with PPACK-IIa, starting complexes included 50 M PAR1GED (49-62,
[15N]-E53, [15N]- D58) in at least 200 M PPACK-IIa. The serial dilutions resulted in PPACK:
PAR1GED ratios that spanned from 4:1 to 0.1:1. C) Determination of the binding Affinity (KD) for
15
N-labeled D58 of PAR1GED interacting with PPACK-IIa led to a KD of 38 ± 6.6 µM. NMR
titrations were performed in duplicate.
15N-HSQC

Titration Studies with PAR1GKE (49-62) Labeled at K51 and E60

The NMR mapping studies moved on to explore the binding affinity of a basic
residue and a second acidic residue within the N-terminal region of PAR1 (49-62). A
careful review of the PAR1 (49-62) – IIa X-ray structure (Figure 35) showed that K51 is
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in close vicinity of IIa ABE I residues R73 and T74. A second acidic residue from the Cterminal segment of PAR1G (49-62) was also chosen for analysis. Like D58, the E60
residue was missing from the thrombin- PAR1 X-ray crystal structure.85 Both [15N]-K51
and [15N]- E60 did not show any change in chemical shift position in the presence of ProT
indicating little if any interaction with pro-ABE I (Figure 44A and 45A). However upon
exosite maturation, the 2D HSQC studies revealed that PAR1 residue K51 showed modest
changes in chemical shift in the hydrogen dimension with a KD of 167 ± 49.2 µM (Δωmax
= 0.09 ± 0.02) and for PAR1 E60 a KD of 280 µM in the nitrogen dimension (Figure 44B,
45B and 46A and 46B, Table 4). Overall, both [15N]-K51 and [15N]- E60 had weak
interactions with both ProT and PPACK-IIa.

Figure 44: 1D HSQC NMR titrations of PAR1GKE (49-62) in the presence of ProT and PPACKIIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH
6.5). A) 1D HSQC of PAR1GKE binding studies with ProT, starting complexes included 50 M
PAR1GKE (49-62, [15N]-K51, [15N]- E60) in at least 150M ProT. The serial dilutions resulted in
ProT: PAR1GKE ratios that spanned from 3:1 to 0.1:1. B) 1D HSQC of PAR1GKE binding studies
with PPACK-IIa, starting complexes included 50 M PAR1GKE (49-62, [15N]-K51, [15N]- E60)
in at least 200 M PPACK-IIa. The serial dilutions resulted in PPACK: PAR1GED ratios that
spanned from 3:1 to 0.1:1. NMR titrations were performed in duplicate.
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Figure 45: 2D 1H-15N HSQC NMR titrations of PAR1GKE (49-62) in the presence of ProT and
PPACK-IIa. All NMR samples were in 25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 %
D2O (pH 6.5). A) 2D 1H-15N HSQC of PAR1GKE binding studies with ProT, starting complexes
included 50 M PAR1GED (49-62, [15N]-K51, [15N]- E60) in at least 150M ProT. The serial
dilutions resulted in ProT: PAR1GKE ratios that spanned from 3:1 to 0.1:1. B) 2D HSQC of
PAR1GKE binding studies with PPACK-IIa, starting complexes included 50 M PAR1GKE (4962, [15N]-K51, [15N]- E60) in at least 150 M PPACK-IIa. The serial dilutions resulted in
PPACK: PAR1GKE ratios that spanned from 3:1 to 0.1:1. NMR titrations were performed in
duplicate.

Figure 46: Determination of the binding Affinity (KD) for 15N-labeled K51 and E60 of PAR1GKE
interacting with PPACK-IIa led to a KD of 167 ± 49.2 µM and 280 µM respectively. NMR titrations were
performed in duplicate. The reported KD values were determined using in-house scripts written using
Python. The term and Δδobs| 1H ppm = δ1Hbound – δ1H free reflects the absolute difference in chemical shift
between the bound and free states of the particular 1H-residue. NMR titrations were performed in
duplicate.
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1D and 2D 1H-15N HSQC NMR Titration for Long-Range Communication Studies
Previously published HDX-MS experiments from our lab demonstrated that when
a triply phosphorylated GpIb (269-282) peptide bound to thrombin ABE II, there was a
long-range influence over to the ABE I region.60,78 To further characterize this dual ligand
binding system, NMR titration studies were carried out with complexes consisting of
unlabeled GpIb (269-282), PPACK-IIa, and two distinct

15

N- labeled PAR based

peptides. PAR1GED and PAR3GEL were selected for this study. Our previous HSQC
titrations had shown that both of these PAR peptides could document information about
the maturation of the 30 and 70 loops of thrombin.
The following experimental strategies were carried out to monitor dual ligand
allostery. Prior to the titration, a saturated amount of triply phosphorylated GpIb (269282) was added to PPACK-IIa followed by the desired

15

N-labeled PAR peptide. Both

GpIb and PPACK-IIa were then serially diluted with constant amounts of

15

N- labeled

peptide. The same ratios of PPACK IIa - PAR1 and PPACK IIa-PAR3 were maintained as
in the single ligand experiments described earlier. Interestingly, titrations with PAR1GED
revealed that E53 went from an affinity for thrombin ABE I that was too weak to detect by
NMR to one with an improved KD of 125 ± 36 µM (Δωmax = 0.32 ± 0.05) in the presence
of GpIbα peptide (Figure 42B, 43B, 47A, 47B, 48A, Table 4 and Table 5). By contrast,
PAR1 D58 did not respond much to the presence of GpIb binding at ABE II. The KD for
D58 went from 36 ± 6.6 µM (Δωmax = 0.41 ± 0.05) to 75 ± 14.9 µM (Δωmax = 0.52 ± 0.05)
(Figure 42B, 43B, 47B and 48B, Table 4 and Table 5).
The PAR3GEL peptide displayed a more dramatic response to GpIbα binding at
thrombin ABE II than PAR1GED. Prior studies had shown that L52 bound to ABE I with a
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KD of 124 µM and E48 had a KD of >200 µM. With GpIbα binding to ABE II, the PAR3
peaks broadened so much there were insufficient data pints for calculating the KD values.
PAR3GEL had entered into the tighter binding intermediate exchange regime. From these
studies, NMR could document long range influence from thrombin ABE II over to ABE I.
(Figure 49A and 49B, Table 5 and Table 6).

Figure 47: 1D and 2D 1H-15N HSQC NMR titrations of PAR1GED (49-62) in the presence of
saturated amounts of GpIba (269-282) and PPACK-IIa . All NMR samples were in 25 mM H3PO4,
150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 6.5). A) 1D HSQC of PAR1GED binding studies
with PPACK-IIa, starting complexes included 50 M PAR1GFD (49-62, [15N]-E53, [15N]- D58) in
at least 150M PPACK-IIa. The serial dilutions resulted in PPACK: PAR1GED ratios that spanned
from 3:1 to 0.1:1. B) 2D 1H-15N HSQC PAR1GED binding studies with PPACK-IIa, starting
complexes included 50 M PAR1GED (49-62, [15N]-E53, [15N]- D58) in at least 150M PPACKIIa. The serial dilutions resulted in PPACK-IIa: PAR1GFD ratios that spanned from 3:1 to 0.1. (free
peptide).
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Figure 48: Determination of the binding Affinity (KD) for 15N-labeled E53 and K51 of PAR1GED
interacting with GpIba (269-282) + PPACK-IIa led to a KD of 125 ± 36 µM and KD of 75 ± 14.9
µM respectively. NMR titrations were performed in duplicate. The reported KD values were
determined using in-house scripts written using Python.

Figure 49: 1D, and 2D 1H-15N HSQC NMR titrations of PAR3GEL (44-56) in the presence of
saturated amounts of GpIba (269-282) and PPACK-IIa. All NMR samples were in 25 mM
H3PO4, 150 mM NaCl, 0.2 mM EDTA, and 10 % D2O (pH 6.5). A) 1D HSQC of PAR3GEL
binding studies with PPACK-IIa, starting complexes included 50 M PAR3GEL (44-56, [15N]E48, [15N]- L52) in at least 150M PPACK-IIa. The serial dilutions resulted in PPACK:
PAR3GEL ratios that spanned from 3:1 to 0.1:1. B) 2D 1H-15N HSQC PAR3GEL binding
studies with PPACK-IIa, starting complexes included 50 M PAR1GED (49-62, [15N]-E48,
[15N]- L52) in at least 150M PPACK-IIa. The serial dilutions resulted in PPACK-IIa:
PAR3GEL ratios that spanned from 3:1 to 0.1. (free peptide).
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Peptide

Residue [PPACK-IIa]
(M)

PAR1GED

E53

PAR1GED+GpIb

E53

Too weak for
NMR
12636

PAR1GED

D58

366.6

PAR1GED+GpIb

D58

7515

|Δωmax|
(ppm)
NA
0.32 ±
0.05
0.41±
0.05
0.52 ±
0.05

IIa residues in
contact with PAR1
(49-62)
In vicinity of T74,
R75, and Y76
In vicinity of T74,
R75, and Y76
Not seen in X-ray
(might see R77a)
Not seen in X-ray
(might see R77a)

Table 5: KD and |Δωmax| Values Determined from 2D HSQC Titrations for 15N Labeled PAR1GED
when bound to GpIb+PPACK-IIa and PPACK-IIa

Peptide

Residue

[PPACK-IIa]
(M)154

|Δωmax|
(ppm)154

PAR3GEL154

L52

47 ± 6

1.84± 0.08

PAR3GEL+GpIb
PAR3GEL154

L52
E48

Too tight for NMR
Too tight for NMR

PAR3GEL+GpIb

E48

Too tight for NMR

NA
Insufficient
data points
NA

IIa residues
in contact
with PAR3
(44-56)50
F34, L65, I82
F34, L65, I82
R75
R75

Table 6: KD and |Δωmax| Values Determined from 2D HSQC Titrations for 15N Labeled PAR3GEL
when bound to GpIb+PPACK-IIa and PPACK-IIa.

DISCUSSION
Thrombin is a multifunctional serine protease that is originally derived from the
zymogen Prothrombin. Besides the thrombin active site region, ligands and substrates also
can bind to the regulatory anion binding exosites ABE I and II. PAR1 and PAR3 both have
segments that target ABE I thereby providing a second anchoring point on to the thrombin
surface. PAR1 and PAR3 can use their ABE I binding capabilities to help promote
thrombin dependent cleavage of PAR4.86,166

Once activated, PARs help in platelet

activation, platelet aggregation, and triggering inflammatory processes.
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An important goal of the current project was to characterize the diversity of ligand
binding interactions that exists as PAR residues bind to zymogen ProT versus mature
thrombin. New studies with PAR1 peptides were carried out and later compared with our
previously published PAR3 titrations when bound to ProT and PPACK-IIa.154 Because
GpIb can function as a cofactor for PAR1 hydrolysis by thrombin, we also wanted to
explore the conformational features of the ternary GpIb-IIa-PAR1 complex. While
saturated amounts of GpIbα peptide interacted at ABE II, binding affinities of ABEIdirected PAR1 (49-62) and later PAR3 (46-52) were probed. All our experiments were
carried out with active site inhibited thrombin to eliminate autolysis from occurring during
the long NMR titration experiments. Prior NMR relaxation studies proved that
communication can still exist between the active site and ABE I when the active site is
inhibited with PPACK.133-135 For all NMR experiments, pH was maintained at 6.5 to avoid
extensive amide proton exchange with solvent.
1D 1H line broadening studies revealed that PAR1P (49-62) and PAR1G (49-62)
showed moderate line broadening with ProT, and the line broadening increased upon
formation of mature thrombin (Figure 37A-F). Weaker line broadening was observed for
PAR1G (49-62), containing a P54G substitution, thus suggesting this modified PAR1
sequence would work, if needed, as a lower affinity version of PAR1 (49-62). A similar
strategy had been employed for our previous PAR3G project.154
PAR1 peptides were synthesized with 15N amide labeling at D50, K51, E53, F55,
D58, and E60. The first two residues examined included F55 and D50. The 15N-D50 of
PAR1P (49-62) forms an ionic pair with thrombin R73, an important residue of the 70 loop
in ABE I. PAR1 F55 is involved in hydrophobic interactions with IIa F34, L65, and
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I8249,85. Unfortunately, the [15N]-D50 amide proton was in fast exchange with the 10%
D2O found in the solvent and was never visible during the course of the NMR titration
series at pH 6.5. More success occurred with the PAR1P F55 residue. NMR titrations
revealed that [15N]-F55 was in fast exchange with the ProT protein surface and had a
binding affinity of 99 ± 39.4 M. These results indicated that pro-ABE I is already
available for hydrophobic interactions with the PAR1P peptide (Figure 39A-C, Table 4).
The same [15N]-F55 exhibited extensive peak broadening when bound to PPACK- IIa due
to increased affinity to mature ABE I.
The fact that [15N]-F55 appeared to be in intermediate exchange with PPACK-IIa
was a major hindrance to the project since KD values could not be determined. To address
this issue, the P54G replacement was chosen to help generate a weaker binding PAR1
peptide defined as PAR1G. Subsequent 1H-15N HSQC titration studies revealed that [15N]F55 of PAR1GFD now made only modest interactions with ProT (Figure 40A and 40B) and
affinity was too weak to calculate a KD. This result contrasts with the [15N]-L52 of
PAR3GFD which shares common hydrophobic interactions with thrombin residues (F34,
L65, and I82) (Figure 50). The KD for PAR3GEL [15N]-L52 binding to ProT was 124 M.
See Chapter 3 for a summary of all KD values determined from our previous work with 15N
labeled PAR3 residues.154
Following ProT to thrombin maturation, [15N]-F55 of PAR1GFD exhibited greater
interactions with PPACK- IIa and was now in fast exchange with the ABE I surface. The
broad range of chemical shifts occurring during the NMR titration is consistent with
PAR1GFD [15N]-F55 encountering a new binding environment. The PAR1 P54G
substitution had successfully weakened the affinity into an NMR manageable range and
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the binding affinity KD was 251 M (Figure 41A- 41C, Table 4). These studies indicate
that an improved binding environment for F55 of PAR1GFD is generated when pro-ABE I
on ProT is converted to ABE I on thrombin. However, this F55 does not exhibit strong
stabilizing interactions with ABE I. By contrast, the L52 in PAR3GEL had a KD of 47 M
towards PPACK-IIa.154 The interactions with thrombin hydrophobic cluster (F34, L65,
and I82) are more effective in promoting binding affinity of L52 in PAR3GEL than F55 in
PAR1GFD.

Figure 50: Interactions between thrombin ABE I (30 and 70 loop), PAR1 (49-62), and PAR3 (44-56)

As NMR is an excellent technique to probe the binding affinities of residues which
are in fast exchange, we next selected E53 and D58 for 15N labeling. PAR1 E53 is involved
in hydrogen bonding with thrombin Y76 and T74 and is also in proximity to thrombin
R7549,85. PAR1 D58 is the first residue of a flexible acidic C-terminal tail of PAR1 (49-62)
that has not been detected in X-crystal structures. The 1H-15N HSQC titrations studies
revealed that [15N]-E53 of PAR1GED showed no substantial interaction with either ProT or
PPACK-IIa (Figure 42A, 42B, 43A and 43B). This E53 effect might be worsened because
of replacement of the adjacent PAR1 Pro54 with Gly (P54G). As a result, E53 may be
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hindered from adopting a proper orientation to promote effective interactions with (pro)ABE I. By contrast, PAR3 E48 is known to participate in a neighboring electrostatic
interaction with ABE I R75. Binding affinities went from a KD value of >200 uM for ProT
to a too tight to calculate by NMR for thrombin (See Chapter 3).
Next, PAR1 D58 which is part of the acidic C-terminal tail segment provided
valuable, new mapping information. The [15N]-D58 of PAR1GED did not detect significant
interactions with ProT. However, upon exosite maturation, [15N]-D58 was in fast exchange
with PPACK-IIa yielding a KD of 36 ± 6.6 M. (Figure 42A, 42B, 43A, 43B and 43C,
Table 4) Our NMR titration results thus provided the first solution-based evidence for D58
making direct contact with ABE I. Effective binding interactions occurred with the
thrombin surface and a new chemical environment was encountered.
An alignment of PAR3 and PAR1 residues suggests that PAR1 D58 might be near
to thrombin R77a (Figure 50). Consequently, thrombin R77a may help to stabilize PAR1
D58 like the strong electrostatics seen between PAR3G D54 and IIa R77a. With the PAR3
peptide, D54 exhibited a KD of 65 ± 12 µM with immature ProT and the affinity became
too tight to calculate with mature thrombin ABE I.154 Future mutations to thrombin ABE
I may help confirm the key thrombin residues involved in binding of PAR1 D58.
So far, the NMR titrations studies have focused on hydrophobic and acidic residues.
To check whether a basic residue of PAR1 can interact with ABE I, PAR1 K51 which is
in the vicinity of thrombin R73 and T74 was selected.49,85 To probe another residue from
the PAR1 C-terminal tail, E60 was chosen. Both [15N]-K51 and [15N]-E60 did not show
significant interactions with ProT (Figures 44A and 45A). Later upon exosite maturation,
the K51 amide nitrogen did not exhibit chemical shift changes but the amide hydrogen did
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undergo movement in chemical shift (KD = 167 ± 49.2 M, Figure 46A, Table 4). These
observations highlight NMR as a sensitive technique to explore environments around
different atoms such as hydrogen and nitrogen. Like PAR1 K51, the acidic C-terminal
PAR1 residues [15N]-E60 showed a binding interaction too weak to quantitate by NMR for
ProT that later increased to a measurable KD of 280 µM with mature PPACK-thrombin.
(Figure 44A, 44B, 45A, 45B, and 46B, Table 4). With these NMR titrations results, a
second residue within the X-ray invisible region could be probed. Both PAR1 acidic
residues D58 and E60 could document contact with thrombin ABE I, but the affinities
indicate that D58 is better anchored to ABE I than E60. In comparison to PAR1 E60, the
PAR3 E56 contacts thrombin I82 and K110. Additional NMR mapping studies are needed
to assess how the full C-terminal region of PAR1 interacts with thrombin ABE I. The
flexibility of this PAR1 tail might have hindered the ability to promote greater binding
affinity.
From our 1H-15N-HSQC titration series, we can conclude that all

15

N-labeled

residues of PAR1G (49-62) showed little or no interaction with ProT. However, upon
exosite maturation, interactions with PPACK-IIa increased with KD values ranging from
36 to 280 M. Interestingly, the previously published PAR3G residues were, better at
binding the immature pro-ABE I region of thrombin than the PAR1 residues.154 After
determining individual binding affinities of labeled residues in both PAR1 (49-62) and
PAR3 (44-56), we proceeded further to explore whether binding of GpIb at ABE II would
influence the affinities of ABE I ligands.
Allosteric communication between exosites and the active site is an important step
in thrombin substrate specificity and catalysis.48,56,57,89 However, allosteric communication
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between the exosites is less well explored.58,164 Physiologically, GpIb bound to thrombin
ABE II helps in activating the ABE I directed ligand PAR1.80 In addition, allowing
zymogen fragment F2 to bind to thrombin ABE II reduces the conversion of fibrinogen to
fibrin.167 The first direct evidence for direct allosteric communication between the exosites
was reported by Weitz et al using F2 as the ABE II directed ligand and Hirudin as the ABE
I directed ligand.58,164,168 However, Bock et al., cautioned that changes in affinity could be
due to competitive overlapping binding sites or additional interactions between the ligands
themselves.59
To further decipher long-range allosteric communication in thrombin, a triply
phosphorylated GpIbα (269-282) was used in this project as the ABE II ligand and PAR
peptides would target ABE I. With the GpIbα- PPACK-IIa complex, an increased affinity
of [15N]-E53 towards ABE- I was observed. (Figure 47A, 47B, 48A, 48B, Table 4, and
Table 5). The non-optimal orientation of E53 binding to ABE I may have been overcome
by the introduction of GpIbα. By contrast, GpIbα did not have much of an effect on the Cterminal PAR1 residue D58 as evident from the modest change in KD that occurred after
taking error limits into account (Figure 47A, 47B, 48A, 48B, Table 4, and Table 5).
Titration with PAR3GEL revealed that PAR3 [15N]-E48 and [15N]-L52 both exhibited
extensive peak broadening already at low PPACK-IIa: PAR3GEL ratios (Figure 49A and
49B). The affinity of PAR3 [15N]-L52 for ABE I went from 47 ± 6 M to too tight to
calculate in the presence of ABE II ligand GpIbα. PAR3 [15N]-E48 continued to remain
too tight to calculate even in the presence of GpIbα. Once gain GpIbα can influence
affinities at distinct sites on ABE I.
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When aligning the PAR3 and PAR1 sequences, GpIbα binding is shown to have
influenced the conformation of a set of thrombin residues (Figure 50). PAR3 E48, PAR3
L52, and PAR1 E53 all underwent increased affinity in the presence of GpIbα-thrombin.
The corresponding thrombin residues that interact with these PAR residues can be clustered
as (F34, L65, I82) and (T74, R75, Y76). In support of the current NMR titrations, HDXMS studies previously reported that GpIbα binding exerts a long-range solvent accessibility
effect over to the thrombin 65-84 ABE I region.60 Future studies could probe how GpIbα
influences additional PAR1 and PAR3 residues. Unlike the PAR3 and PAR1 residues
mentioned above, the more C-terminal PAR1 D58 which had the best PAR-thrombin KD
value was less affected by GpIbα binding. PAR1 D58 is postulated to bind in the vicinity
of thrombin R77a. Binding of GpIbα at thrombin ABE II may not further promote
interactions between thrombin ABE I R77a and PAR1 D58.
Overall, we conclude that although PAR1 and PAR3 both target similar areas of
the thrombin 30 and 70 loop regions the individual PAR amino acids make unique
contributions to the overall binding affinities. Furthermore, our novel NMR titration
approach allowed us to probe such distinctions compared with previously published PAR3
(44-56) 1H-15N-HSQC titration results.154 PAR1G (49-62) exhibited weaker interactions
with ProT. These results suggest that drugs that mimic PAR1G interactions may be less
inclined to target immature pro-ABE I. By contrast, PAR3G interactions are tighter and
could already bind to immature pro-ABE I. As a result, therapeutics based on PAR3G could
help block the maturation of active thrombin. Finally, NMR studies involving the ternary
complex GpIbα – PPACK-IIa -PAR1/3 provided strong evidence that GpIbα binding can
exert a long-range effect over to thrombin residues F34, L65, R75, T74, Y76, and I82. In
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the future, the new knowledge gained from this project may help in development of drug
candidates that target specific hot spots on (pro)- ABE I and II.
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CHAPTER V
SECONDARY STRUCTURE INFORMATION AS A CLUE TO EXPLAIN THE
WEAK KINETICS OF THROMBIN-CATALYZED RELEASE OF
FIBRINOPEPTIDE B

INTRODUCTION
Thrombin utilizes an active site region and two exosites ABE I and ABE II to
initiate and regulate its functions. The serine protease activity of thrombin is supported by
a catalytic triad composed of D102, H57, and S195 (Figure 51A).37,169 Thrombin substrate
specificity is controlled by the 60s loop also known as the β-insertion loop (residues Y60aK60f). Two critical 60s loop residues that limit substrate entrance into the active site
include Y60a and W60d (Figure 51A). Other important thrombin residues that help
accommodate substrates are part of the aryl binding pocket and include W215, I174, and
L99 (Figure 51A). Following substrate binding at the active site, thrombin cleaves the
substrate scissile bond (R/K-X) designated by the P1-P1' nomenclature.61 Substrate amino
acids N-terminal of the hydrolysis site are labeled P2, P3, P4 etc. whereas those that are Cterminal are labeled P2', P3', P4' etc. The substrate residue at the P1 position (R or K) forms
a salt bridge with thrombin D189 at the bottom of the active site cleft. The P2 residue makes
extensive contacts with the 60s loop, the P4 interacts with the aryl binding site, and P3 is
not so critical in binding thrombin. Figure 1B shows an example of contacts between the
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P4-P1 segment (34VVPR37) of the FXIII Activation Peptide and critical residues of
thrombin.71

A

B

W60
d

Y60a
L99

34VVPR37

P4P3P2P1
I174
W215
E217
Figure 51:X-ray crystal structure of thrombin highlighting key residues that surround the active
site.A) Ribbon diagram of thrombin (gray) showing selected residues as colored sticks (PDB ID:
1DE7). Residues include the catalytic triad (red), Y60a and W60d (purple), L99 and I174 (blue),
W215 and E217 (green). B) The enzyme-bound FXIII AP segment (orange) (P4-P1) surrounded by
same thrombin residues shown in figure 1A.

A key procoagulant activity of the serine protease thrombin is to convert fibrinogen
(Fbg) into fibrin. Fibrinogen (340kDa) is the most abundant coagulation protein in the
blood, and it consists of six polypeptide chains, two each of the Aα, Bβ, and γ chains.30,33,36
The N-terminal ends of all six chains meet at the central E region, and the C-terminal ends
meet at the two peripheral D regions. Thrombin first cleaves at the R16-G17 peptide bond
of the Fbg Aα chain to release Fibrinopeptide A (FpA) (Figure 52). This cleavage helps in
formation of half-staggered, double stranded protofibrils involving D:E:D interactions.
Later thrombin cleaves at the R14-G15 peptide bond of the Fbg Bβ chain to release
Fibrinopeptide B (FpB).34,63,170
Once both peptides are released, transglutaminase FXIIIa helps in cross linking
fibrin protofibrils through isopeptide bond formations.171 Steady-state kinetic studies of
thrombin-catalyzed hydrolysis of fibrinogen revealed that release of FpA follows a first-
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order reaction. Interestingly, initial release of FpB is slow and the rate of FpB release is
accelerated after protofibril formation. Hence, the release of FpB is considered
“biphasic”.172

Figure 52: Fibrin clot formation is initiated by the cleavage of FpA leading to the formation
of protofibrils, next the cleavage of FpB results in lateral aggregation of fibrin. Finally, FXIIIa
imparts isopeptide bonds between two fibrin molecules there by stabilizing fibrin
architecture. Cartoon was adapted from Weisel, J.W. (2007).

Mutations have been identified that involve fibrinogen Bβ chain residues or that
influence this chain.173,174 Fibrinogen Ijmuiden (R14C) and Fibrinogen Nijmegen (R44C)
mutations are common in patients with thrombophilia and have been associated with
defective fibrin polymerization.175 The F8Y mutation in the fibrinogen Aα chain leads to
preferential cleavage of Fbg Bβ over Fbg Aα.176 The X-ray crystal structure of the Fbg Aα
F8Y mutant revealed that the carbonyl oxygen of Y8 shifted 1.8Å relative to the original
carbonyl oxygen of F8 leading to distortion of the scissile bond. As a result, the release of
FpA becomes greatly hindered.
Unexpectedly when fibrinogen is adsorbed on surfaces like glass, carbon,
polyethylene, and polystyrene, it takes on two kinds of orientations. One is “side-on”

104

(laying on the surface) occurring at low fibrinogen concentration and the other is “end-on”
(standing on the surface) at high fibrinogen concentration.177 For each orientation, only a
portion of fibrinopeptides are accessible for thrombin cleavage. In the “side-on”
orientation, 36% of FpA and 35% of FpB are released, whereas in the “end-on” orientation,
37% of FpA and a higher 64% of FpB is released.
Over the years, researchers have further explored the initial steps of fibrin
formation. Using recombinant fibrinogen proteins, Mullin et al., suggested that thrombin
specificity is what dictates the order of fibrinopeptide release.178 Based on modeling
studies of the N- terminal ends of both the Aα chain and the Bβ chains, Pechik et al
predicted that it is the length and orientation of the chains that lead to the weaker kinetics
of FpB release.170 Brummel et al., made the critical observation that release of FpA and
activation of FXIII occur simultaneously, thus allowing FXIIIa to first cross-link the γchains in the newly formed fibrin protofibrils.179 Later when FpB is released by thrombin,
the fibrinogen αC domains become exposed and FXIIIa is responsible for additional α-α,
α-γ, and higher order crosslinking of protofibrils (Figure 52).
All the work discussed above has been done with different lengths of Fbg Aα and
Bβ chains. None of them could provide information on the structural features of the Fbg
Bβ segment that comes in direct contact with thrombin. Such Fbg Bβ interactions will
dictate the orientation of the substrate- enzyme complex and thus control the ability of
thrombin to cleave the FpB sequence. An important focus of the chapter was to determine
individual kinetic parameters for thrombin- catalyzed hydrolysis of Fbg Bβ (5-16). The
kinetic parameters obtained were compared with other thrombin substrates including FXIII
AP (28-41) V34X,180,181 PAR1 (29-45),64 and PAR4 (38-51).65 Such comparisons led to
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the conclusion that Fbg Bβ (5-16) had the lowest kcat/Km value thereby making it rather a
poor substrate for thrombin. Solution NMR was employed to elucidate the structural
features behind the weak cleavage of Fbg Bβ (5-16). Unlike FXIII AP (28-41) V34F, Fbg
Bβ (5-16) does not appear to take advantage of the aromatic Phenylalanine (F) at P4 and P5
positions to promote improved binding interactions with thrombin. Another striking reason
behind the poor kinetics is probably the smaller Alanine residue at the P2 position that
cannot serve as an additional anchor point below the thrombin 60s loop.

MATERIALS AND METHODS
Materials
Bovine thrombin was purchased from Haematologic Technologies, Inc (Essex
Junction, VT). Human recombinant thrombin was a generous gift from Dr. Enrico Di Cera
and Ms. Leslie Pelc, Saint Louis University, St. Louis, MO. D2O (99.96%) was from
Cambridge Isotope Laboratories (Andover, MA).
Synthetic peptide
Fbg Bβ (5-16) was synthesized by New England Peptides (Gardner, MA). The
amino acid sequence of this peptide is as follows: (Ac-DNEEGFFSARGH-Amide). The
purity of Fbg Bβ (5-16) was verified by high-performance liquid chromatography and
matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Initial stock
solutions of peptide were solubilized in deionized water. The peptide was completely
soluble at pH 7.0, and the concentrations were determined by quantitative amino acid
analysis (AAA Service Laboratory, Inc., Damascus, OR).
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Sample preparation for HPLC based kinetic assay
The HPLC based kinetics assay of Trumbo et al., was employed.69 Briefly, a 6-7
mM peptide stock solution was prepared. Later, the peptide solution was diluted into assay
buffer (50 mM H3PO4,100 mM NaCl, 0.1% PEG, pH 7.4) and heated to 25 °C in a heat
block. The final concentrations of the Fbg Bβ (5-16) substrate spanned from 100 to 1500
µM. Hydrolysis of Fbg Bβ (5-16) at the R14-G15 peptide bond was initiated with the
addition of 134 nM of recombinant human thrombin. An aliquot of the reaction mixture
was removed at 3, 5, 7, 9, 11, 13 and 17 mins and then quenched with 12.5% H3PO4. For
all kinetic assay runs, ≤ 15% of the substrate Fbg Bβ (5-16) was cleaved by thrombin to
release the product FpB (5-14). Quenched reaction time points were analyzed by RP-HPLC
using a Waters X-Bridge BEH130 C18 5µm column on a Waters 2695 HPLC system.
Peaks for the substrate Fbg Bβ (5-16) and the resultant product FpB (5-14) were separated
using an acetonitrile based gradient of [15% CH3CN, 0.09% trifluoroacetic acid in dI
water] to [50% CH3CN, 0.09% trifluoroacetic acid in dI water]. Product peak areas were
converted to concentration using calibration curves constructed for Fbg Bβ. The slopes of
product concentration versus time plots were used to determine the initial velocities (in
μM/s) for the different thrombin-catalyzed reactions. The kinetic experiments were done
in triplicate, and kinetic constants were determined following nonlinear regression analysis
fits to the equation. V =Vmax/ (1 + Km/[S]) in Kaleidagraph (Synergy). The kcat values were
calculated by knowing the Vmax values and a final thrombin concentration of 134 nM.
Sample preparation for solution NMR experiments
All NMR experiments were performed at pH 5.6. Bovine plasma thrombin was
buffer exchanged into NMR buffer- [25 mM H3PO4, 150 mM NaCl, 0.2 mM EDTA, (pH
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5.6)] using a Vivaspin 2 ultrafiltration unit with a 5000 Da molecular weight cutoff
(Sartorius, Göttingen, Germany). Thrombin concentration was determined using an
extinction coefficient (E1%280 nm) of 18.3 and a MW of 36,500 g/mol. For our 1D and 2D
1

H NMR based studies, ligand-protein complexes with ratios of at least 10:1 were then

prepared. The complexes included 1600 M Fbg Bβ (5-16) and 160 M thrombin. Fbg Bβ
at a minimum concentration of 1.5 mM was used as a free ligand control.
NMR experiments were then performed at 25 °C on a Varian Inova 700 MHz
spectrometer with a triple resonance cold probe and pulsed-field Z-axis gradients. Proton
chemical shift values for all the Fbg Bβ amino acid residues were determined using a
combination of 2D TOCSY and 2D-transferred NOESY spectra. Standard TOCSY and
NOESY pulse sequences were employed. Parameters for the 2D NMR experiments
included nt=16, ni=512, np= 2486, gain= 20 and sweep widths of 7022.5 Hz for both direct
and indirect dimensions. A mixing time of 400 msecs was employed for the 2D tr-NOESY.
The 1D 1H NMR spectra were processed using Mnova NMR (Mestrelab Research
software). 2D TOCSY and tr-NOESY data were processed using NMRPipe and nmrDraw
and then further visualized using Sparky.

RESULTS
Thrombin-catalyzed release of Fibrinopeptide B
An HPLC based kinetic assay was employed to determine the individual kinetic
constants associated with hydrolysis of Fbg Bβ (5-16) by human recombinant thrombin.
Thrombin cleaves Fbg Bβ at the R14-G15 peptide bond releasing peptide fragment (5-14).
As evident from the HPLC chromatogram in Figure 53, the substrate peak Fbg Bβ (5-16)

108

eluted first from the C18 column followed by the product (5-14). This elution order
occurred because all the HPLC-based kinetic assays were done using an acetonitrile
gradient with 0.09% trifluoroacetic acid. This acidic solution environment makes substrate
Fbg Bβ (5-16) more hydrophilic (+2 charge) than the product FpB (5-14) (+1 charge). The
higher hydrophilicity thus causes the substrate to elute first from the C18 column.
Substrate peak (5-16)

Product peak (5-14)

Figure 53: Hydrolysis of Fbg Bβ (5-16) as a function of incubation time. 500 µM Fbg Bβ (5-16)
was hydrolyzed by 130 nM thrombin for 3, 5, 7, 9, 11,15 and 17 mins. Each quenched time point
was run on a C18 column using a Waters HPLC system. A linear gradient of 15% acetonitrile, 0.09%
trifluoroacetic acid in water to 50% acetonitrile, 0.09% trifluoroacetic acid in water in 20 min at a
flow rate of 0.5 ml/min was employed. The original substrate peptide Fbg Bβ (5-16) eluted at
approximately 4.6 mins whereas the hydrolyzed product FpB (5-14) eluted at approximately 5.7
mins.

Figure 53 corresponds to a representative 500 M Fbg Bβ (5-16) kinetic reaction.
The product peak area increased over the course of the 0-17 min reaction time. Peaks
neighboring the product FpB 5-14 corresponded to contaminants found in the 90% pure
synthetic peptide. To allow for kinetic parameter determination, the substrate
concentrations then spanned from 100 to 1500 M Fbg Bβ (5-16). Non-linear regression
analysis methods were used to calculate Km, kcat, and kcat/ Km values for the hydrolysis of
Fbg Bβ (5-16). With human recombinant thrombin, the kinetic parameters included a Km
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of 1271 ± 154 µM, a kcat of 1.0 ± 0.075 s-1, and a kcat/ Km of 8.2x10-4 ± 1.2x10-4 s-1 µM-1
(Table 7 and 8).
Table 7: Human substrate sequences that target the thrombin active site region.  indicates
the cleavage between R-X.
_______________________________________________________________________
P4 P3 P2 P1
Fibrinogen Bβ (5-16)
Fibrinogen Aα (7-20)
Factor XIII (28-41) V34 AP
Factor XIII (28-41) V34F AP
Factor XIII (28-41) V34W AP
Factor XIII (28-41) V34L AP
PAR1 (29-45)
PAR4 (38-51)

5D

N E E G F F
7D F L A E G G
28T V E L Q G V
28T V E L Q G F
28T V E L Q G W
28T V E L Q G L
29K A T N A T L
38S T P S I L P

S
G
V
V
V
V
D
A

A
V
P
P
P
P
P
P

R
R
R
R
R
R
R
R










G
G
G
G
G
G
S
G

H16
P R
V N
V N
V N
V N
F L
Y P

V20
L41
L41
L41
L41
L45
G51

_________________________________________________________________________________________

Table 8: Kinetic constants for the hydrolysis of Arg-Xaa by thrombin
________________________________________________________________________
Substrate peptides
Km (µM)
kcat (s-1)
kcat/ Km (s-1 µM-1)
________________________________________________________________________
Fibrinogen Bβ (5-16)a
1271 ± 154
1.0± 0.075
8.2x10-4 ± 1.2x10-4
62
Fibrinogen Aα (7-20)
569 ± 76
31.0 ± 0.005
5.5x10-2 ± 7.0x10-3
FXIII (28-41) V34 AP62
298 ± 42
2.6 ± 0.005
8.6x10-3 ± 1.0x10-3
62
FXIII (28-41) V34L AP
315 ± 42
23 ± 0.003
7.3x10-2 ± 1.2x10-3
FXIII (28-41) V34F AP180
442 ± 93
6.3 ± 0.54
1.4x10-2 ± 3.0x10-3
181
FXIII (28-41) V34WAP
637 ± 56
7.6 ± 0.3
1.2x10-2 ± 1.2x10-3
PAR1 (29-45)64
900
35
4.0x10-2
65
PAR4 (38-51)
113 ± 19
10.2 ± 0.8
9.0x10-2 ± 1.7x10-2
________________________________________________________________________
a

The results shown here represent averages of at least three independent experiments. Kinetic values were
calculated using nonlinear regression analysis methods using Kaleidagraph. The error values correspond to
standard error of the mean (SEM).

Solution NMR studies of free and thrombin bound FpB (5-16)
Chemical shift assignments for all the Fbg Bβ residues were derived from 2D
TOCSY and 2D tr-NOESY experiments. N6NH-CH, G9NH-CH, G15NH-CH, and
H16NH-CH peaks were not seen in the fingerprint region since they merged with the
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solvent peaks (Appendix 47). The loss of the G15 and H16 peaks in the Fbg Bβ -thrombin
sample is consistent with thrombin cleaving Fbg Bβ (5-16) at the R14-G15 peptide bond
even at the lower NMR pH of 5.6 (Appendix 47 and 50). 1D 1H line broadening
experiments for free Fbg Bβ (5-16) (Figure 54A, and 54B) and Fbg Bβ (5-16) in the
presence of bovine thrombin were acquired. Curiously, the R14-NH peak undergoes an
upfield chemical shift after IIa cleavage suggesting that the R14-NH in the product peptide
(5-14) encounters more shielded environment. By contrast, the proton attached to side
chain ε nitrogen is shifted downfield.

A

B

Figure 54: A) 1D Amide proton region of free Fbg Bβ (5-16). B) 1D amide proton region for FpB
(5-14) bound to bovine thrombin.

Extensive line broadening was seen for residues A13-NH and F10-NH. NOEs are
numbered from 1 to 30 in the fingerprint, aliphatic and amide regions (Figures 55, 56, and
57). These include several intra and inter NOEs: 1 (E8H-G9NH), 2 (E8αH-G9NH), 3
(D5NH-E8H), 4 (A13H-R14NH), 5 (F11H-S12H), 6 (F11αH-S12NH), 7 (A13αHR14NH), 8 (G9αH –F10H), 9 (S12αH-A13NH), 10 (S12H-A13NH), 11 (N6H-
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E7NH), 12 (F11H-S12H), 13 (F10αH- F11NH), 14 (D5αH-N6NH), 15 (F11(2,6H)F11αH), 16 (F10(2,6H)-F10αH), 17 (F10(2,6H)-F11αH), 18 (F10αH-F11(2,6H)), 19
(R14NH-γCH2), 20 (F10(2,6H)-F10βH), 21 (F11(2,6H)-F11βH), 22 (F10(3,5H)-F11βH), 23
(F10(3,5H)-F10βH), 24 (F11(3,5H)-F11βH), 25 (F10βH- F11βH), 26 (G9NH-F10NH), 27
(F10NH-F11NH), 28 (A13NH-R14NH), 29 (F11NH-S12NH), 30 (E8NH-G9NH).

Figure 55: 2D NOESY Fingerprint region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin.
Sample was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 5.6)
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Figure 56: 2D NOESY Aliphatic region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 5.6)

Figure 57: 2D NOESY Amide region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 5.6)

113

114

Figure 58: Cartoon showing through space interactions between the residues of Fbg Bβ (5-16) when bound to thrombin.

DISCUSSION
Much data is available on the binding of Fbg Aα (7-20) to the thrombin active aite
from previous kinetic, NMR and X-ray crystal studies. Less is known about the binding of
Fbg Bβ to thrombin. The focus of the current study was Fbg Bβ (D5-H16), a sequence that
interacts with the active site region of thrombin and can be cleaved at the R14-G15 peptide
bond. Kinetic parameters for thrombin-catalyzed release of FpB (5-14) were determined.
In addition, 1D and 2D NMR methods were used to structurally characterize the binding
of individual FpB residues to the thrombin active site region.
HPLC kinetic assay results suggest that thrombin- catalyzed hydrolysis of Fbg Bβ
(5-16) exhibited a Km value of 1271± 154 µM, a kcat value of 1.0±0.075 s-1, and a kcat/ Km
value of 8.2x10-4 ±1.2x10-4 s-1 µM-1. When compared to the kinetic parameters of Fbg Aα
(7-20),62 Fbg Bβ (5-16) is 2-fold higher in Km and 30-fold lower in kcat value (Table 7 and
8). Such results reveal that binding interactions for Fbg Bβ (5-16) at the active site are
weaker and turnover into product is greatly hindered. Fbg Bβ (5-16) is definitely not as
well optimized to interact with thrombin as Fbg Aα (7-20). Moreover, Fbg Bβ (5-16)
exhibits the lowest kcat value of the peptide substrates shown in Table 8. With its high Km
and low kcat, Fbg Bβ (5-16) becomes the weakest peptide substrate in terms of substrate
specificity (kcat/Km). A careful review of thrombin substrate sequences indicates that
although the Ala 13 at the P2 position in FpB (5-14) exhibited line broadening in the
presence of thrombin, it might not be large enough to effectively promote optimal contacts
with thrombin Y60a and W60d of the thrombin β-insertion loop. In addition, solution NMR
studies on FpA (7-16) identified that Phe 8 at the P9 position compensates for the absence
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of a common Proline at the P2 position by making a through space interaction with its
13

GGV15 (P4-P2) region (Table 7 and 8).
Comparing the kinetics parameters for thrombin catalyzed hydrolysis of Fbg Bβ (5-

16) with those of FXIII AP (28-41) V34F and V34W is also valuable, as both FXIII variants
contain an aromatic residue at the P4 position.180,181 The presence of such an aromatic
residue helped both FXIII AP (28-41) V34F and V34W to improve their kcat 3-fold relative
to FXIII AP (28-41) V34 and 6-fold relative to Fbg Bβ (5-16) (Table 7 and 8). The
presence of two Phe residues at the P5 and P4 positions of Fbg Bβ (5-16) clearly did not
improve kcat.
Another interesting substrate to compare is the PAR series. Even though PAR1 (2945) has a similar Km value (1271 µM vs 900 µM)64 as Fbg Bβ (5-16), the substrate
specificity (kcat/Km) of PAR1 is far higher than that of Fbg Bβ (5-16) (Table 7 and 8). The
PAR1 L35 and P37 at the P4 and P2 positions interact optimally below the β insertion loop
and help orient the PAR1 sequence for effective cleavage by IIa. This benefit is reflected
in the 35-fold improvement in kcat that occurs with the PAR1 sequence. The PAR4 (38-51)
sequence has proline at the P4 and P2 positions (44PVPR47). This arrangement provides
effective binding contacts with the thrombin active surface leading to a 10-fold
improvement in Km and kcat relative to Fbg Bβ. Once again, the individual kcat and Km values
of Fbg Bβ (5-16) reveal that the

10

FFSAR14 segment hinders productive binding and

orientation for IIa cleavage.
Solution NMR was employed in this project to further explain the weak kinetics of
Fbg Bβ (5-16). The 1D proton line broadening studies revealed that A13-NH and F10-NH
interacted with thrombin. The thrombin bound product FpB (5-14) did not have peaks for
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G15 and H16 highlighting that thrombin catalyzed cleavage had indeed occurred at the
R14-G15 peptide bond. (Figure 55,56,57, and 58). Furthermore, a substantial number of
transferred NOEs were seen for the sequence 8EGFFSAR14. A prevalence of nearest
neighbor NOEs indicates that there is no evidence of helices adopted by this peptide
sequence when bound to thrombin. A weak NOE from D5NH-E8CβH suggests the
possibility of a turn like structure within the N-terminal region of the FpB sequence.
Previously published molecular modeling studies on Fbg Bβ suggested that F10 at
the P5 position has hydrophobic interactions with thrombin Y60a and W60d.182 Such
hydrophobic interactions with the thrombin 60s loop might have led to the extensive line
broadening of the F10-NH. However, Fbg Bβ F11 at the P4 position did not change peak
intensity suggesting no interactions with thrombin W215 and E217. Such results agree with
the in-silico studies, predicting that F11 projects away from thrombin surface.182 Also, no
NOE cross peaks between F11 (P4) and A13 (P2) were observed, indicating that Fbg Bβ
(5-16) does not take advantage of a P4 to P2 interaction to stabilize the enzyme-substrate
complex. By contrast, FXIII AP (28-41) V34L,183 and V34F184 utilized P4 to P2 contacts to
anchor better on to the IIa surface. A large number of NOEs between FpB F10 and F11
suggests that their amino acid side chains are interacting with each other through space
even though both side chains may be oriented in somewhat opposite directions. Unlike
FpA (7-16),69,183 no NOES were observed between the N- terminal portion of the FpB
peptide and the P4-P2 region.
Overall, the HPLC based kinetic assay results that Fbg Bβ (5-16) is a relatively
poor thrombin substrate because of its high Km and low kcat relative to other common
thrombin substrates. Our 1D and 2D solution NMR results suggest that FpB (5-14) cannot
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take advantage of stabilizing P4 to P2 interactions when bound to thrombin. The presence
of two Phe residues at the P5 and P4 positions along with a small Ala at the P2 position are
proposed to hinder optimal contacts between Fbg Bβ (5-16) and thrombin.
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CHAPTER VI
RESEARCH SUMMARY AND FUTURE DIRECTIONS
Thrombin with a catalytic triad of His 57, Asp 102, and Ser 195 is highly homologous
to such serine proteases as trypsin and chymotrypsin.37 Thrombin enzyme specificity is
controlled through several loops including the 60s loop (or βinsertion loop) and the γ loop
(or autolysis loop). Another important structural feature is the Na+ ion binding loop which
contributes to thrombin allostery. The sodium bound form of thrombin is considered to be
in the “fast” state and thrombin now has procoagulant activity. In contrast, thrombin is
considered “slow” and leans toward anticoagulant functions in the absence of Na+ ion.45,185
Secondary anchoring sites rich in positively charged amino acids are called anion binding
exosite- I and II (ABE I and ABE II) and are present at opposite sides of the active site.
ABE II interactions with ligands are mainly electrostatic; however, ABE I can have both
electrostatic and hydrophobic interactions with ligands. Ligands that bind to ABE- I
include the Protease Activated Receptors PAR1 (49-62),49 PAR3 (44-56),50 and Hirudin
(54-65).51,161 Ligands binding to ABE-II include glycoprotein GpIbα (269-286),79
fibrinogen γ´(410-427),53 Haemadin (45-57),54 and heparin.186
Allosteric communication is possible among the two exosites and between the
exosites and the active site. Amide hydrogen/deuterium exchange coupled with mass
spectrometry (HDX-MS) revealed that ligand binding at the exosites exhibited both local
and long-range effects but not all showed identical conformational changes to thrombin.60
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Effects of Hirudin are only restricted to the ABE I region, whereas PAR3, PAR1, and
GpIbα showed both local and long-range effects.60
Thrombin is originally produced as the 72kDa zymogen, Prothrombin (ProT). ProT
is composed of Fragment-1 (1-155), Fragment-2 (156-271) and a protease domain (272579). Fragment-1 contains a Gla domain and disulfide containing Kringle-1. Vitamin K is
needed for the formation of Gla residues in Fragment -1. Fragment-2 contains Kringle-2,
the A chain (272-320), and the B chain (321-579). The Thrombin A and B chains together
constitute the protease domain. ProT is physiologically activated by the Prothrombinase
complex consisting of a serine proteinase Factor Xa and the cofactor Factor Va, a
phospholipid membrane, and Ca2+. ProT is anchored to the membrane surface through the
Gla domain of Fragment 1 (F1).38,187
In platelets, cleavage of ProT at R271 leads to the formation of the inactive precursor
Prethrombin-2 (PT2) and Fragment 1.2. Subsequent cleavage at R320 gives rise to the
active protease α-thrombin (36.7kDa).38,40

α-thrombin can also be autolysed to

catalytically hindered β and γ- thrombin.39,41 ProT and PT2 have immature anion binding
exosites called (pro)- ABE-I and II. Upon formation of α-thrombin, these exosites become
more mature and are called ABE – I and II. These mature exosites help with substrate
specificity and ligand binding. Unexpectedly, there are certain ligands that can already bind
to pro-ABE I.125-128 The published literature has provided global KDs for various ligands
that bind to (pro)-ABE I. Following maturation events at the single amino acid level is
however missing. Solution NMR studies have revealed that thrombin is highly dynamic
and there are a few residues in the thrombin ABE I region that cannot be monitored due to
exchange broadening.133 As a result, isotopically labeled thrombin has limitations in its
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ability to understand the conformational changes of few regions that occur during thrombin
activation. To decipher the missing information about maturation events and help to probe
interactions between various physiological substrates, we divided our research into three
projects.
The first project was to probe the maturation events of (pro)- ABE I at the single
amino acid level by using various solution NMR methods on peptides based on a member
of the protease activated receptor PAR family. The first peptides studied were derived from
PAR3. 1D proton line broadening NMR revealed that PAR3 (44-56) and weaker binding
PAR3G (44-56) could already interact with pro-ABE I on prothrombin. 1H-15N-HSQC
(Heteronuclear Single Quantum Coherence) NMR titrations were then used to probe
binding of individual 15N-labeled PAR3G residues (F47, E48, L52, and D54). PAR3G E48
and D54 could interact electrostatically with prothrombin and tightened upon thrombin
maturation. The higher affinity for PAR3G D54 suggests the region surrounding thrombin
R77a is better oriented to bind D54 than the interaction between PAR3G E48 and thrombin
R75. Aromatic PAR3G F47 and aliphatic L52 also both reported on significant changes in
chemical environment upon conversion of prothrombin to thrombin. The ABE I region
surrounding the 30s loop was already available than the hydrophobic pocket (F34, L65,
and I82). These NMR titrations demonstrate that PAR3 residues document structural
rearrangements occurring during exosite maturation that are missed by reported X-ray
crystal structures.50,154
Later, the project was extended to better understand the diversity of PAR ligand
binding interactions towards zymogen ProT vs mature thrombin. 1D proton line
broadening confirmed that PAR1P (49-62) and weaker binding version PAR1G (49-62)
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already exhibited line broadening with ProT and such broadening increased when bound
to thrombin. 2D tr-NOESY revealed that PAR1P (49-62) when bound to pro-ABE I
adopted an extended conformation with the Xaa-Pro bond existing in the trans
conformation.
1

for

15

H-15N HSQC titrations then provided quantitative estimates of binding interactions

N-labeled PAR peptides interacting with ProT vs thrombin. The F55 of PAR1P

peptides revealed that the hydrophobic pocket of pro-ABE I (F34, L65, and I82) is
available for peptide binding, and the affinity increased with mature thrombin. For both
PAR3154 and PAR1 peptides, a proline to glycine substitution was needed to sufficiently
weaken the affinity and allow us to characterize the thrombin-peptide interactions. Xcrystal structures reveal almost the same thrombin binding partners for both PAR1 (49-56)
and PAR3 (44-56). However, the solution NMR methodologies demonstrated that even
though the PAR residues target the same regions of (pro)- ABE I, the binding affinities of
K51, E53, and E60 residues in PAR1G (49-62) are weaker than PAR3G (44-56). When
bound to thrombin, the acidic C-terminal tail of PAR1 (49-62) remains unresolved by
crystallography.49 NMR titrations are making it possible, for the first time, to evaluate the
binding affinities of D58 of the PAR1 (58DEEKN62) segment to pro-ABE I and ABE I.
We also found striking evidence that allosteric communication can be possible
between ABE I and ABE II. When triply phosphorylated GpIbα (269-282) bound at ABE
II, it affected the binding affinities of ABE I ligands. Previous HDX-MS studies revealed
that GpIbα (269-282) had a long-range effect on ABE- I segment L65 to M84.60 Our NMR
protein-ligand titration studies showed that the allosteric effect of GpIbα is directed more
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towards the center of the sequences in both PAR3 (44-56) and PAR1 (49-62) than towards
the C-terminal end.
The final project of the dissertation was to determine kinetic parameters associated
with thrombin-catalyzed hydrolysis of Fbg Bβ (5-16). HPLC-based kinetic assay results
suggested that Fbg Bβ (5-16) has Km value of 1271± 154 µM, kcat value of 1.0±0.075 s-1,
and kcat/Km value of 8.2x10-4 ± 1.2x10-4 s-1 µM-1. A comparison of individual kinetic
parameters indicates that Fbg Aα (7-20),62 is a better substrate for thrombin than Fbg Bβ
(5-16). Fbg Bβ is hindered by having both high Km and low kcat values. These limitations
helped explain why FpB is released from fibrinogen later than that of FpA. FXIII AP (2841) V34L and V34F are known to take advantage of an aromatic residue at the P4 position
to improve optimal contacts with the active site region.183,184 From this project, we
identified that Fbg Bβ (5-16) was not able to utilize its two aromatic Phe residues at the P4
and P5 positions to help generate good kinetic parameters when compared to FXIII AP (2841) V34F and V34L. Even though the Km values for PAR1 (29-45)64 and Fbg Bβ (5-16) are
comparable, substrate specificity for PAR1 is 35-fold higher than Fbg Bβ (5-16). PAR1
(29-45) took advantage of Proline at the P2 position to improve substrate orientation for
thrombin- catalyzed hydrolysis at the thrombin active site surface. Our solution NMR
studies then helped to further understand the weak kinetics observed for the hydrolysis of
Fbg Bβ (5-16). Unlike PAR1, the Phe residues at P4 and at P5 did not show any stabilizing
through space NOEs with the small Alanine residue at the P2 position. The

10
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sequence in Fbg Bβ (5-16) plays a key role in forming a stable thrombin- FpB substrate
complex, however the interactions are not as effective as those found with the other
physiological substrates Fbg Aα, PAR1, and FXIII AP.
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Preliminary results and future directions
Chapter 3 and 4 were mainly focused on calculating individual KD values for amino
acids that were hypothesized to contact critical residues of thrombin ABE I. It would also
be valuable to know the global KDs for PAR3P/G (44-56) and PAR1P/G (49-62) in the
solution NMR buffer conditions of 150 mM NaCl and at pH 6.5. Literature provides global
KDs for PAR3 (2 µM) and PAR1 (0.5 µM) towards thrombin using a fluorescence based
approach at very high concentration of NaCl (800 mM) and at pH 8.0.148 We wanted to
measure the global binding affinities of PAR3P/G (44-56) and PAR1P/G (49-62) using a
label free technique in solution. For that, a Nano Isothermal Titration Calorimeter (ITC)
from TA instruments was employed. ITC is a label -free biophysical technique which not
only gives the binding affinities between a ligand and protein but also reveals the
thermodynamic parameters of the complex formation. ITC works best if the binding
affinities fall between the nM to low µM range. Hence, we initiated our ITC project with a
positive control DNA aptamer whose KD was already published in the literature (64 nM).188
The 15 base DNA aptamer (HD 1), GGTTGGTGTGGTTGG is documented to bind at
ABE I of thrombin. Figure 59 represents our ITC binding curve between the DNA aptamer
and bovine thrombin that gave a reasonable KD of 164 nM (Appendix 10).
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Figure 59: ITC binding curve of 2 µL injections of a 50 μM aptamer solution binding to a
7 μM solution of bovine thrombin.

With the success of ITC with the DNA aptamer and bovine thrombin, we proceeded
to employ ITC for the PAR3- thrombin complex. As all our NMR titrations were performed
using PPACK-thrombin, the solution conditions were matched in the ITC experiments and
the PAR3 ligand was titrated into PPACK-IIa. As shown in Figure 60, the curve shape and
fitting were not as good as seen with the DNA aptamer (Appendix 11). Unlike the ITC
binding curve between TM and thrombin,188 we found that binding of PAR3 (44-56) to
thrombin generated low heats. Weak binding and lower ΔH values likely contributed to
this problem. The enzyme- ligand titration system needs to be better optimized before
moving on to PAR3G (44-56) or PAR1P/G (49-62) and the ternary complex consisting of
GpIbα + thrombin + ABE I ligand. So far, the HSQC NMR titration was a more successful
strategy for probing the affinities of PAR3 and PAR1 peptides bound to (pro)thrombin.
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Figure 60: ITC binding curve of 2 µL injections of a 75 μM aptamer solution binding to a 50 μM
solution of bovine thrombin.

The NMR titration studies from Chapter 3 and 4 revealed the roles of several
individual

15

N- labeled amino acids from PAR3 (44-56) and PAR1 (49-62) that are

involved in binding to (pro)-ABE I. There are additional residues within the sequences of
PAR3 and PAR1 that are needed to be explored. A few of them would however be highly
costly for custom peptide synthesis. An alternative strategy would be to express the
peptides in E. coli. With this strategy, estimates of the binding affinities for all the
individual PAR ligand amino acids could be assessed. However to study the direct
thrombin-ligand contact sites and to observe long-range effects of the ligands on the
thrombin, the enzyme-ligand NMR titrations should need to be switched to the protein
perspective. A protocol for expressing 15N-labeled thrombin has already been published189
and should yield a decent amount of enzyme to carry out NMR studies. The significance
of having uniformly 15N labeled thrombin expression is the ability to map more thrombinpeptide contact sites and to understand the consequences of ligand-induced allostery of
thrombin.
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HPLC- based kinetics and solution structural information for Fbg Bβ (5-16) bound
to thrombin in Chapter 5 indicated that Fbg Bβ (5-16) has weak kinetic parameters when
compared to common physiological substrates like Fbg Aα (7-20),62 FXIII (28-41)
V34X,180,181 PAR1,64 and PAR4.65 An excellent strategy to compare Fbg Bβ binding
interactions with thrombin would to replace the Ala residue at the P2 position of Fbg Bβ
(5-16) with a large valine or proline. Also, the P5 position occupied by the bulkier
phenylalanine could be replaced by a slightly smaller amino acid. These substitutions may
help in assessing whether there can be any improvements in the kinetic parameters and
secondary structure when bound to thrombin. This information may help in assessing
whether it is the thrombin specificity or the availability of Fbg Bβ that plays an important
role in permitting Fbg Aα (7-20) to be cleaved by thrombin prior to Fbg Bβ (5-16).
Overall, results from this dissertation project support the conclusion that thrombin
is a highly dynamic enzyme that is allosterically controlled. Key regions that are affected
include areas surrounding the active site, the insertion loops, and the two exosites ABE I
and ABE II.133-135,190 Our studies have demonstrated that physiological peptide ligands
based on PARs can already bind to the immature pro- ABE I of zymogen ProT. Critical
maturation events not visible by X-ray crystallography have now been successfully probed
through solution based NMR methodologies. For the first time, KD values for individual
15

N-labeled amino acids of PAR3154 and PAR1 were estimated. As part of these studies,

the changes in conformational environments that occur during the maturation events were
clearly documented. Finally, long-range communication between ABE II and ABE I was
proven and characterized at the single amino acid level. It would be interesting to know
whether conformational changes in other clotting factors could be probed through such a
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ligand perspective. A long-range goal of this research would be to develop new drugs that
target unique sites within the active site region or the (pro)exosites and thereby modulate
the procoagulant and anticoagulant events of thrombin.
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APPENDICES

APPENDIX 1
An overlay of the 2D 13C-1H natural abundance HSQC NMR spectra of 1 mM PAR3
(44-56) and 1mM PAR3G (44-56):

All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O
(pH 6.5). The PAR3 residues are in red whereas the PAR3G are in black. The expected
cross peaks for the unique residues Pro51 versus Gly51 are labeled.
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APPENDIX 2
1D

15N-HSQC

NMR titrations of PAR3FD (44-56) in the presence of ProT and

PPACK- IIa:

All NMR samples were in 25mM H 3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 %
D2O (pH 6.5). A) For the PAR3FD binding studies with ProT, starting complexes
included 50 M PAR3FD (44-56, 15N-F47, 15N-D54) in 137 M ProT. The serial
dilutions resulted in ProT to PAR3 ratios that spanned from 3:1 to 0.1:1. B) For
PPACK- IIa, starting complexes included 50 M PAR3FD (44-56, 15N-F47, 15N-D54)
in 210 M PPACK- IIa. The serial dilutions resulted in PPACK- IIa to PAR3FD ratios
that spanned from 4:1 to 0.1:1. Representative data sets are shown
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APPENDIX 3
2D 1H-15N HSQC NMR titrations of PAR3FD (44-56) in the presence of ProT and
PPACK- IIa:

All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH
6.5). A) For the PAR3FD binding studies with ProT, starting complexes included 50 M
PAR3FD (44-56, 15N-F47, 15N-D54) in 130 M ProT. The serial dilutions resulted in ProT to
PAR3FD ratios that spanned from 3:1 to 0.1:1. B) For PPACK -IIa, starting complexes
included 50 M PAR3FD (44-56, 15N-F47, 15N-D54) in 210 M PPACK-IIa. The serial
dilutions resulted in PPACK-IIa to PAR3FD ratios that spanned from 4:1 to 0.1:1.
Representative data sets are shown. Colors for the HSQC crosspeaks span from blue (highest
protein-peptide ratio) to red (free peptide).
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APPENDIX 4
1D 15N-HSQC NMR titrations of PAR3GFD (44-56) in the presence of ProT and
PPACK- IIa:

All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 %
D2O (pH 6.5). A) For the PAR3GFD binding studies with ProT, starting complexes
included 37.5 M PAR3GFD (44-56, 15N-F47, 15N-D54) in 70 M ProT. The serial
dilutions resulted in ProT to PAR3G ratios that spanned from 2:1 to 0.3:1. B) For
PPACK- IIa, starting complexes included 37.5 M PAR3GFD (44-56, 15N-F47, 15ND54) in 70 M PPACK- IIa. The serial dilutions resulted in PPACK- IIa to PAR3GFD
ratios that spanned from 2:1 to 0.05:1. Representative data sets are shown.
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APPENDIX 5
15N

HSQC NMR titrations of PAR3GEL (44-56) in the presence of ProT and

PPACK- IIa:

All NMR samples were in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH
6.5). A) For the PAR3GEL binding studies with ProT, starting complexes included 50 M
PAR3GEL (44-56, 15N-E48, 15N-L52) in 180 M ProT. The serial dilutions resulted in ProT to
PAR3G ratios that spanned from 4:1 to 0.1:1. B) For PPACK- IIa, starting complexes
included 50 M PAR3GEL (44-56, 15N-E48, 15N-L52) in 211 M PPACK- IIa. The serial
dilutions resulted in PPACK- IIa to PAR3GEL ratios that spanned from 4:1 to 0.1:1.
Representative data sets are shown.
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APPENDIX 6
Determination of Binding Affinity (KD) for 15N-labeled F47 and D54 of PAR3GFD
interacting with PPACK-R77aA IIa:

For this NMR titration series, the peptide ligand concentration was kept constant and the ProT
and PPACK-R77aA IIa concentrations were serially diluted. As a result, the NMR titrations
were measuring the binding of protein to a defined peptide concentration. A) Interactions
between PPACK-R77aA IIa and PAR3G 15N-D54 led to a KD = 168 ± 88 µM and B) ProT and
PAR3G 15N-F47 led to a KD = 173 ± 85 µM. NMR titrations were done in duplicate. The
reported KD values were determined using in-house scripts written using Python. The term
|Δδobs| 15Nppm = δ15NBound – δ15N Free reflects the absolute difference in chemical shift between
the bound and free states of the particular 15N-amide. Error analysis was carried out using a
Monte-Carlo approach assuming a 10% error in the serially diluted protein samples. See
Materials and Methods for more details.
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APPENDIX 7
Determination of Binding Affinity (KD) for

15N-labeled

L52 and E48 of PAR3GFD

interacting with Prothrombin and PPACK-IIa:

For this NMR titration series, the peptide ligand concentration was kept constant and the
ProT and PPACK-IIa concentrations were serially diluted. As a result, the NMR titrations
were measuring the binding of protein to a defined peptide concentration. A) Interactions
between ProT and PAR3G 15N-L52 led to a KD = 124 ± 27 µM, B) ProT and PAR3G 15NE48 led to a KD = > 200 µM, and C) PPACK-IIa and PAR3G 15N-L52 led to a KD = 47 ±
6 µM. NMR titrations were done in triplicate. The reported K D values were determined
using in-house scripts written using Python. The term |Δδobs| 15Nppm = δ15NBound – δ15N
Free reflects the absolute difference in chemical shift between the bound and free states of
the particular 15N-amide. Error analysis was carried out using a Monte-Carlo approach
assuming a 10% error in the serially diluted protein samples. See Materials and Methods
for more details.
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APPENDIX 8

1H-15N

2D HSQC titration of PAR3GFD (44-56) when bound to thrombin.

Sample was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and
10 % D2O (pH 6.5). This titration is done without PPACK:

4:1 to 0.14:1

F47

D54, already broadened at 0.3:1
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APPENDIX 9
1H-13C

HSQC spectra of PAR1 (49-62) [A] used for assigning aromatics in 1H-1H

2DNOESY of PAR1 (49-62) [B]:

A

B

A) 1H-13C HSQC spectra of 1 mM PAR1 (49-62). B) 1H-1H 2DNOESY of 780 µM PAR1
(49-62) when bound to 59 µM ProT.
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APPENDIX 10
Procedure for ITC experiment between DNA aptamer and thrombin:
558 nmole of aptamer (HD 1, GGTTGGTGTGGTTGG) was solubilized in 500 µL
dI water. 1.12 mM aptamer was then aliquoted in 20 tubes, lyophilized, and later stored at
-80ºC until needed. One the day of experiment, bovine thrombin was buffer exchanged into
50 mM Bis-tris propane (pH 7.4), 150 mM NaCl through dialysis. 75 µL of aptamer
samples were reconstituted using the same buffer. 500 µL of 7 µM bovine thrombin was
placed in the calorimetric cell of the Nano ITC (New Castle, DE). 2 µL of DNA aptamer
was added 25 times into the cell followed by an initial delay of 250 s. The final
concentration of DNA aptamer in the calorimetric cell was 50 µM. During data processing
using the Nano Analyze, initial heat was masked as it resulted from the heats of dilution.
The individual heats were then plotted as a function of the molar ratio, and nonlinear
regression of the data was performed using Nano Analyze software supplied with the
instrument. A single binding site model was used for data processing.
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APPENDIX 11
Procedure for ITC experiment between PAR3 (44-56) and thrombin:
Prior to the titration bovine thrombin was incubated with a 4-fold excess of PPACK
at 37ºC for 30 mins. Later, PPACK-thrombin was buffer exchanged into 25 mM H3PO4,
150 mM NaCl, 0.2 mM EDTA, (pH 6.5). Lyophilized PAR3 (44-56) was solubilized into
the same buffer. Since the affinity of PAR3 (44-56) for thrombin is not as strong as the
DNA aptamer, quite an excess of thrombin concentration was tested. 500 µL of 50 µM
bovine thrombin was placed into the calorimetric cell of the Nano ITC (New Castle, DE).
2 µL of PAR3 (44-56) was added 25 times into the cell followed by the initial delay of 250
s. The final concentration of PAR3 (44-56) was 75 µM. Same software and processing
model was used to analyze the data.
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APPENDIX 12
2D TOCSY Fingerprint region of 1 mM PAR3 (44-56). Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O
(pH 6.5):
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APPENDIX 13
2D TOCSY Aliphatic region of 1 mM PAR3 (44-56). Sample was prepared
in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):

HOUIJHOI
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APPENDIX 14

2D TOCSY Aliphatic region of 1 mM PAR3 (44-56). Sample was prepared
in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 14

2D TOCSY Fingerprint region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 15

2D TOCSY Aliphatic region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 16
2D TOCSY Amide region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 17

2D tr-NOESY Fingerprint region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH
6.5):
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APPENDIX 18

2D tr-NOESY Aliphatic region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 19

2D tr-NOESY Amide region of 1 mM PAR3 (44-56) + 74 μΜ ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 20

2D TOCSY Fingerprint region of 1 mM PAR3G (44-56). Sample was prepared in
25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 21

2D TOCSY Aliphatic region of 1 mM PAR3G (44-56). Sample was prepared in
25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 22

2D TOCSY Amide region of 1 mM PAR3G (44-56). Sample was prepared in 25mM
H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 23

2D TOCSY Fingerprint region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH
6.5):
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APPENDIX 24

2D TOCSY Aliphatic region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 25

2D TOCSY Amide region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 26

2D NOESY Fingerprintregion of 1 mM PAR3G (44-56) + 76 μM ProT. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH
6.5):
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APPENDIX 27

2D NOESY Aliphatic region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 28

2D NOESY Amide region of 1 mM PAR3G (44-56) + 76 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 29

2D TOCSY Fingerprint region of 1 mM PAR1P (49-62). Sample was prepared in
25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 30

2D TOCSY Aliphatic region of 1 mM PAR1P (49-62). Sample was prepared in
25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 31

2D TOCSY Amide region of 1 mM PAR1P (49-62). Sample was prepared in 25mM
H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 32

2D TOCSY Fingerprint region of 1 mM PAR1P (49-62) + 59 μM ProT Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 33

2D TOCSY Aliphatic region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 34

2D TOCSY Amide region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 35

2D NOESY Fingerprint region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH
6.5):
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APPENDIX 36

2D NOESY Aliphatic region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 37

2D NOESY Amide region of 1 mM PAR1P (49-62) + 59 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 38

2D TOCSY Fingerprint region of 1 mM PAR1G (49-62). Sample was prepared in
25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 39

2D TOCSYAliphatic region of 1 mM PAR1G (49-62). Sample was prepared in
25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 40

2D TOCSYAmide region of 1 mM PAR1G (49-62). Sample was prepared in 25mM
H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 41

2D TOCSY Fingerprint region of 830 μM PAR1G (49-62) + 83 μM ProT. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH
6.5):
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APPENDIX 42

2D TOCSY Aliphatic region of 830 μM PAR1G (49-62) + 83 μM ProT. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH
6.5):
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APPENDIX 43

2D TOCSY Amide region of 830 μM PAR1G (49-62) + 83 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 44

2D NOESY Fingerprint region of 830 μM PAR1G (49-62) + 83 μM ProT. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH
6.5):
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APPENDIX 45

2D NOESY Aliphatic region of 830 μM PAR1G (49-62) + 83 μM ProT. Sample
was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH

6.5):
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APPENDIX 46

2D NOESY Amide region of 830 μM PAR1G (49-62) + 83 μM ProT. Sample was
prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 6.5):
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APPENDIX 47

2D
of 1.5 region
mM Fbg
Sample
was
prepared
in 25mM
2D TOCSY
TOCSY region
Fingerprint
of Bβ
1.5 (5-16).
mM FpB
(5-16).
Sample
was prepared
H
0.2 NaCl,
mM EDTA
andEDTA
10 % and
D2O10
(pH
in3PO
25mM
H3mM
PO4,NaCl,
150 mM
0.2 mM
% 5.6):
D2O (pH 5.6):
4, 150
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APPENDIX 48
2D TOCSY Aliphatic region of 1.5 mM Fbg Bβ (5-16). Sample was prepared in
25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 5.6):
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APPENDIX 49
2D TOCSY Amide region of 1.5 mM Fbg Bβ (5-16). Sample was prepared in
25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10 % D2O (pH 5.6):
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APPENDIX 50

2D TOCSY Fingerprint region of 1.5 mM Fbg Bβ (5-16) and 160 µM
thrombin. Sample was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM
EDTA and 10 % D2O (pH 5.6):
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APPENDIX 51
2D TOCSY Aliphatic region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin.
Sample was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10
% D2O (pH 5.6):
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APPENDIX 52
2D TOCSY Amide region of 1.5 mM Fbg Bβ (5-16) and 160 µM thrombin.
Sample was prepared in 25mM H3PO4, 150 mM NaCl, 0.2 mM EDTA and 10
% D2O (pH 5.6):
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APPENDIX 53
ABBREVIATIONS

ABE-I
ABE-II
AP
AT
AUC
EDTA
Fbg Aα
Fbg Bβ
FpA
FpB
FXIII
FXIII AP
Gla
GpIbα
HDX-MS
HK/HMWK
His 57
HSQC
ITC
kcat
KD
Km
kcat/Km
koff
kon
MALDI-TOF MS
NMR
PAI1
PAR
PAR1P
PAR1G
PAR3
PAR3G
PPACK
ProT
PT1

Anion binding exosite – I
Anion binding exosite – II
Activation peptide
Antithrombin
Analytical Ultra Centrifugation
Ethylenediaminetetraacetate
Fibrinogen Aα chain
Fibrinogen Bβ chain
Fibrinopeptide A
Fibrinopeptide B
Transglutaminase FXIII
Transglutaminase FXIII Activation Peptide
γ-carboxyglutamic acid
Glycoprotein Ibα found on the receptor
Hydrogen Deuterium Exchange -Mass
Spectrometry
High Molecular Weight Kininogen
Histidine at 57th position of the thrombin sequence
Heteronuclear Single Quantum Coherence
Isothermal Titration Calorimetry
Product turnover/ Catalytic Constant
Binding affinity
Michaelis Constant
Specificity Constant
Dissociation Rate Constant
Association Rate Constant
Matrix Assisted Laser Desorption Ionization
Time of Flight Mass Spectrometry
Nuclear Magnetic Resonance
Plasminogen Activator Inhibitor 1
Protease Activated Receptor
Protease Activated Receptor-1 with Proline at 54th
position
Protease Activated Receptor-1 with Glycine at 54th
position
Protease Activated Receptor-3
Protease Activated Receptor-3 with Glycine at 51st
position
D-Phe-Pro-Arg chloromethyl ketone
Prothrombin
Prethrombin 1
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PT2
R
RP-HPLC
R77a
R77aA
SLEX
T
T1
T2
TF
TFPI
TM
vWF
W60d
Y60a
YP
1D
2D
2D TOCSY
2D tr-NOESY
IIa
ω
τc
H
ΔG
ΔS









Prethrombin 2
Gas constant
Reversed Phase High Performance Liquid
Chromatography
Arginine at 77th position of the thrombin sequence,
“a” indicates first residue in 70 loop
Arginine at 77th position of the thrombin is replaced
by alanine
Systematic Evolution of Ligands by Exponential
Enrichment
Absolute temperature
Spin-lattice Relaxation with time constant T1
Transverse Relaxation with time constant T2
Tissue factor
Tissue Factor Pathway Inhibitor
Thrombomodulin
von Willebrand Factor
Trptophan at 60th position of the thrombin
sequence, “d” indicates fourth residue in 60s loop
Tyrosine at 60th position of the sequence, “a”
indicates first residue in 60s loop
Phosphotyrosine
One Dimensional
Two Dimensional
Two-Dimensional Total Correlational
Spectroscopy
Two- Dimensional Transferred Nuclear
Overhauser Spectroscopy
Thrombin
Resonance Frequency
Rotational Correlation Time
Change in enthalpy
Change in Gibbs Free energy
Change in Entropy
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Department of Chemistry, University of Louisville, KY
•
•
•
•
•
•
•

Biochemistry Laboratory (CHEM 546)
Organic Chemistry Laboratory I (CHEM 343)
Chemical Analysis Laboratory IV (CHEM 210)
Chemical Analysis Laboratory III (CHEM 209)
Chemical Analysis Laboratory II (CHEM 208)
Chemical Analysis Laboratory I (CHEM 207)
Assisted Chemistry professors in organizing, proctoring, and grading exams
Lecturer

•

September 2011- June 2012

Engineering Chemistry (JNTUH, EC)
206

PROFESSIONAL MEMBERSHIP
•
•
•
•
•

Golden Key International Honor Society - Lifetime member
Biophysical Society - 2017 to 2018
American Heart Association - 2017
Biophysical Society - 2014 to 2016
American Chemical Society - 2012-2013
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